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Role of ectopic fat in the pathogenesis and organ dysfunction associated with type 2 diabe-
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Introduction and outline of the thesis
inCiDEnCE Of ObESiTy AnD TyPE 2 DiAbETES MELLiTuS (T2DM)
Global increases in overweight and obesity are attributable to a number of factors including 
a shift in diet towards increased intake of energy-dense food and a trend towards decreased 
physical activity, due to the increasingly sedentary nature of many forms of work, chang-
ing modes of transportation and less physical exercise. Once, the obesity epidemic was 
considered to be a problem in high-income countries only, however, overweight and obesity 
are now dramatically on the rise in low- and middle-income countries, particularly in urban 
settings.
The World Health Organization (WHO) defines “overweight” as a body mass index (BMI) 
(calculated as the bodyweight in kilograms divided by the square of the height in meters (kg/
m2)) equal to or more than 25 kg/m2, and “obesity” as a BMI equal to or more than 30 kg/m2. 
The WHO estimates that in 2005 worldwide approximately 1.6 billion adults had overweight 
and at least 400 million adults were obese. They further calculated that by 2015 approxi-
mately 2.3 billion adults will have overweight and more than 700 million will be obese (http://
www.who.int; obesity and overweight fact sheet).
Obesity presents a risk to health and this risk increases progressively as BMI increases. 
Obesity per se is associated with an increased mortality rate (Table 1). Furthermore, obesity 
is tightly associated with insulin resistance, hyperlipidemia and hypertension, and thus with 
diseases such as type 2 diabetes mellitus (T2DM), stroke and ischemic heart disease. But also 
other diseases have a higher incidence in overweight or obese people, such as gallstones, 
disruption of the menstrual cycle, infertility and arthrosis (Table 1) (1-4).
It is therefore not surprising that the prevalence of T2DM is rising steadily along with the 
obesity epidemic. The WHO estimates that there will be at least 366 million people worldwide 
suffering from T2DM in 2030, which is more than 5% of the adult population (5). Diagnostic 
Table 1. The estimated relative 10-year risk for mortality and disease in overweight (BMI 25-30 kg/m2) and obese (BMI ≥ 30 kg/m2) men and 
women.
Overweight Obesity
Men Women Men Women
Mortality rate 1.1 1.1 1.3 - 2.2 1.4 - 1.6
Type 2 Diabetes Mellitus 3.5 4.6 11.2 - 23.4 10.0 - 17.0
Cardiovascular disease 1.5 1.4 2.0 - 2.2 1.5 - 1.6
Stroke 1.2 1.2 2.0 - 2.3 1.0 - 1.1
Hypertension 1.7 1.7 2.7 - 3.0 2.1 - 2.3
Gallstones 1.4 1.9 2.3 - 2.9 2.5 - 3.0
Colon carcinoma 1.2 1.2 1.7 - 1.8 1.3 - 1.8
The relative risks for the women are derived from the follow-up study of the Nurses’ Health Study and for the man from the Health Professionals 










































criteria for T2DM set by the WHO and the American Diabetes Association (ADA) are HbA1c 
≥ 6.5% OR fasting (defined as no caloric intake for at least 8 hours) plasma glucose (FPG) 
≥ 7.0 mmol/L OR 2-hour glucose ≥ 11.1 mmol/L during a 75 grams oral glucose tolerance 
test (OGTT), confirmed by repeat testing on a different day in the absence of unequivocal 
hyperglycemia OR when classical symptoms of hyperglycemia are present a random plasma 
glucose level ≥ 11.1 mmol/L (6).
The cut-off points of overweight and obesity (25 and 30 kg/m2) provide a benchmark for 
individual assessment, but there is evidence that the risk of chronic disease in the popula-
tion increases progressively above a BMI of 21 kg/m2 (7). The BMI provides the most useful 
measure of overweight and obesity at the population level as it is the same for both sexes 
and for all ages. However, the BMI should be interpreted with caution at the individual level, 
because it does not predict body composition let alone regional body fat distribution. Indi-
viduals, especially the groups of elderly (8), children (9) and people from a different ethnicity 
(10), with equal BMI can be highly variable in terms of body fat mass and regional body fat 
distributions (visceral and subcutaneous fat mass) (11,12). This is of note since visceral fat 
accumulation is associated with a greater risk to develop T2DM and cardiovascular disease. 
Waist circumference is a valid index for visceral fat mass and can therefore be used as an 
indicator of health risk associated with excessive visceral fat mass (13).
PAThOPhySiOLOgy T2DM
T2DM is a multifactorial, chronic disease characterized by hyperglycemia (Figure 1). The 
complex nature of T2DM is reflected in the multifaceted genetic background and the varied 
environmental interaction. There is cross-sectional evidence which suggests a strong genetic 
component of the disease. Positive family history confers a 2.4 fold increased risk for T2DM. 
The lifetime risk of T2DM is 7% in a general population, 38% in offspring of one parent with 
T2DM and about 70% if both parents have T2DM (14,15). Furthermore, it is well established 
that about 80% of T2DM is associated with obesity especially visceral fat accumulation and 
sedentary life styles (16). The pathophysiology of T2DM also comprises a combination of 
insulin resistance of target tissues (liver, adipose tissue, skeletal muscle) and impaired insulin 
secretion in the pancreatic β-cell. This leads to a combination of defects in insulin-mediated 
glucose uptake (predominantly muscle tissue), dysregulation of the adipocyte as a storage 
and secretory organ, dysregulation of the endogenous glucose production (predominantly 
in the liver), and a progressive decline in beta-cell function and mass in the pancreas leading 









































Introduction and outline of the thesis
Skeletal muscle
Muscle glucose uptake accounts for 75-80% of insulin stimulated glucose uptake by the 
body (17). Therefore in T2DM patients the largest part of the impairment in insulin-mediated 
glucose uptake is explained by the defect in skeletal muscle. This involves both impaired 
glucose uptake as well as impaired glucose disposal. The major pathway for overall glucose 
metabolism is glycogen synthesis or non-oxidative glucose disposal (NOGD). In patients with 
T2DM glycogen synthesis is only 60% of that of healthy lean control subjects.
The cellular events through which insulin initiates its stimulatory effect on glucose uptake 
start with the binding of insulin to the α-subunit of the insulin receptor (IR) leading to a con-
formational change that induces a process of autophosphorylation; the intracellular kinase 
domain of one half of the receptor phosphorylates the tyrosine residues of the other half of 
the receptor (18). The phosphorylated tyrosines on the IR can now serve as docking sites for 
other proteins such as the insulin receptor substrate 1 (IRS1) (19). Phosphorylated IRS1 binds 
to phosphatidylinositol 3-kinase (PI3K) (20), which is recruited to the plasma membrane 
and converts phosphatidylinositols-4,5-bisphophate (PIP2) to phosphatidylinositols-3,4,5-
trisphophate (PIP3). PIP3 subsequently attracts phosphatidylinositol-dependent protein 
kinase (PDK) and protein kinase B (PKB)/Akt to the plasma membrane where Akt is activated 
by PDK-mediated phosphorylation (21,22). Activated Akt thereupon dissociates from the 
cellular membrane to affect several metabolic processes, such as glycogen synthesis and glu-
cose transport into the cell (23). Activated Akt inactivates glycogen synthase kinase 3 (GSK3), 
hereby abrogating the inhibitory action of GSK3 on glycogen synthase, and thus stimulating 
glycogen synthesis (24). Activated Akt also leads to phosphorylation of Akt substrate 160 
(AS160) that allows glucose transporter 4 (GLUT4) storage vesicles to move to, dock, and 
Figure 1. Type 2 Diabetes Mellitus (T2DM) is a multifactorial disease.
T2DM
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fuse with the plasma membrane. GLUT4 translocation consists of 4 stages: vectorial transfer: 
GLUT4 vesicles are transported to the cell periphery; tethering: GLUT4 vesicles are retained 
near the cell periphery; docking: GLUT4 vesicles bind to plasma membrane; fusion: irrevers-
ible incorporation of GLUT4 vesicles in the plasma membrane (25-27). Activated Akt also 
phosphorylates the nuclear protein Proline-rich Akt Substrate of 40 kDa (PRAS40). The exact 
function of PRAS40 is still under debate. Possibly phosphorylation of PRAS40 disrupts the in-
teraction between mammalian target of rapamycin complex 1 (mTORC1) and PRAS40, which 
may relieve an inhibitory constraint on mTORC1 activity. The mTORC1 signaling pathway 
abrogates insulin-mediated activation of the PI3K-PKB/Akt pathway by inducing inhibitory 
serine phosphorylation on the insulin receptor and IRS1/2 (28) (Figure 2).
In T2DM patients a number of defects in the insulin signaling cascade have been described 
as compared to lean insulin sensitive control subjects, however it has been difficult to replicate 
the results in different studies both in vitro and in vivo. The complexity of the insulin signaling 
pathway grows, new studies lead to the discovery of new proteins, protein isoforms and new 
regulatory sites and defects in insulin resistant subjects or T2DM patients. In Table 2 a sum-
mary of the defects in the insulin signaling cascade in T2DM patients are shown compared 
to findings in lean healthy controls (29-40). One of the mechanisms by which insulin signal 
transduction is disturbed is excessive ectopic triglyceride storage in the skeletal muscle cell 
(as will be discussed in the following sections).





















IR: Insulin receptor; IRS: insulin receptor substrate; PI3K: phosphatidylinositol 3-kinase; PIP2: phosphatidylinositols-4,5-bisphophate; PIP3: 
phosphatidylinositols-3,4,5-trisphophate; PDK: phosphatidylinositol dependent protein kinase; PKB/AKT: Protein kinase B/AKT; AS160: Akt 










































Introduction and outline of the thesis
adipose tissue
In lean healthy subjects approximately 10% of insulin-stimulated glucose uptake occurs in 
adipose tissue. This suggests a minor role of adipose tissue in the pathophysiology of insulin 
resistance. However, in the adipose tissue of patients with T2DM the expression of GLUT4 
is down-regulated, hereby leading to a diminished uptake of glucose in this organ. Also, 
adipocyte-selective GLUT4 knockout mice show a systemic insulin resistance (41), suggest-
ing that adipocytes secrete proteins that are responsible for cross-organ communication. 
Factors secreted by adipocytes that may alter insulin action and hepatic glucose production 
include adipokines (like adiponectin, resistin, leptin) (as reviewed in (42)), and free fatty acids 
(FFAs) (see in section ectopic fat depositions). In obesity, the adipose tissue is characterized 
by adipocyte hypertrophy and increased lipolysis leading to elevated production of FFAs. 
Furthermore, macrophages are present in much higher numbers in adipose tissue of obese 
subjects.
Cross-sectional studies have shown that insulin resistant states such as obesity and T2DM 
are associated with chronic low-grade inflammation (43,44). Macrophages, in the adipose tis-
sue appear to be major sources of inflammatory mediators that are linked to insulin resistance 
such as pro-inflammatory cytokines (interleukin 6 (IL6) and tumor necrosis factor α (TNFα)) 
and elevated levels of highly sensitive C-Reactive Protein (hsCRP) (45,46). These cytokines 
can inhibit insulin signaling downstream of the IR, this might be the primary mechanism 
through which the chronic low-grade inflammatory status causes insulin resistance. TNFα 
and IL6 stimulate phosphorylation of serine residues of the IRS1/2. This phosphorylation 
reduces tyrosine phosphorylation of IRS1/2 in response to insulin which prevents further 
downstream signaling pro-inflammatory cytokines vesicles and thus GLUT4 translocation to 
the cellular membrane (47).
Visceral fat has a higher lipolytic activity and is less responsive to the anti-lipolytic activity 
of insulin as compared to subcutaneous adipose tissue (48,49). In addition, the adipokines, 
FFAs and (pro-inflammatory) cytokines produced by the visceral adipose tissue will be se-
creted directly into the portal vein and will have direct detrimental effects in the liver (50-52). 
However the visceral adipose tissue contributes only 10-15% of the total systemic free fatty 
Table 2. Defects in insulin signaling pathway in the skeletal muscle in type 2 diabetes mellitus (T2DM) patients compared to healthy controls.
T2DM vs. healthy controls reference
IR activity or autophosphorylation unchanged 30, 31, 32
IRS1 tyrosine phosphorylation impaired 31, 33, 34, 35
IRS1 association with PI3K impaired 30, 32, 36
PKB/AKT phosphorylation impaired or unchanged 32, 34, 37, 38, 39, 40
GS activity impaired 30-40
Glucose disposal rate impaired 30-40










































acid flux, thus the impact of excess visceral adipose tissue on peripheral insulin sensitivity is 
questioned. It seems that the combination of excessive subcutaneous adipose tissue with 
excessive visceral adipose tissue is important in insulin resistance.
Liver
The liver has the ability to both consume, store as well as produce glucose and lipids. The 
liver is the major source of endogenous glucose production (EGP) but with prolonged fasting 
the contribution of the kidney increases (to 20% or even higher). EGP comprises 2 pathways: 
glycogenolysis (the conversion of glycogen to glucose) and gluconeogenesis (the generation 
of glucose from non-sugar carbon substrates (such as amino acids, mainly alanine, glycerol 
and lactate)).
In the post-absorptive state, the liver of healthy subject produces glucose at a rate of 2.0 
mg/kg/min. This glucose efflux is essential to meet the need of the brain and other neural 
tissue, since these tissues lack the ability to store glucose (53,54). In the post-absorptive state, 
hepatic insulin resistance of T2DM is manifested by overproduction of glucose despite fasting 
hyperinsulinemia. Indeed the increased rate of EGP by the liver is the primary determinant of 
the elevated FPG concentration in T2DM individuals. In the non-fasting state hepatic insulin 
resistance leads to an impaired suppression of the EGP by the liver which contributes to the 
postprandial hyperglycemia (54).
The first steps of insulin signaling in hepatocytes is quite similar to that in skeletal muscle 
cells; binding of insulin to its receptor leads to phosphorylation of the tyrosine-kinase on the 
IR. This is followed by ligand-receptor interaction. In the liver, as opposed to skeletal muscle, 

















IR: Insulin receptor; IRS: insulin receptor substrate; PI3K: phosphatidylinositol 3-kinase; PKB/AKT: Protein kinase B/AKT; FOXO: forkhead box 









































Introduction and outline of the thesis
the PI3K/Akt pathway is not only controlled by IRS1 but also by IRS2 (55,56). In addition, 
Akt in the liver regulates the expression of numerous genes important in controlling lipid 
synthesis and gluconeogenesis (57). For example Akt can regulate the phosphorylation of 
the forkhead box protein O (FOXO) family of transcription factors, which in turn inhibit the 
expression of the glucose-6-phosphatase catalytic subunit (G6Pase), leading to a suppression 
of glucose production (58). Also, insulin promotes glycogen synthesis by inactivating the 
enzyme glycogen synthase kinase 3 (GSK3) through the PI3K/AKT pathway. In the absence of 
insulin GSK3 phosphorylates glycogen synthase, which becomes inactive and thus glycogen 
synthesis will be inhibited (Figure 3).
Due to ethical considerations liver biopsies in human studies with T2DM patients are 
rare. Animal studies confirm impaired insulin signaling form IRS1/2 to PI3K/Akt leading to 
increased gluconeogenesis (54). In, addition glycogen synthesis is inhibited (59). One of the 
mechanisms by which insulin signal transduction is disturbed is excessive ectopic triglyceride 
storage in the liver (as will be discussed in the following sections).
pancreatic β-cells
Early in the development of T2DM, insulin resistance is well established but glucose tolerance 
remains normal because of a compensatory increase in insulin secretion. There is a dynamic 
interaction between insulin secretion and overall insulin resistance within the early stages 
of T2DM. The progression from impaired glucose tolerance to T2DM is characterized by an 
inability of the beta cell to maintain the previously elevated rate of insulin secretion in re-
sponse to a glucose challenge. Tissue sensitivity to insulin deteriorates only minimally in this 
stage (unless of course the patient is able to lose weight) (Figure 4) (60,61).
Insulin secretion is biphasic with an early burst of insulin release within the first 10 minutes 
followed by a progressive increase in insulin secretion that persists as long as the hyperglyce-
mic stimulus is present (62). Loss of the first phase insulin secretion is a characteristic and an 
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early abnormality in patients developing T2DM. Loss of the first phase insulin secretion has 
important pathogenic consequences, because this early burst of insulin primes insulin target 
tissues, especially the liver (63,64). The second phase insulin secretion is important to prevent 
hyperglycemia by stimulating the uptake of glucose by the different target tissues.
A number of genetic and acquired factors have been implicated in the progressive impair-
ment in both first and second phase insulin secretion (65-67), including chronic hyperglyce-
mia (glucotoxicity) (68), chronic hyperlipidemia (lipotoxicity) (69,70) and pro-inflammatory 
cytokines (IL6 and TNFα) (71). However, the exact pathogenesis has not been elucidated yet.
rOLE Of ECTOPiC fAT in ThE PAThOgEnESiS AnD OrgAn DySfunCTiOn 
ASSOCiATED wiTh T2DM
Adipocytes have a unique capacity to store large amounts of excess FFAs in cytosolic lipid 
droplets. Under healthy conditions, most triglycerides are stored in adipocytes. Cells of non-
adipose tissues (such as the liver, the skeletal muscle, myocardium and the pancreas) have 
a limited capacity for storage of lipids and this is very tightly regulated. When the capacity 
of the adipose tissue to store triglycerides is exceeded, lipids accumulate in non-adipose 
tissues, termed ectopic fat deposition. Ectopic fat disturbs cellular function and may even 
lead to cell death, called lipotoxicity (72,73). The reason this ectopic deposition occurs is 
not elucidated. Bluher (74) recently proposed a model in which genetic and environmental 
factors lead to adipocyte hypertrophy, hypoxia and endoplasmatic reticulum stress causing 
inflammation within adipose tissue (via attraction of macrophages) and a different adipokine 
secretion profile. This leads to impaired adipocyte differentiation, reduced lipid accumula-
tion and increased lipolysis in adipocytes, altogether culminating in a redirection of lipids 
towards non-adipose tissues.
Obesity and especially T2DM is associated with elevated plasma FFA concentrations post-
prandially. The ability of insulin to inhibit the elevated basal rate of lipolysis and hence to 
reduce the plasma FFA concentration is markedly impaired (75,76). The surplus of FFA in the 
circulation will lead to ectopic fat depositions in several organs including the skeletal muscle 
(intramyocellular lipid accumulation (IMCL)); the liver (steatosis hepatis); and the heart (peri-
cardial fat and intramyocardial triglyceride (TG) content) and may result in lipotoxicity. The 
surplus fatty acids enter non-oxidative pathways leading to re-esterification into triglycerides 
within the non-adipose cell. Triglycerides per se are not harmful, however it is the availability 
of fatty acid derivatives like diacylglycerol (DAG), ceramide and long chain fatty acid-CoA 










































Introduction and outline of the thesis
Skeletal muscle (IMCL)
Cross-sectional studies have demonstrated that intramyocellular lipid (IMCL) accumulation is 
increased in obesity and T2DM (77-80). IMCL positively correlates with insulin resistance both 
in obese and non-obese subjects with or without T2DM (77,78,81).
Triglyceride derivatives, such as DAG, ceramide and LC-CoA are known to activate protein 
kinase C (PKC) that, in turn, phosphorylates the serine residues of IRS1. Serine-phosphory-
lated IRS1 is unable to associate with and activate PI3K, leading to disruption early in the 
insulin-signaling cascade and hence diminished trafficking of GLUT4 to the cell membrane 
(as reviewed by Morino et all (82)). Furthermore LC-CoA upregulates the de novo synthesis of 
TNFα, which is also associated with diminished insulin signaling, through the same pathway 
(83). In addition, an increase in the cytosolic pool of LC-CoA could directly inhibit glycogen 
synthase activity which leads to lower glycogen storage (80,81,84). Via these mechanisms, 
lipotoxicity can disturb cellular processes leading to insulin resistance in the skeletal muscle 
cell (Figure 5).
A decreased metabolic flexibility in T2DM patients is part of the explanation how lipids can 
accumulate in the skeletal muscle cell. The switch in fuel oxidation is normally dependent on 
the amount of nutrients (glucose, FFA or amino acids) available for oxidation. After a meal, in 
the insulin-stimulated state, glucose oxidation is high while lipid oxidation is suppressed. In 
the fasting/postabsoptive state the situation is just the opposite. However, in T2DM patients 
the switch in fuel oxidation is impaired, termed metabolic inflexibility (as reviewed in (85)). 
This leads to decreased oxidation of FFA and FFA derivatives. The reduction in metabolic 






















FFA: free fatty acid; LC-CoA: long chain fatty acid-CoA; TNFα: tumor necrosis factor α; DAG: diacylglycerol; PKC: protein kinase C; IR: insulin 
receptor; IRS: insulin receptor substrate; PI3K: phosphatidylinositol 3-kinase PKB/AKT: Protein kinase B/AKT; GLUT4: glucose transporter protein 










































flexibility can partly be explained by reduced mitochondrial function and capacity. Indeed 
studies show reduced mitochondrial density and function in skeletal muscle cells of T2DM 
patients (86-88).
Liver (hepatic steatosis)
Cross-sectional studies show a positive correlation between hepatic steatosis (high hepatic 
TG content) and hepatic insulin resistance, both in T2DM patients and non-diabetic subjects 
(89,90).
The exact underlying pathophysiological mechanism by which hepatic triglyceride ac-
cumulation leads to hepatic insulin resistance is unknown. However, it is very likely that 
similarly as in the skeletal muscle lipid intermediates (such as DAG) are important. In the liver 
as well as in the skeletal muscle, DAG activates PKC which in turn binds and inactivates the IR 
resulting in reduced IRS1/2 and hence PI3K/AKT phosphorylation. Subsequently, this leads to 
an increase in GSK3 and decrease in FOXO phosphorylation, and thus respectively reduced 
liver glycogen synthesis and impaired suppression of hepatic gluconeogenesis. Thus there is 
augmented glucose release into the circulation (Figure 6) (as reviewed by Morino et all (82)).
Figure 6. Cellular processes leading to insulin resistance in the liver cell.
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FFA: free fatty acid; LC-CoA: long chain fatty acid-CoA; DAG: diacylglycerol; PKC: protein kinase C; IR: insulin receptor; IRS: insulin receptor 
substrate; PI3K: phosphatidylinositol 3-kinase PKB/AKT: Protein kinase B/AKT; GSK3: glycogen synthase kinase 3; FOXO: forkhead box protein O; 
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heart (Myocardial triglyceride content; pericardial fat mass)
Cross-sectional studies report that stores of myocardial triglyceride are positively related to 
FFA exposure and are increased in obese and T2DM subjects (91,92). Ectopic fat depositions 
in the heart lead to diminished heart function. Triglyceride intermediates, such as DAG, 









































Introduction and outline of the thesis
thus function of the heart. In cross-sectional studies, the increase in myocardial triglyceride 
stores in obese or T2DM subjects is associated with impaired systolic and diastolic function 
(92).
Pericardial fat is the adipose tissue surrounding the heart. The physiological function of 
this fat depot is still under debate. It may serve as protection for the coronary arteries and/
or energy supply for the myocardium. On the other hand, it may be a metabolically active 
organ and secrete pro-inflammatory cytokines (93,94). Several cross-sectional studies have 
suggested a positive relation between an increased pericardial fat volume and coronary 
artery disease and insulin resistance in obese patients with or without T2DM (95-97).
QuALiTy Of LifE (QOL)
Several studies have shown that patients with T2DM have a worse Quality of Life (QoL) as 
compared to healthy controls. Lower QoL scores were associated with the use of insulin, the 
presence of diabetic complications or co-morbidities, physical inactivity and poor glycemic 
control. As in the normal population, socioeconomic status, demographic location and age 
are also of influence (98-101).
Obesity per se is also associated with a diminished quality of life. This is due to symptoms 
of obesity-related diseases, a negative general health perception, restricted physical activ-
ity, decreased self-image and a decline in social functioning. An improvement in QoL can 
increase patients’ compliance with their diabetes treatment and enhances their commitment 
to self-management, resulting in positive adjustments in lifestyle and diabetes care (101).
DiET-inDuCED wEighT LOSS (uSing VEry LOw CALOriE DiETS)
Weight reduction with diet and exercise is one of the cornerstones in the treatment of obese 
and T2DM patients. Weight loss improves morbidity associated with obesity such as insulin 
resistance, dyslipidemia and hypertension (77,102-104). In obese patients a substantial 
energy restriction for a longer period of time is necessary to achieve weight loss. Moreover, 
in obese T2DM patients substantial weight loss is needed to improve peripheral insulin 
sensitivity, the mainstay of glucose disposal. Eight percent weight loss improved hepatic 
but not skeletal muscle insulin resistance (105) while 9-11% weight loss slightly (106) and 
20% weight loss greatly improved peripheral insulin sensitivity (107). To achieve such energy 
restriction and weight loss very low calorie diets (VLCD) can be used. VLCDs contain 800 kcal/
day or less. Usual food intake is completely replaced by specific foods or liquid formulas. 
Weight loss on VLCDs averages 1.5 to 2.5 kg/week; total loss after 12 to 16 weeks averages 










































day, which lead to weight losses of 0.4 to 0.5 kg/week and an average total loss of only 6 to 
8 kg in 12 to 16 weeks.
Studies show that VLCDs can be used safely in obese insulin-dependent T2DM patients even 
up to a year (107). Already after 2 days of a VLCD, basal EGP declines (108). VLCD-induced loss 
of 50% of the excess weight significantly improves hepatic and peripheral insulin sensitivity. 
The more than 100% increase in insulin-stimulated glucose disposal was accompanied by an 
improvement in insulin signaling at the cellular level. Both basal and insulin-stimulated phos-
phorylation of AS160 improved after the loss of 50% of the excess weight by the VLCD (107).
Some (101,109,110) but not (111) all investigators have found an improvement in QoL after 
diet-induced weight loss. This was mainly due to a reduction in symptoms of the diseases 
associated with excess weight such as low self-image and joint pain. Long-term studies on 
the effect of diet-induced weight loss on QoL in obese T2DM patients are lacking.
Diet-induced weight loss induces a decline in low-grade inflammation (as expressed in 
hsCRP levels), both in obese non-diabetic subjects as well as in obese T2DM patients (112-
114). No data is available on the specific effect of long-term VLCDs on low-grade inflamma-
tion in T2DM.
Diet-induced weight loss might decrease ectopic fat depositions and hereby decrease the 
harmful effects of these excess lipids in non-adipose tissues. Indeed, a decrease in IMCL accu-
mulation following weight loss has been shown in obese subjects and obese T2DM patients 
by some but not all investigators (107,115-117). Even a relatively small drop in BMI consid-
erably reduces hepatic triglyceride content as measured by proton magnetic resonance 
spectroscopy (1H-MRS). The main reduction in hepatic TG content already occurs in the first 
two weeks of the diet (116,118). This is associated with improved hepatic insulin resistance 
as measured by the hyperinsulinaemic euglycaemic clamp technique (78,105,119,120). The 
effect on myocardial TG stores following weight loss in obese T2DM patients has not yet been 
studied.
Long-term maintenance of weight loss with VLCDs is not very satisfactory and is no better 
than with other forms of weight reducing treatment with the exception of bariatric surgery.
ExErCiSE
Physical activity has long been recognized as an effective interventional strategy in the 
treatment of T2DM. The current guidelines for the treatment of diabetes from the ADA, The 
European Association for the Study of Diabetes (EASD) or the American College of Physi-
cians (ACP) all firmly recognize the therapeutic strength of exercise interventions. The ADA 
states that “to improve glycemic control, assist with weight maintenance, and reduce risk of 
CVD, at least 150 min/week of moderate-intense aerobic physical activity is recommended 









































Introduction and outline of the thesis
Prolonged application of either endurance or the combination of resistance- and 
endurance-type exercise training has been shown to increase whole body insulin sensitiv-
ity and improve cardiovascular risk profile in obese T2DM and non-diabetic subjects. This 
is attributed to the concomitant induction of modest weight loss, the up-regulation of 
GLUT4 via non-insulin mediated pathways (i.e. adenosine monophosphate-activated kinase 
(AMPK)), improved nitric oxide-mediated skeletal muscle blood flow, and the normalization 
of blood lipid profiles (123-127). However, studies assessing the effect of exercise training in 
long-standing, insulin-dependent T2DM patients are lacking since these patients are usually 
unable to perform a reasonably intensive exercise program. Literature regarding the effect of 
exercise on QoL in patients with T2DM is conflicting. Exercise can either improve QoL because 
it increases physical fitness and is associated with increased social activity or it can decrease 
QoL due to an increase in body or joint pain, or the negative perception of high psychological 
demands and pressure of participating in an exercise program (128-131).
The effects of acute and chronic exercise are different with respect to the effect on low-
grade inflammation (132,133). Acute exercise can elicit a pro-inflammatory response whereas 
chronic exercise is thought to mediate an anti-inflammatory effect (134). However, in several 
long-term exercise studies the effects on low-grade inflammation were less clear as they 
showed an improvement of hsCRP and IL6 without effects on TNFα levels.
OuTLinE ThESiS
In previous studies we showed that 50% reduction of excess body weight in obese insulin-
dependent T2DM patients using a VLCD without an exercise program significantly improved, 
but not normalized hepatic and peripheral insulin resistance (107). In these studies ectopic 
fat depositions, mitochondrial capacity, QoL and low-grade inflammation were not studied. 
Therefore in this thesis, we studied both short and long-term effects of addition of exercise 
to a 16-week VLCD on insulin sensitivity, ectopic fat depositions, QoL and low-grade inflam-
mation. Our study population consisted of obese insulin-dependent T2DM patients, who still 
had endogenous insulin secretion as measured by a 1 mg glucagon stimulation test.
Our first aim was to systematically review the literature to look at the effect of diet-induced 
weight reduction and exercise on ectopic fat depositions in the liver, skeletal muscle and 
heart and the function of these organs (hepatic and peripheral insulin sensitivity and cardiac 
function) (Chapter 2).
The second aim was to evaluate whether the addition of exercise had extra beneficial 
effects on insulin sensitivity. Our a priori hypothesis was that addition of exercise would 
further improve and might even normalize insulin sensitivity in T2DM patients. We therefore 
studied both hepatic and peripheral insulin sensitivity before and after the 16-week inter-










































and [6,6-2H2]-glucose). In addition, muscle biopsies were taken to evaluate the (differential) 
effects of the two interventions on insulin signaling at the myocellular level. Importantly, we 
also evaluated the possible additional effects of an exercise program on mitochondrial copy 
number (muscle biopsy), maximum aerobic capacity (incremental cyclo-ergometer exercise 
test) and substrate (lipid and glucose) oxidation (indirect calorimetry with a ventilated hood) 
(Chapter 3).
The third aim was to evaluate long-term effects (18 months) on weight en glycemic control 
of a 16-week VLCD with or without exercise, and to evaluate the (differential) effects of the 
two interventions (Chapter 4).
Improvement of QoL in T2DM patients is an important treatment goal. Interventions aimed 
at improving the perception of patients of their physical and mental health can enhance their 
commitment to self-management and adherence to therapy that will lead to positive lifestyle 
changes and better diabetes control. Therefore, the fourth aim was to evaluate whether QoL 
could be improved or even normalized using a 16-week VLCD with or without exercise in 
obese T2DM patients. The both short and long-term (18 months) results of a 16-week VLCD 
with or without exercise on QoL are described in Chapter 4. QoL of the patients was com-
pared to that of a healthy lean and healthy obese control population.
Chronic low-grade inflammation is a pathogenetic factor in the development of insulin 
resistance and T2DM. Diet and exercise have been recognized to control T2DM and to amelio-
rate the classic CVD risk factors, such as hyperlipidemia and hypertension (7,135). Reduction 
in bodyweight in obese subjects is associated with a decline in hsCRP levels, and hence low-
grade chronic inflammation. However, it is unclear whether exercise has additional beneficial 
effects, besides the weight loss effect, on chronic low-grade inflammation. Most physical/
fitness studies have been cross-sectional in nature. Therefore, the fifth aim was to study 
both the short- and long-term effect of a 16-week VLCD with or without exercise in obese 
insulin-dependent T2DM patients on low-grade inflammation and cardiovascular risk factors 
(Chapter 5).
Our sixth aim was to evaluate both short (Chapter 6) and long-term (Chapter 7) effects of 
a 16-week VLCD with or without the addition of exercise on quantity and functional effects 
of ectopic fat depositions in the heart. To this end a subpopulation of the study patients was 
studied before, directly after and 18 months after the intervention. Ectopic fat deposition 
in the heart (intramyocardial TG content) was measured using 1H-MRS and was related to 
function of the heart.
Our last and seventh aim was to examine the short (Chapter 6) and long-term (Chapter 
8) effects of a 16-week VLCD with or without the addition of exercise on quantity of visceral 
and subcutaneous fat mass and ectopic fat depositions (in the liver and the pericardium). To 
this end magnetic resonance imaging (MRI) was used to measure pericardial fat, visceral and 
subcutaneous fat mass and 1H-MRS for hepatic TG content.
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Obesity predisposes to the development of insulin resistance, type 2 diabetes mellitus 
(T2DM) and cardiovascular disease. In obese subjects that develop insulin resistance, adipose 
tissue dysfunction plays a role, causing redirection of triglycerides (TG) towards non-adipose 
tissues. If in these tissues TG supply exceeds oxidative capacity intracellular lipid accumula-
tion occurs. Ectopic fat is defined as storage of TG in tissues other than adipose tissue, that 
normally contain only small amounts of fat, such as the liver, skeletal muscle, heart and 
pancreas. The consequences of ectopic fat accumulation depend on the specific cell type 
and organ in which TG are deposited. Ectopic fat in the liver and muscle are positively cor-
related with insulin resistance and T2DM. Myocardial steatosis refers to TG accumulation in 
the myocardiocytes and is associated with impaired diastolic function. In this review we will 
discuss the consequences of ectopic fat accumulation in the liver, muscle and heart and, if 
known, the underlying pathophysiological pathways. In addition, we will discuss the effect of 
diets with or without exercise on these ectopic fat localizations and the effect of diminishing 









































Ectopic fat and insulin resistance
inTrODuCTiOn
The amount of people with obesity has increased dramatically over the past decades to 
an estimated number of 400 million adults worldwide with a projected 700 million in 2015 
(http://www.who.int/mediacentre/factsheets/fs311/en/index.html). Obesity predisposes to 
the development of insulin resistance, type 2 diabetes mellitus (T2DM) and cardiovascular 
disease (CVD) (1-6). However, about 30% of obese men and women are metabolically healthy 
(7), that is, do not have hypertension, dyslipidemia or disturbances in glucose metabolism. 
Vice versa, these metabolic abnormalities occur in 20-30% of normal weight people.
Adipose tissue consists of adipocytes and the so-called stromal-vascular fraction that 
encompasses blood vessels and stroma with macrophages. Adipose tissue has the unique 
capacity to store large amounts of energy in the form of triglycerides (TG). Before long, it has 
been presumed that this was the only function of adipose tissue. However, adipose tissue 
acts as an endocrine organ by secreting various hormones and cytokines (also referred to 
as adipokines) with effects on glucose and lipid metabolism and energy homeostasis (8). 
It now appears that in those obese subjects that develop insulin resistance, adipose tissue 
dysfunction plays a role as reviewed by Bluher (9). Adipose tissue dysfunction is character-
ized among others by large adipocytes, secretion of adipokines with a pro-inflammatory 
profile and ectopic fat deposition. Ectopic fat is defined as storage of TG in tissues other than 
adipose tissue, that normally contain only small amounts of fat, such as the liver, skeletal 
muscle, heart and pancreas.
The cause for adipose tissue dysfunction and ectopic fat storage is largely unknown. Bluher 
recently proposed a model in which genetic and environmental factors lead to adipocyte 
hypertrophy, hypoxia and endoplasmatic reticulum stress causing inflammation within 
adipose tissue (via attraction of macrophages) and a different adipokine secretion profile 
(9). For example, tumor necrosis factor alpha (TNFα) and interleukin 6 (IL6) impair adipocyte 
differentiation, reduce lipid accumulation and increase lipolysis in adipocytes. Hence, lipids 
are redirected towards non-adipose tissues. If in these tissues lipid supply exceeds oxidative 
capacity intracellular lipid accumulation occurs.
 The consequences of ectopic fat accumulation depend on the specific cell type and organ 
in which TG are deposited. Ectopic fat in the liver (10) and muscle (11) are positively cor-
related with insulin resistance and T2DM. Myocardial steatosis refers to TG accumulation in 
the myocardiocytes and is associated with impaired diastolic function (12). Recently, increas-
ing interest has focused on fat deposition around the heart: epicardial and pericardial fat. 
In cross-sectional studies pericardial fat accumulation is associated with coronary artery 
disease (13) and related to whole body insulin resistance (14). As to the existence and clinical 
consequences of lipid accumulation in the pancreas controversy exists as elegantly reviewed 
recently (15). Ectopic fat depositions can be measured with several techniques. Traditionally, 










































studies use non-invasive methods such as computertomografie (CT), ultrasound and proton 
magnetic resonance spectroscopy (1H-MRS) (Figure 1).
 In this review we will discuss the consequences of fat accumulation in the liver, muscle and 
heart and, if known, the underlying pathofysiological pathways. In addition, we will discuss 
the effect of diet with or without exercise on these ectopic fat localizations and the effect of 
diminishing ectopic fat on insulin resistance in obesity and T2DM.
METhODS
The following databases were searched: PubMed (1949 to November 2010), EMBASE (OVID-
version, 1980 to November 2010), Web of Science (1945 to November 2010), and Cochrane 
Library (1990 to November 2010). The search strategy consisted of the AND combination of 
three main concepts:
1. Type 2 Diabetes Mellitus, Obesity, or Insulin Resistance;
2. Weight Loss, Diet or Exercise;
3. Ectopic Fat.
For these three concepts, all relevant keyword variations were used. References were limited 
to human studies, adults, written in English or Dutch. In addition, only studies that used 
techniques that can quantify the amount of lipid accumulation and measured insulin sen-
sitivity were included. Studies using surrogate markers for lipid accumulation (e.g. alanine 
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Ectopic fat and insulin resistance
aminotransferase (ALT) or aspartate aminotransferase (AST) as a proxy for hepatic steatosis) 
were excluded. Hypocaloric diets are defined as containing less calories than required for 
energy demands and usually contain 1000-1200 kcal/day. Very low calorie diets (VLCD) typi-
cally contain less than 800 kcal/day.
SkELETAL MuSCLE
Intramyocellular lipids and peripheral insulin resistance
Several factors are involved in skeletal muscle insulin resistance: muscle fibre type (less type 
I, oxidative fibres), impaired capillary recruitment, diminished free fatty acid (FFA) oxidative 
capacity and an increased plasma FFA concentration (leading to perturbations in insulin sig-
naling). The latter 2 conditions are involved in accumulation of intramyocellular lipid (IMCL). 
FFAs are taken up by the cell mainly by protein-mediated membrane transport (CD36, fatty 
acid transport protein (FATP)), along with passive diffusional uptake (16). Inside the cell fatty 
acid binding protein (FABPc) is the most important cytosolic protein for guiding long-chain 
fatty acids in the cell to places of oxidation or esterification. Long-chain fatty acyl-CoA is taken 
up by the mitochondria via carnitine-palmitoyl transferase 1 (CPT1). Inside the mitochondria 
β-oxidation and further degradation in the tricarboxylic acid cycle takes place. Therefore, 
IMCL accumulation occurs as a consequence of continuous oversupply of FFAs (caused by 
enhanced lipolysis, adipocyte dysfunction) together with an impairment in FFA oxidation in 
the mitochondria.
Accumulation of IMCL is associated with insulin resistance (17-20) and T2DM (11). However, 
it is not synonymous with the condition given the fact that endurance-trained athletes, who 
are highly insulin sensitive, also have a high IMCL content (11). Rather, the capacity to oxidize 
IMCL determines whether they represent a physiological or a pathological role as reviewed 
by van Loon and Goodpaster (21). In endurance-trained athletes IMCL serve as a readily avail-
able energy source. The close proximity of lipid droplets to the mitochondria supports this 
hypothesis. In these athletes, IMCL are not deleterious because of the increased capacity to 
oxidize lipids.
T2DM is characterized by a low oxidative capacity which leads to accumulation of lipids 
and intermediates of fatty acid metabolism such as long chain acyl-CoA (LC-CoA), diacyl-
glycerol (DAG) and ceramides. These fatty acid metabolites induce a sustained activation 
of serine/threonine kinases such as protein kinase C (PKC) isoforms, IКB-kinase-β and Jun 
N-terminal kinase, which phosphorylate insulin-receptor substrate (IRS) 1 on serine residues 
(22). Serine-phosphorylated forms of IRS1 cannot associate with and activate phosphatidyl-
inositol-3-kinase (PI3K), resulting in a decreased glucose transporter 4 (GLUT4) regulated 










































The fact that impaired oxidation is involved led to the speculation that mitochondrial 
dysfunction is the cause of IMCL accumulation and the ensuing insulin resistance. Indeed, 
a decreased mitochondrial density and/or function has been reported in insulin-resistant 
offspring of T2DM patients (23-25) and T2DM patients (26-29). However, three of these stud-
ies reported decreased mitochondrial function at normal IMCL levels (27-29) suggesting 
that impaired mitochondrial function is not a prerequisite for IMCL accumulation. Rather, 
it might be that mitochondrial dysfunction is the consequence of the increased amount of 
fatty acid metabolites, for example via the formation of lipid peroxides (30). In that case it 
might be that the lipid-induced mitochondrial dysfunction induces progressive deterioration 
of oxidative capacity and further accumulation of lipid intermediates in the skeletal muscle 
cell. Further investigations are warranted to elucidate which one is cause or consequence: 
IMCL or mitochondrial dysfunction. In this review we focus on IMCL and will not elaborate on 
mitochondrial function.
In summary, an imbalance between fatty acid supply and oxidation (the contribution of 
esterification is very low) leads to accumulation of IMCL and lipid intermediates that interfere 
with insulin signaling and hence reduce insulin-stimulated glucose uptake in the skeletal 
muscle cell. Therefore, IMCL are associated with insulin resistance with the exception of 
endurance-trained athletes.
effect of diets on IMCL accumulation
In a 6-month study in normal glucose tolerant (NGT) obese subjects, 25% calorie restriction 
(amount of calories not mentioned) leading to 10% weight loss (8 kg) had no effect on insulin 
sensitivity or IMCL. A parallel group that received a low calorie diet (890 kcal/day) but also 
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Ectopic fat and insulin resistance
had moderate weight loss (14%,11 kg) showed a significant improvement in insulin sensitiv-
ity as measured by the insulin-modified frequently sampled intravenous glucose tolerance 
test and a tendency to decreased IMCL (measured by 1H-MRS) that was not significant (31). In 
another 6-month study in morbidly obese NGT subjects, 10% weight loss (14 kg) by hypoca-
loric diet (1200 kcal/day) also had no significant effect on insulin sensitivity as measured with 
the hyperinsulinaemic euglycaemic clamp technique nor on IMCL as measured by skeletal 
muscle biopsies (32). In obese T2DM patients, a similar percentage of weight loss (10%, 8 kg) 
with a 1200 kcal/day very low fat (3%) diet during an average of 7 weeks, also had no effect 
on peripheral insulin sensitivity as measured with the hyperinsulinaemic euglycaemic clamp 
technique nor on IMCL (measured by 1H-MRS) (33).
Moderate weight loss of 10-11% using a VLCD (600-800 kcal/day) for around 8 weeks in 
obese NGT persons improved insulin sensitivity as measured by homeostasis model assess-
ment insulin resistance index (HOMA-IR) but had no effect on IMCL as measured by skeletal 
muscle biopsies (34). On the contrary, one study (35) showed a significant decrease in IMCL 
accumulation but no significant effect on peripheral insulin sensitivity after a 6-days VLCD 
(700 kcal/day) with a weight loss of 2.5% (in T2DM patients) and 5% (in obese subjects) 
compared to baseline. It should be noted however IMCL were measured by 1H-MRS in the 
soleus muscle which has different characteristics than the vastus lateralis muscle. All other 
studies measured IMCL by muscle biopsy or 1H-MRS of the vastus lateralis muscle. In addi-
tion in this study, a very high insulin infusion rate (200 mU/m2/min) was used during the 
hyperinsulinaemic euglycaemic clamp, leading to supraphysiological insulin concentrations 
and hence higher glucose uptake rates as compared to other studies.
Moderate weight loss with hypocaloric diets seems to have no effect on IMCL or on insulin 
sensitivity in either obese or obese T2DM patients (31-33,36-39). More pronounced weight 
loss using a VLCD leads to a decrease in IMCL. A prolonged VLCD (450 kcal/day, on average 
17 weeks duration) leading to 50% reduction of excess weight (mean 22 kg) in obese insulin-
treated T2DM patients led to a significant improvement of both peripheral insulin sensitivity 
as well as IMCL in skeletal muscle biopsies (40) (Table 1).
effect of diet and exercise on IMCL accumulation
Several studies investigated the effect of the addition of exercise to a hypocaloric or VLCD in 
obese NGT or T2DM patients. One group investigated the effect of a hypocaloric diet (goal 
weight loss 7 kg) with or without exercise (3 to 5 times weekly at 60-70% of maximal heart 
rate) in obese NGT (41) and obese T2DM patients (42), respectively. The obese NGT groups 
(diet-only and diet with exercise) both lost ~ 10% of body weight (9-10 kg) and had equal 
increases in glucose disposal rates. IMCL decreased in the diet-only group, not in the diet 
with exercise group. In the other study of the same group, 10 obese T2DM patients lost 7% 
of body weight (7 kg) and had an 54% increase in insulin-stimulated glucose disposal and a 





















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































(31,43), obese impaired glucose tolerant (IGT) (44) or obese T2DM patients (38) consistently 
showed increased insulin sensitivity with no differences between diet-only or diet with exer-
cise group (with the exception of (31) all measured with the hyperinsulinaemic euglycaemic 
clamps) The effect on IMCL in these studies was less consistent showing either no effect 
(31,43) or a decrease (38,44) in IMCL accumulation (Table 1).
effect of exercise on IMCL accumulation
Few studies have addressed the effect of exercise-only on IMCL and insulin sensitivity. A 
4-month exercise program (4-5 times weekly 45 minutes at 75% of maximal heart rate) in 
obese NGT subjects increased insulin-stimulated glucose disposal as well as IMCL (by 21%) 
as measured by muscle biopsy (45). Interestingly intramuscular ceramide and DAG levels 
decreased. No control group participated in the study. A study in obese subjects with IGT 
investigated the effect of exercise-only (5 days/week 60 min at 75% maximum aerobic capac-
ity (Vo2max)) vs. diet (circa 1300 kcal/day) combined with exercise for 12-week. The diet with 
exercise group lost more body weight but the improvement in peripheral insulin sensitivity 
and the decline in IMCL were similar in the two intervention groups (44). Recently the ef-
fect of a 12-week combined aerobic and resistance exercise program was investigated in 18 
T2DM (body mass index (BMI) 30 kg/m2, HbA1c 7.2%, age 59 years) and 20 healthy controls 
matched for age, body weight and BMI. The intervention had no effect on body weight (46). 
Exercise increased insulin-stimulated glucose disposal only in the T2DM patients but not to 
levels comparable to that in the control group. In addition, exercise had no effect on IMCL 
in the controls and increased IMCL in the T2DM patients along with an increase in insulin-
stimulated glucose oxidation and suppression of fat oxidation (Table 1).
Conclusion
Moderate weight loss has no effect on IMCL but can improve peripheral insulin sensitivity if a 
VLCD is used. Larger weight losses are needed to improve both peripheral insulin sensitivity 
and deplete IMCL stores. With respect to the effect of exercise on IMCL the story is more 
complex. Athletes have increased IMCL stores that serve as a readily available energy supply 
and training further increases IMCL in healthy subjects. On the other hand, sedentary insulin-
resistant subjects also have increased IMCL, caused by diminished oxidative capacity. These 
are associated with increased intramyocellular lipid intermediates that interfere with insulin 
signaling and other cellular processes. Exercise training in these subjects either increases, 
decreases or has no effect on IMCL accumulation. This is probably associated with the stage 
of disease (can fat oxidation and/or mitochondrial function be restored) as well as with the 
intensity of the exercise program and sort (aerobic/resistance) exercise. Overall, studies 
show that exercise improves peripheral insulin sensitivity. Factors involved are a reduction 
in lipid intermediates and hence improved insulin signaling and mitochondrial function, 









































Ectopic fat and insulin resistance
hypoxia activate adenosine monophosphate-activated protein kinase (AMPK) which leads to 
increased GLUT4 translocation independent of insulin.
LiVEr
Intrahepatic lipids and insulin resistance of the liver
Accumulation of fat in the liver in the absence of excessive alcohol ingestion is referred to 
as non-alcoholic fatty liver disease (NAFLD). The spectrum of liver abnormalities within this 
entity ranges from hepatic steatosis with or without mild increases in serum AST/ALT to non-
alcoholic steatohepatitis (NASH) with or without fibrosis, cirrhosis and incidental hepatocel-
lular carcinoma. The world-wide estimated prevalence in the general population is about 
20%, with large differences across countries (47). There is a strong association with obesity. A 
cross-sectional study in 1515 severely obese NGT subjects showed abnormal liver biopsies in 
90% of people (48). The majority had hepatic steatosis, but one third had portal inflammation 
and fibrosis. A prospective study demonstrated a 4-times increased risk to develop hepatic 
steatosis in obese persons as compared to controls (49).
Non-invasive methods for measuring hepatic TG content such as ultrasound, CT and 
1H-MRS cannot distinguish NAFLD from NASH and fibrosis. A definite diagnosis can only 
be made by liver biopsy with histologic examination. The cut-off value for abnormal lipid 
accumulation in the liver has been defined as more than 5% of liver volume or when more 
than 5% of hepatocytes contain visible intracellular lipids (50). Two recent studies in respec-
tively a NGT mixed (Hispanic, non-Hispanic, African American) population (51) and a lean 
Caucasian population (52) found that the 95th percentile for hepatic TG content was 5.6% 
and 3% respectively, using 1H-MRS. The Pathology Committee of the NASH Clinical Research 
Network designed and validated scoring system of 14 histological features examining liver 
biopsy findings detailing steatosis, fibrosis, inflammation, and liver cell injury (53). An NAFLD 
activity score > 5 was universally associated with NASH.
Fat accumulation in the liver is associated with hepatic insulin resistance as well as with 
peripheral insulin resistance in skeletal muscle and adipose tissue (10,54-56). In a large 
European cohort of 1307 middle-aged NGT subjects, patients with a high fatty liver index 
(an estimate for hepatic steatosis based on an algorithm including BMI, waist circumference, 
TG, and gamma-glutamyltransferase) had a lower glucose disposal rate as measured by a 
euglycaemic hyperinsulinaemic clamp as well as higher FFA levels at the end of the insulin 
infusion (57). The latter is suggestive for decreased insulin sensitivity of adipose tissue. Ko-
renblat et al. (54) found a negative correlation between hepatic insulin sensitivity measured 
by the hyperinsulinaemic euglycaemic clamp and hepatic TG content (measured by 1H-MRS) 
in 42 nondiabetic obese subjects. Indeed, a multivariate linear regression analysis found that 










































adipose tissue, independent of BMI and percent body fat. Some claim that the amount of 
hepatic TG content is directly correlated with the severity of insulin resistance but this cannot 
be confirmed by others.
 The mechanism behind hepatic TG accumulation and the development of hepatic insulin 
resistance is similar to that described for skeletal muscle (22,58). An increase in DAG in he-
patic cells leads to activation of PKC, leading to decreased insulin receptor kinase activity and 
subsequently lower insulin-stimulated IRS2 tyrosine phosphorylation and lower IRS2–associ-
ated PI3K-activity which results in reduced insulin stimulation of glycogen synthase activity. 
This ultimately leads to decreased insulin-stimulated hepatic glucose uptake and reduced 
insulin suppressibility of hepatic glucose production. Furthermore, reduced activity of AKT2, 
a protein kinase downstream of IRS and PI3K, results in decreased phosphorylation of the 
forkhead box O (FOXO) transcription factor, allowing it to enter the nucleus and activate the 
transcription of the rate-controlling enzymes of gluconeogenesis. The result is increased 
hepatic glucose production and decreased hepatic glucose uptake, which both contribute to 
increased plasma glucose levels (Figure 3).
effect of diet on intrahepatic lipids
Non-invasive techniques like CT and 1H-MRS have shown that weight loss by nutritional 
interventions can result in a large decrease in hepatic TG content in obese and T2DM subjects 
(33,37,38,59-63). Because of the different populations and differences in baseline hepatic 
TG content, studies are not well comparable with respect to the individual effect of level of 
caloric restriction and/or amount of weight reduction on loss of hepatic TG content. Nonethe-
less, it has been shown that even a relatively small drop in BMI of 3-6% is associated with a 
Figure 3. Cellular processes leading to insulin resistance in the liver cell.
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β –oxidation ↓
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FATP: fatty acid transport protein; FFA: free fatty acid; LC-CoA: long chain fatty acid-CoA; DAG: diacylglycerol; PKC: protein kinase C; IR: insulin 
receptor; IRS: insulin receptor substrate; PI3K: phosphatidylinositol 3-kinase; GSK3: glycogen synthase kinase 3; FOXO: forkhead box protein O; 









































Ectopic fat and insulin resistance
considerable reduction in hepatic TG content of 34-40% (37,60,61). The main reduction in 
hepatic TG content already occurs in the first two weeks of dietary restriction (38,59). The 
percentual decline in hepatic TG content positively correlates with the hepatic TG content at 
baseline, as patients with a high hepatic TG content at start of the diet lose relatively more TG 
than patients with low hepatic TG content, with the same amount of weight loss (59,60,62). 
Two studies measured both hepatic TG content and hepatic insulin sensitivity with a hyper-
insulinaemic euglycaemic clamp (33,63). In obese (BMI 30.1 kg/m2) T2DM patients, 7 weeks 
of a liquid formula diet (1200 kcal/day) led to a weight reduction of 8%. Hepatic TG content 
decreased by 81% and insulin mediated suppression of the endogenous glucose production 
(EGP) improved substantially (33). Viljanen et al. (64) found similar results in obese NGT sub-
jects (BMI 33.7 kg/m2). In this 6-week study a VLCD (550 kcal/day) led to a weight reduction of 
around 11 kg, a decrease in hepatic TG content of 60% together with a 40% decrease in basal 
EGP and hepatic insulin resistance index as well as a diminished hepatic FFA uptake.
Although the abovementioned studies clearly show that diet-induced weight loss leads 
to a decrease in hepatic TG content, the effect of this decrease in hepatic TG content on liver 
histology (i.e with liver biopsies) has only been scarcely studied. In obese patients with NASH 
moderate weight loss over a 12-month period, obtained with dietary advices only, led to 
an improved steatosis score in 9 of the 15 subjects. The improvement was associated with 
greater weight loss as compared to the patients that showed no change in steatosis (64). 
Another study in 15 patients with obesity and NASH combined a hypocaloric diet with 
exercise during 12 weeks while 10 obese subjects with NASH served as controls. The BMI 
decreased by 3 kg/m2 in the intervention group and the steatosis score decreased from 2.3 to 
1.3 (30-50% steatosis to less than 30%) while no changes were observed in the control group 
(65). In contrast, severe caloric restriction during 8 months in 41 morbidly obese (BMI 43.3 
kg/m2) subjects leading to an impressive median weight loss of 34 kg (-27% of BMI) showed 
normalization of liver architecture in 19 patients (66). However, they also found an increase in 
hepatic inflammation and fibrosis in some patients, this was associated with a greater weight 
loss and elevated FFAs.
effect of diet and exercise on intrahepatic lipids
Studies on the effect of exercise on hepatic steatosis are scarce (review (67)). Most of these 
combine an exercise program with a hypocaloric diet. Both in obese as well as in T2DM 
patients these combined interventions led to a reduction of hepatic steatosis. Even a 2-week 
intervention with minimal weight reduction led to a significant 20% reduction in hepatic TG 
content in T2DM patients (38). However, since moderate weight loss alone already reduces 
hepatic steatosis the role of exercise is uncertain. Larson-Meyer studied a diet-only (25% 
calorie restriction (CR)) vs. a diet (12.5% CR) combined with exercise (12.5% CR) obese NGT 
group. In this 6-month study no additional effect of exercise upon the diet was found at an 










































effect of exercise on intrahepatic lipids
Only one study has investigated the influence of exercise alone on hepatic TG content in 
overweight (BMI 27.7 ± 0.5 kg/m2) sedentary men (68). After a 6-week aerobic exercise pro-
gramme (60-85% of VO2max for a minimum of 20 min. at least three times per week) without 
significant effect on body weight no changes were found in hepatic TG content as measured 
by 1H-MRS, although both peripheral and hepatic insulin sensitivity (measured by the hyper-
insulinaemic euglycaemic clamp) improved. In this study, the hepatic TG content was already 
low at the start of the intervention and the amount of exercise was modest. Nevertheless, this 
study suggests that exercise alone (without weight loss and/or dietary caloric restriction) has 
beneficial effects on hepatic insulin resistance. The mechanism by which exercise improves 
hepatic insulin resistance is probably different than that in muscle. Indirect signals via factors 
mediated by the muscle and adipose tissue and a decrease in circulating FFAs are thought 
to play a role.
EPiCArDiAL AnD PEriCArDiAL fAT
Pericardial fat is the adipose tissue surrounding the heart. It consists of two layers: epicardial 
fat (visceral fat) originating from mesothelial cells and paracardial or mediastinal fat, originat-
ing from mesenchymal cells (69). For more in depth information on the anatomic and patho-
physiologic role of pericardial fat we refer to two excellent reviews on this subject (69,70).
Several functions have been proposed for epicardial fat tissue (70). Scientific proof is how-
ever rather difficult to obtain since most animal species have very little epicardial fat (71). In 
guinea pigs, rates of lipolysis and lipogenesis were 2-fold higher in epicardial fat than in other 
fat depots. This led to the assumption that epicardial fat might act as a buffer to protect the 
myocardium from highly toxic fatty acid levels and to provide fatty acids as a direct energy 
source in times of energy demand (71,72). Coronary arteries are embedded in epicardial fat 
so that another putative function might be to protect the coronary arteries from the tension 
and torsion induced by the arterial pulse wave and provide an environment in which the 
coronary arteries can easily expand. This fat compartment also acts as a metabolically active 
organ, secreting cytokines (73,74).
Several cross-sectional studies have suggested a positive relation between an increased 
epicardial fat volume and coronary artery disease (14,75-77). Furthermore, an increased epi-
cardial fat volume has been associated with insulin resistance in non-diabetic obese patients 
(13) and with the presence of T2DM in a Han Chinese population (78,79).
effect of diet on epicardial fat
Two studies have examined the effect of diet-induced weight loss on epicardial fat. Kim et 









































Ectopic fat and insulin resistance
a 12-week weight loss intervention study. Epicardial fat thickness measured over the right 
ventricle wall by echocardiography decreased by 17% from baseline. Iacobellis et al. (81) 
studied 20 severely obese (BMI 45 ± 5 kg/m2) subjects (probably including patients with IGT 
or T2DM) who followed a 6-month low calorie diet (900 kcal/day) and lost 20% (25 ±10 kg) 
of bodyweight. Epicardial fat decreased by 32% from baseline. This was accompanied by an 
improvement in left ventricular mass and diastolic cardiac function. The change in diastolic 
function was also positively correlated with the change in epicardial fat thickness. Moreover, 
in 15 obese patients with T2DM, we found a significant decrease in pericardial fat after weight 
loss with a 16-week VLCD, measured with MRI (unpublished data) (82).
effect of exercise on epicardial fat
To date, only two studies examined the effect of (aerobic) exercise on epicardial fat (83). 
In one study, 24 obese NGT (BMI 30.7 ± 3.3 kg/m2) middle-aged Japanese men followed a 
supervised exercise program for 3 months. The exercise intensity was gradually increased in 
4 weeks from 50-60 to 60-70% of the maximum heart rate 3 days/week 60 minutes, which was 
continued for the remainder of the study. Following the intervention the BMI decreased by 
4.3 ± 3.0% (circa -1 kg/m2) and VO2max increased by 20%. Epicardial fat thickness measured by 
echocardiography over the free wall of the right ventricle decreased significantly. The change 
in visceral adipose tissue (-15%) was significantly correlated with the change in epicardial 
adipose tissue (-8.6%).
In the other study, 32 obese postmenopausal women were randomized to diet-only or diet 
combined with moderate or intensive exercise for 20 weeks. All three groups had a similar 
15% reduction in bodyweight and a 17% reduction in pericardial fat. However, no differences 
were observed between the diet-only or diet with exercise group (84).
MyOCArDiAL TrigLyCEriDE COnTEnT
In addition to the epicardial/pericardial fat depositions, TG can also be stored within the car-
diomyocytes. This is referred to as myocardial TG content or myocardial steatosis. Myocardial 
TG accumulation can be measured with great sensitivity by 1H-MRS (85). Patients with IGT 
and T2DM have an increased myocardial TG content compared to obese and lean controls 
(12,86,87). This accumulation of myocardial TG is a result of excessive fatty acid uptake rela-
tive to the oxidation. If fatty acids are converted to myocardial TG, several intermediates are 
released (e.g. ceramide) which in animal models caused cardiac dysfunction (88,89). In T2DM 
patients, myocardial steatosis was associated with impaired left ventricular diastolic function 
(12). Indeed, an increased fatty acid uptake in the myocardium has been found in healthy 
obese and T2DM patients compared to healthy lean subjects (90,91). But in the one study 










































T2DM patients as compared to controls an increase, not a decrease in fatty acid oxidation was 
found. Fatty acid re-esterification was negligible but lower in T2DM patients as compared 
to the controls (91). Interestingly, neither plasma FFA levels nor myocardial blood flow was 
increased both in subjects with obesity (90) and T2DM (91) suggesting another mechanism, 
for example at the (cellular) level of the FAT/ CD36, to account for the increased fatty acid 
uptake (Figure 4).
The myocardial TG content is not static. Three days of severe caloric restriction (450 kcal/day 
to complete starvation) in healthy volunteers and patients with T2DM increases myocardial 
TG content, which is associated with a decrease in left ventricular diastolic function (92,93).
effect of diet on myocardial triglyceride content
Thirty-four obese (BMI 33.7 ±0.7 kg/m2) healthy persons underwent a 6-week VLCD (550 
kcal/day). Before and after the intervention intramyocardial TG were measured, a hyperinsu-
linaemic euglycaemic clamp was performed and either glucose uptake or fatty acid uptake 
was measured by positron emission tomography. The intervention led to a weight loss of 
11.2± 0.6 kg and a non-significant decrease in myocardial TG content of 31% (n=8, p=0.076). 
Myocardial fatty acid uptake decreased significantly. Myocardial mass and work decreased 
significantly by 7 and 26% respectively (94).
Our group investigated the effect of a 16-week VLCD (450 kcal/day) on myocardial TG 
content in obese patients with T2DM (95). We showed that a decrease in BMI (from 35.6 ± 1.2 
to 27.5 ± 1.3 kg/m2) was associated with a significant decrease in myocardial TG content and 
an improvement in left ventricular diastolic function.
Figure 4. Cellular processes in the cardiomyocyte leading to myocardial dysfunction
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Figure 4
FATP: fatty acid transport protein; FFA: free fatty acid; LC-CoA: long chain fatty acid-CoA; DAG: diacylglycerol; PKC: protein kinase C; IR: insulin 









































Ectopic fat and insulin resistance
effect of exercise on myocardial triglyceride content
No other studies regarding the effect of diet-induced weight loss and/or exercise are avail-
able. It would be interesting to study endurance trained athletes to see whether they have, 
like in skeletal muscle, higher levels of intramyocardial TG than healthy controls and whether 
this can be accounted for by impaired myocardial fatty acid oxidation, and is related with 
cardiac function.
DiSCuSSiOn
T2DM is a multifactorial disease in which genetic, environmental and lifestyle factors induce 
insulin resistance and impaired insulin secretion, ultimately leading to chronic hyperglyce-
mia and its complications. Given the association between T2DM and obesity the recent focus 
of research has been the link between them. Vague already described a link between visceral 
adipose tissue, insulin resistance and T2DM in 1947 (96). But it has not been until the start of 
the obesity and diabetic epidemic that further elaboration on his work started. This research 
revealed that adipose tissue is not merely a storage depot for TG but actively secretes a vast 
array of factors such as cytokines, metalloproteinases and adipokines that can induce inflam-
mation and insulin resistance (8).
In addition, with the advancement of radiological techniques it has become apparent that 
patients with insulin resistance and T2DM not only have a higher visceral to subcutaneous 
fat ratio as compared to healthy subjects but that TG are also stored in other organs called 
ectopic fat depositions for example in the liver, skeletal muscle, heart, and perhaps the 
pancreas (97,98). TG in the cells of these organs disrupts normal metabolic processes leading 
to increased hepatic glucose production, decreased insulin-stimulated glucose disposal and 
impaired cardiac function respectively. The consequences of elevated fatty acids and/or lipid 
accumulation in the pancreas seem to be only in order when elevated glucose levels are 
already present (15). Whether these ectopic fat storage is cause or consequence of insulin 
resistance and T2DM is currently under investigation. If ectopic fat is the cause of insulin 
resistance than it should be present already before the onset of insulin resistance (primary 
steatosis). On the other hand, when ectopic fat is the consequence of insulin resistance than 
insulin resistance should always be present. To date only cross-sectional studies have been 
performed.
Several large lifestyle intervention studies such as the Diabetes Prevention Study (99), the 
Da Qing study (100) and the Diabetes Prevention Program (101) all showed that lifestyle 
changes aimed at weight loss decrease the risk of developing T2DM by 31-58%. In patients 
already affected by T2DM, weight loss also decreased insulin resistance and improved gluco-
regulation (40). The data in this review show that substantial weight loss mobilizes ectopic 










































of that organ. Thus, a reduction in hepatic TG was accompanied by a decline in fasting EGP 
(33,63) and an improvement in the insulin-suppressibility of EGP. A decrease in myocardial 
TG (95) and epicardial fat (81) were both associated with improved diastolic cardiac func-
tion. Finally a decline in IMCLs leads to an improved insulin-stimulated glucose disposal (40). 
It should be noted however that the amount of weight loss and/or the severity of caloric 
restriction are of influence on the effect and that there seems to be a tissue-specific reaction. 
For example, around eight kilograms weight loss following a 1200 kcal/day diet for 7 weeks 
led to a decrease in hepatic TG and improved insulin sensitivity of the liver but had no effect 
on insulin-stimulated glucose disposal or IMCL in obese T2DM patients. When obese women 
with a history of gestational diabetes were subdivided in groups with high and low liver fat, 
a similar weight loss led to greater loss of hepatic fat in the high liver fat group while both 
groups lost an equal amount of visceral and subcutaneous fat (62). A prolonged VLCD in 
more severely obese insulin-dependent T2DM patients leading to around 22 kg of weight 
reduction also decreased IMCL and improved insulin-stimulated glucose disposal (40). We 
recently corroborated these findings in a similar group of patients who underwent a 16-week 
VLCD. The largest reduction occurred in hepatic TG content (-85%) whereas IMCL accumula-
tion in the skeletal muscle decreased by 38%. The relative reduction in visceral fat was larger 
than the reduction in subcutaneous abdominal fat (-60%, -45% resp.) (82). The above studies 
suggest that hepatic TG content is the most easily mobilized, followed by visceral fat. The 
tissue-specific reaction to dietary interventions is also present when, vice versa, patients 
are subjected to high-fat feeding. Three days of a high-fat high-energy diet in health young 
males greatly increased hepatic TG stores but had no effect on myocardial TG (102).
Few studies have investigated the effect of exercise per se, that is exercise without weight 
loss and/or caloric restriction. The effect of exercise varies in the different organs with respect 
to TG accumulation. In muscle, exercise can even increase IMCL. However, when this is ac-
companied with increased fatty acid oxidation this is positive and in accordance with the 
athlete’s paradox. The latter refers to the fact that endurance-trained athletes have increased 
IMCL but are very insulin sensitive. In these athletes the IMCL are a substrate source during 
exercise and the high turnover rate prevents accumulation of lipid intermediates that have a 
negative effect on insulin signaling and can form lipid peroxides. In the sedentary state, when 
metabolic flexibility is low, IMCL accumulate with the aforementioned deleterious effect 
on cellular processes. Exercise can either, increase, decrease or have no effect on IMCL but 
does improve insulin sensitivity. Apart from a decrease in lipid intermediates/increased fatty 
acid oxidation, an increase in capillary density and activation of AMPK with subsequently 
enhanced GLUT4 translocation are also involved. Exercise in combination with diet also 
depletes hepatic TG content and improves hepatic insulin sensitivity whereas the one study 
that investigated the effect of exercise alone found no effect on hepatic TG content but an 
increase in hepatic insulin sensitivity. The underlying mechanism is probably not direct but 









































Ectopic fat and insulin resistance
investigated the effect of exercise on epicardial fat: this was reduced but cardiac function 
was not measured. No studies on the effect of exercise on myocardial TG content have been 
published.
The clinical significance of measuring ectopic fat depositions after weight-loss interven-
tions is limited. Performing an MRI/1H-MRS in every patient is not practical from a logistical 
and cost perspective, especially since it has no implications for treatment at this moment.
From a scientific point of view the most intriguing question is how and why ectopic fat 
storage begins and whether this process is genetically determined or can be modified by 
measures other than the always so difficult to obtain weight loss. Therefore, it is interesting 
that exercise leads to improvements in insulin sensitivity, whereas it does not lead to de-
creases in ectopic fat. For that matter it is interesting that Europeans are relatively protected 
from (diet-induced) obesity and insulin resistance. On the other hand, aboriginals adapting 
a Western lifestyle rapidly obtain obesity and diabetes (103). Whether this is associated with 
the deposition of ectopic fat is unknown although reasonable to assume. Also the sequence 
of affected organs is unknown. The fact that people adapting a Western lifestyle develop 
obesity and T2DM suggests however that food might induce an inflammatory process. This 
of course upon a genetic background that, from an evolutionary standpoint, is set to store 
calories. Dietary intervention studies in which radiologic techniques, metabolic studies 
and tissue biopsies are combined hopefully will shed more light upon the question what 
determines why people store fat in non-fat compartments. And more importantly, what is the 
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Objective. Loss of 50% overweight using a very low calorie diet (VLCD, 450kcal/day) improves 
insulin sensitivity in obese type 2 diabetes mellitus patients. This study investigates whether 
adding exercise to the VLCD has additional benefits.
Methods. Twenty-seven obese (BMI 37.2±0.9kg/m2 (mean±SEM)) insulin-treated type 
2 diabetes mellitus patients followed a 16-week VLCD. Thirteen of them simultaneously 
participated in an exercise program (E) consisting of one-hour in-hospital training and four 
30-minute training sessions on a cyclo-ergometer weekly. Oral glucose-lowering agents 
and insulin were discontinued 3 weeks prior to and at the start of the VLCD respectively. 
Anthropometric measurements, hyperinsulinaemic euglycaemic clamp with skeletal muscle 
biopsies and peak oxygen consumption testing (VO2max) were performed before and after the 
intervention.
results. Baseline characteristics were identical in both groups. Substantial weight loss 
occurred (-23.7±1.7kg VLCD-only vs. -27.2±1.9kg VLCD+E, p=NS). The exercise-group lost 
more fat mass. Glycemic control improved considerably. Insulin-stimulated glucose disposal 
increased similarly in both study groups (15.0±0.9 to 39.2±4.7μmol.min-1.kglbm-1 VLCD-only 
vs. 17.0±1.0 to 37.5±3.5 μmol.min-1.kglbm-1 in VLCD+E), as did phosphorylation of PI3K-PKB/
AKT insulin signaling pathway. In contrast, skeletal muscle mitochondrial DNA (mtDNA) 
content increased only in the VLCD+E group (1211±185 to 2288±358, arbitrary units p=0.016 
vs. 1397±240 to 1196±179, p=NS VLCD-only group). VO2max also only increased significantly 
in the VLCD+E group (+6.6±1.7 ml.min-1.kglbm-1 vs. +0.7 ±1.5 ml.min-1.kglbm-1 VLCD-only, 
p=0.017).
Conclusions. Addition of exercise to a 16-week VLCD induces more fat loss. Exercise aug-
ments VO2max and skeletal muscle mtDNA content. These changes are, however, not reflected 









































Effect of a VLCD with and without exercise on insulin resistance
inTrODuCTiOn
In the obese type 2 diabetes mellitus patients (T2DM) insulin resistance is of pivotal impor-
tance. Caloric restriction, increasing physical activity and cognitive restructuring are the main-
stays of the treatment of obesity especially in case T2DM is present (1). Diet-induced weight 
loss in obese T2DM improves insulin resistance and phosphatidylinositol 3-kinase-protein 
kinase B/AKT (PI3K-PKB/AKT) insulin signaling in the skeletal muscle (2).
Moderate exercise (70% of maximum aerobic capacity) does not play a major role in losing 
body weight but helps to maintain diet-induced weight loss. Moderate exercise can enhance 
peripheral insulin sensitivity even without weight loss (3). Exercise plays an important role in 
improving mitochondrial capacity and aerobic fitness in healthy individuals (4).
The current study compares the effect of a very low calorie diet (VLCD) with and without 
an exercise program in obese insulin-dependent T2DM patients to elucidate whether the 
addition of exercise to a VLCD has incremental benefits in terms of weight reduction, gluco-
regulation, insulin sensitivity, myocyte morphology and mitochondrial capacity.
PATiEnTS AnD METhODS
patients
Twenty-seven sedentary (14 males, 13 females) T2DM patients were enrolled in the study. 
Clinical details are summarized in Table 1. All patients were obese (BMI >30 kg/m2) and used 
at least 20 units of insulin per day, with or without oral glucose-lowering medication. In ad-
dition, patients had to have residual beta-cell capacity, defined as a fasting plasma C-peptide 
level greater than 0.8 ng/mL and a 2-fold increase of the basal C-peptide level in response to 
administration of 1 mg glucagon intravenously (5). The residual beta-cell capacity is neces-
sary to safely stop all glucose-lowering medication.
Exclusion criteria were smoking, recent weight change, any other chronic (endocrine) con-
ditions and silent cardiac ischemia. Written informed consent was obtained from all patients. 
The study was approved by the local ethics committee.
Study design
Throughout the 16-week intervention period no blood glucose-lowering medication (both 
oral and insulin therapy), was utilized by the patients. All oral blood glucose and lipid lower-
ing medication was discontinued 3 weeks prior to the study (because of the longer half-life 
of some of the oral glucose-lowering medication). Insulin therapy was intensive during these 
three weeks to prevent hyperglycemia. One day before the start of the intervention only 
short-acting insulin was prescribed, and long-acting insulin was omitted to prevent the pres-










































After a baseline visit (outlined below), all patients started a 16-week VLCD (Modifast®, Nutri-
tion & Santé, Antwerpen, Belgium). Modifast® provides a total of ~450 kilocalories per day and 
all necessary vitamins and micronutrients, divided over 3 meals of liquid shakes. Modifast 
provides about 50 g protein, 50 to 60 g carbohydrate, 7 to 9 g lipid, and 10 g of dietary fibre.
Thirteen of the 27 subjects were randomized to follow an exercise program simultane-
ously. This exercise program consisted of at least four training sessions per week at home 
and an one-hour in-hospital training. For the home-training sessions patients had to exer-
cise at least 4 times a week for 30 minutes at 70% of their maximum aerobic capacity on a 
cyclo-ergometer. The one-hour in-hospital training entailed primarily aerobic exercise, under 
supervision of a physiotherapist. Patients in the VLCD-only group were instructed not to alter 
their pattern of physical activity.
During the 16-week intervention period patients visited the outpatient clinic weekly to 
confirm compliance by questionnaires, providing sachets of Modifast® and reading the heart 
rate monitor (Polar S610 i
tm, Polar Electro Oy, Finland), which recorded the duration, heart 
rate and intensity of every training session. Patients were instructed not to perform physical 
activity in the last 48 hours before the hyperinsulinaemic euglycaemic clamps.
hyperinsulinaemic euglycaemic clamp
All studies started after an overnight fast. Height, weight and waist circumference were mea-
sured. Lean body mass was assessed by bioelectrical impedance analysis (Bodystat® 1500, 
Bodystat Ltd., Douglas, Isle of Man, UK).
Metabolic studies were performed as described previously (6). In short, first samples were 
taken for the measurement of basal levels of glucose, insulin, and background enrichment of 
[6,6-2H2]-glucose and [
2H5]-glycerol. Basal rates of glucose and glycerol turnover were assessed 
after 3 hours of continuous infusion of [6,6-2H2]-glucose and 1.5 hours of continuous infusion 
of [2H5]-glycerol (Cambridge Isotopes, Cambridge, USA). Subsequently, insulin-stimulated 
rates of glucose and glycerol turnover were measured after 4.5 hours of a hyperinsulinaemic 
euglycaemic clamp (Actrapid®, Novo Nordisk Pharma, Alphen aan de Rijn, The Netherlands; 
rate 40 mU/m2/min). Glucose values were clamped at 5.5 mmol/L via the infusion of a variable 
rate of 20 % glucose enriched with 3 % [6,6-2H2]-glucose.
A physiological and isotopic steady-state was achieved during the last 30 min of both the 
basal as well as the hyperinsulinaemic period, therefore, the rates of appearance (Ra) and dis-
appearance (Rd) for glucose and glycerol were calculated as the tracer infusion rate divided 
by the tracer-to-tracee ratio (7). Endogenous glucose production (EGP) during the basal 
steady-state is similar to the Ra of glucose, whereas EGP during the clamp was calculated 
as the difference between the rates of glucose appearance and infusion. The hepatic insulin 
resistance index (HIR) (μmol/min/kgLBM/pmol*L) was calculated as the product of EGP and 
plasma insulin concentration (8). The metabolic clearance rate of insulin (MCRI) was calcu-









































Effect of a VLCD with and without exercise on insulin resistance
tion corrected for endogenous insulin secretion (basal insulin concentration x [steady state 
c-peptide/basal c-peptide concentration) (9).
aerobic fitness
Each subject performed an incremental cyclo-ergometer exercise test to determine their 
maximum oxygen consumption (VO2 max) both before and directly after the intervention 
period. Exercise intensity was progressively increased while measuring ventilation, oxygen 
and carbon dioxide concentration of the inhaled and exhaled air. VO2 max was reached when 
oxygen consumption remained constant despite an increase in workload.
Indirect calorimetry
Both under basal and hyperinsulinaemic conditions, indirect calorimetry with a ventilated 
hood (Oxycon Beta, Mijnhardt Jaegher, Breda, The Netherlands) was performed for 30-min. 
The molar ratio of oxygen consumed to carbon dioxide produced was used to calculate 
total glucose and lipid oxidation rates as described previously by Simonson and DeFronzo 
(10). Non-oxidative glucose disposal (NOGD), as a measurement for glycogen storage was 
calculated by subtracting the glucose oxidation rate from Rd of glucose.
Muscle biopsy (Mitochondria, Insulin Signalling, Oil red O staining)
Under localised anaesthesia, with 1% lidocaine, muscle biopsies were taken from the vastus 
lateralis muscle under basal conditions and 30 minutes after the start of the insulin infu-
sion (6) using a modified Bergström needle. Muscle samples were divided into two parts: 
one frozen in liquid nitrogen for subsequent determination of insulin signaling, whereas 
the other part was snap-frozen in liquid nitrogen-cooled isopentane and stored at -80°C for 
determination of intramyocellular lipid accumulation (IMCL).
mtDNA content was assessed using a modification of the quantitative real-time PCR-based 
method as we described previously (11). Insulin signaling was measured as described previ-
ously (12). Tissue sections of basal biopsies were stained with Oil Red O (ORO) combined 
with a double-immunofluorescence assay (anti-laminin and a monoclonal antibody  raised 
against adult human slow myosin heavy chain) to allow quantification of IMCL as described 
previously (13).
ASSAyS
Serum insulin was measured with an immunoradiometric assay (Biosource, Nivelles, Bel-
gium). Serum C-peptide levels were measured with a radioimmuno assay (Linco Research, St. 
Charles MO, USA). HbA1c was measured with a semi automated HPLC machine Primus Ultra 










































Plasma free fatty acids (FFAs) concentrations were measured by a commercial kit (Wako 
Chemicals, Neuss, Germany). [6,6-2H2]-glucose and [
2H5]-glycerol were measured in a single 
analytical run using gas chromatography-mass spectrometry as described previously (14).
STATiSTiCAL AnALySiS
Results are expressed as mean ± standard error (SEM). Paired t tests were applied to assess 
mean differences before and after the intervention within groups, whereas unpaired t tests 
were used to assess differences in means or deltas between groups. Non-parametric tests 
(Wilcoxon signed-rank test for paired samples, Mann-Whitney for unpaired samples resp.) 
were performed, when appropriate. Significance level was set at p < 0.05. Statistical analyses 
were performed using SPSS for Windows (release 16.0, SPSS, Inc., Chicago, IL).
rESuLTS
anthropometric measurements
As shown in Table 1, the baseline (pre-intervention) characteristics of the two patient groups 
(VLCD with exercise (VLCD+E) and VLCD-only) did not differ with respect to both clinical and 
metabolic parameters. After the 16-week intervention both groups (VLCD+E and VLCD-only) 
showed significant improvements in clinical and metabolic characteristics.
Similar weight loss was achieved in both patient groups (-27.2±1.9 kg VLCD+E; -23.7±1.6 
kg VLCD-only). The VLCD+E group lost significantly more fat mass (-21.8±2.2 kg VLCD+E; 
-16.6±1.7 kg VLCD-only) and also waist circumference decreased more (-25±1 kg VLCD+E; 
-19±2 kg VLCD-only) compared to the VLCD-only group (Table 1).
Glucose and lipid metabolism
After the intervention fasting plasma glucose, insulin and HbA1C levels improved substan-
tially and similarly in both intervention groups. During the clamp pre- and post-intervention 
steady state plasma glucose concentrations were similar in the two intervention groups 
(VLCD+E 5.4±0.4 vs. 5.4±0.5 mmol/L; VLCD-only 5.5±0.7 vs. 5.6±0.6 mmol/L, pre- and post-
intervention resp.; both NS) Steady state plasma insulin during the clamp was significantly 
lower after the intervention but similar in both groups, as a result of an increase in clearance 
of exogenous insulin after weight loss (Table 2).
There was a similar reduction in basal EGP in both patient groups. The HIR index diminished 
both under basal and hyperinsulinaemic conditions after the intervention to a similar extent 
in both patient groups. Also peripheral insulin sensitivity improved considerably; glucose 









































Effect of a VLCD with and without exercise on insulin resistance
of lipolysis in basal conditions was somewhat higher after VLCD+E (whereas VLCD-only did 
not affect this measure), but the capacity of insulin to suppress lipolysis improved only by 
VLCD+E (Table 2).
Insulin signaling
Both patient groups had a higher insulin receptor (IR) expression after the intervention. 
IR expression increased further in the VLCD+E compared to the VLCD-only. Phosphoryla-
tion of proline rich substrate 40 (PRAS40) was similarly increased in both groups after the 
intervention, in basal as well as in hyperinsulinaemic conditions. AKT substrate 160 (AS160) 
phosphorylation showed a similar trend, but this increase was not statistically significant 
(Figure 1).
Glucose and lipid oxidation rates
Basal lipid oxidation and NOGD increased significantly post-intervention only in the VLCD+E 
group (Table 2). Before the intervention the switch between glucose and lipid oxidation was 
lost, post-intervention this improved in both groups. The basal lipid oxidation and insulin-
mediated suppression of lipid oxidation improved more in the VLCD+E group.
Table 1. Clinical characteristics, body composition and fasting plasma levels before and after a 16-week VLCD +/- exercise in obese insulin-
dependent type 2 diabetes mellitus patients.
VLCD only VLCD + exercise
baseline after 16 wks baseline after 16 wks
sex (M/F) 6/8 8/5
age (years) 56.1 ± 2.4 53.0 ± 2.5
weight (kg) 112.7 ± 5.6 89.0 ± 4.3 * 113.5 ± 5.1 86.3 ± 4.2 *
BMI (kg/m2) 37.9 ± 1.4 30.0 ± 1.1 * 36.4 ± 1.1 27.7 ± 1.0 *
waist (cm) 122 ± 3 103 ± 3 * 123 ± 3 98 ± 3 * $
fat mass (kg) 49.9 ± 3.6 33.2 ± 2.8 * 45.4 ± 3.2 23.5 ± 2.2 * $
systolic bloodpressure (mmHg) 161 ± 4 140 ± 4 * 145 ± 5 132 ± 5 *
diastolic bloodpressure (mmHg) 87 ± 3 78 ± 2 * 81 ± 3 75 ± 3
HbA1c (%) 7.8 ± 0.3 6.7 ± 0.3 * 7.8 ± 0.4 6.3 ± 0.4 *
fasting plasma glucose (mmol/L) 12.1 ± 0.5 7.7 ± 0.6 * 10.9 ± 0.7 6.6 ± 0.8 *
fasting insulin (mU/L) 24.4 ± 4.3 12.6 ± 2.0 * 25.1 ± 2.2 8.8 ± 0.8 *
fasting C-peptide (nmol/L) 2.9 ± 0.3 2.2 ± 0.2 3.5 ± 0.3 2.0 ± 0.1 *
metformin (number of patients) 9 0 10 0
SU-derivative (number of patients) 1 0 3 0
average insulin (IU/day) 86.2 0 77.2 0
Data are presented as mean±SEM. * p<0.001 within the group; $ p< 0.05 between the groups.











































At baseline, VO2max was similar in both groups. Participants in the VLCD-only group had a 
non-significant change (0.7±1.5 mg/kgLBM/min difference from baseline) in VO2max. In contrast 
there was a significant increase in VO2max in the VLCD+E group (6.6±1.7 mg/kgLBM/min differ-
ence from baseline) (Figure 2A).
Mitochondria
Muscle mtDNA content was not affected following a VLCD-only (1398±240 vs. 1127±180 
au, pre- and post-intervention resp.). In contrast, the VLCD+E group showed a significant 
increase following the intervention (1211±185 vs. 2288±359 au, pre- and post-intervention 
resp.; p<0.05) (Figure 2B).
Table 2. Metabolic parameters before and after a 16-week VLCD +/- exercise in obese insulin-dependent type 2 diabetes mellitus patients.
VLCD only VLCD+ exercise
baseline after 16 wks baseline after 16 wks
basal EGP (µmol/kgLBM/min) 17.7 ± 0.7 15.1 ± 0.6 * 17.1 ± 0.7 14.1 ± 0.4 *
clamp EGP (µmol/kgLBM/min) 4.8 ± 0.7 1.2 ± 0.6 * 3.1 ± 0.8 1.8 ± 0.6
suppression EGP (%) -73.7 ± 3.4 -93.1 ± 3.2 * -82.0 ± 4.5 -87.6 ± 4.1
basal HIR (µmol/kgLBM/min/pmol*L) 3009 ± 419 1242 ± 187 * 2644 ± 267 983 ± 136 *
clamp HIR (µmol/kgLBM/min/pmol*L) 3492 ± 558 737 ± 335 * 2135 ± 572 1134 ± 392 *
glucose Rd (µmol/kgLBM/min) 15.5 ± 1.2 38.6 ± 4.6 * 16.6 ± 1.2 41.8 ± 3.6 *
clamp insulin (mU/L) 102.4 ± 9.0 86.6 ± 7.3 * 102.0 ± 5.6 79.4 ± 5.5 *
metabolic clearance rate insulin (ml/m2/min) 8.9 ± 1.6 17.9 ± 4.2 * 7.3 ± 1.3 16.2 ± 2.0 *
basal glucose ox. (µmol/kgLBM/min) 10.9 ± 1.5 6.1 ± 1.4 * 15.8 ± 1.8 3.6 ± 1.1 * $
clamp glucose ox. (µmol/kgLBM/min) 16.2 ± 2.1 17.4 ± 1.8 16.9 ± 2.2 12.9 ± 1.6
increase glucose ox. (µmol/kgLBM/min) 5.2 ± 1.6 11.3 ± 1.9 * 1.0 ± 1.3 9.3 ± 1.2 *
basal NOGD (µmol/kgLBM/min) 6.8 ± 1.4 9.1 ± 1.4 1.4 ± 1.7 10.5 ± 1.2 * $
clamp NOGD (µmol/kgLBM/min) 0.0 ± 2.4 21.3 ± 4.2 * 0.0 ± 2.1 29.0 ± 2.7 *
basal Ra glycerol (µmol/kgFM/min) 11.3 ± 1.2 11.3 ± 1.3 12.9 ± 1.0 15.9 ± 1.1 *
clamp Ra glycerol (µmol/kgFM/min) 5.9 ± 0.9 5.8 ± 1.0 7.2 ± 1.3 7.9 ± 1.3
suppression Ra glycerol (µmol/kgFM/min) -5.4 ± 0.7 -5.5 ± 0.8 -5.6 ± 0.8 -7.9 ± 0.9 *
basal FFA levels (mmol/L) 1.0 ± 0.1 1.0 ± 0.1 0.9 ± 0.1 0.9 ± 0.0
clamp FFA levels (mmol/L) 0.3 ± 0.0 0.2 ± 0.1 0.3 ± 0.0 0.1 ± 0.0
basal lipid ox. (µmol/kgLBM/min) 7.0 ± 0.4 6.6 ± 0.3 4.9 ± 0.4 6.9 ± 0.3 * $
clamp lipid ox. (µmol/kgLBM/min) 4.6 ± 0.6 3.6 ± 0.5 4.7 ± 0.5 4.6 ± 0.5
suppression lipid ox. (µmol/kgLBM/min) -2.4 ± 0.6 -2.9 ± 0.6 -0.2 ± 0.4 -2.4 ± 0.4 *
Data are presented as mean±SEM.* p<0.001 within the group; $ p< 0.05 between the groups.
EGP: endogenous glucose production; LBM: lean body mass; HIR: hepatic insulin resistance index; Rd: rate of disappearance; Ra: rate of 









































Effect of a VLCD with and without exercise on insulin resistance
Muscle morphology and IMCL
In both intervention groups there was a similar decline in IMCL accumulation in the skeletal 
muscle fibers after the 16-week intervention (Figure 2C). The percentage of type 1 fibers 
in the skeletal muscle increased, whereas the percentage of type 2 fibers decreased sig-
nificantly and similarly in both groups (VLCD+E type 1 and 2: 52.4±3.0% and 47.6±3.0% vs. 
58.4±3.2% and 41.6±3.2% pre- and post-intervention resp.; both p<0.05; VLCD-only type 1 
and 2: 51.8±3.0% and 48.2±3.0% vs. 60.7±4.1% and 39.3±4.1%, pre- and post-intervention 
resp.; both p<0.05).
DiSCuSSiOn
A 16-week VLCD in obese insulin-dependent T2DM patients with or without moderate in-
tense exercise resulted in substantial weight reduction and decrease of waist circumference. 
Exercise did not result in extra weight loss. However, it induced a greater loss of fat mass 
Figure 1. A. Insulin receptor (IR) expression at baseline and after 16 weeks of intervention; B. basal (grey bars) and insulin stimulated (black 






















































































































and thus conservation of lean body mass. Glucoregulation improved to the same extent in 
both groups despite the cessation of all glucose-lowering agents including insulin. Insulin 
sensitivity of the liver, adipose tissue and skeletal muscle improved similarly in both groups, 
which is in accordance with the observed similar improvement in insulin signaling and de-
crease in IMCL in skeletal muscle. Also a significant increase in type 1 oxidative muscle fibers 
was observed in both groups. Maximal aerobic capacity and mitochondrial copy number 
increased only in the exercise group while these parameters remained unchanged in the 
VLCD-only group.
The current study confirms that diet-induced weight reduction improves glucoregulation 
in obese patients with T2DM by ameliorating both hepatic and peripheral insulin resistance. 
The high dosage used during insulin infusion almost completely suppressed EGP in both 
groups. Since plasma insulin clearance was increased by weight loss, insulin infusion resulted 
in lower circulating insulin concentrations during clamp steady state after the intervention. 
Thus, for a more accurate comparison of hepatic insulin sensitivity before and after the inter-
vention the HIR was used which showed improved hepatic insulin resistance in both groups. 
Figure 2. A: Maximum aerobic capacity (VO2max); B: mitochondrial DNA (mtDNA) content of the skeletal muscle; C: intramyocellular lipid 
accumulation (IMCL) as relative fraction of cell area containing lipid droplets at baseline (grey bars) and after (black bars) a 16-week VLCD +/- 
























































































































Hoofdstuk 3 Figure 2
* p<0.05 within the group; $ p< 0.05 between the groups.









































Effect of a VLCD with and without exercise on insulin resistance
The current study failed to show additional effects of 16-weeks moderate intense exercise 
on both peripheral and hepatic insulin sensitivity. One possible explanation for this lack of 
an additional effect of exercise might be that the magnitude of caloric restriction and the 
achieved weight loss masked the potential additional effect of exercise.
The substantial increase in peripheral insulin sensitivity is in accordance with the increased 
level of insulin receptor expression and improvement in the PI3K-PKB/AKT insulin signaling 
pathway in skeletal muscle cells as reflected by increased PRAS40 phosphorylation. These 
data confirm the results of other studies showing that diet-induced weight loss (2) or the 
combination with exercise improve peripheral insulin sensitivity (15,16) and the insulin 
signaling pathway (17) in obese patients with or without T2DM. In our study, insulin receptor 
expression increased even further with the addition of exercise. However, this was not ac-
companied by further improvement of glucoregulation, as evidenced by similar baseline and 
insulin induced levels of PRAS40 and AS160 phosphorylation in both groups.
A low oxidative capacity leads to accumulation of lipids in the skeletal muscle. IMCL content 
is elevated in the skeletal muscle in obese type 2 diabetes mellitus patients and associated 
with insulin resistance. Not IMCLs per se, but IMCL derivatives, such as diacylglycerol (DAG) 
and long chain fatty acid-CoA are known to activate protein kinase C, which in turn, phos-
phorylates the serine residue of insulin receptor substrate 1(IRS 1). Serine-phosphorylated 
IRS 1 is unable to activate PI3K and leads to disruption in the PI3K-PKB/AKT insulin signaling 
cascade (18). The improvement in insulin signaling found in our study might partially be ex-
plained by the observed decrease in IMCL content in both intervention groups. IMCL content 
in the skeletal muscle is not only increased in obese and insulin resistant subjects, it is also 
high in endurance trained athletes; here IMCLs represent a physiological role as readily avail-
able energy source. In literature, exercise in obese non-diabetic and obese T2DM subjects, 
either increased (19), decreased (15,20) or led to unchanged (21,22) IMCL accumulation. In 
our group of patients a possible exercise-induced increase in IMCL could be hidden by the 
strong effect of caloric restriction and weight loss.
Prospective studies have shown that a low ability to oxidize fat is a risk factor for weight 
gain, obesity and insulin resistance (23). Impaired muscle fatty acid oxidation, reflected by 
reduced number of mitochondria, could be considered as a primary defect causing IMCL ac-
cumulation in T2DM patients (24). T2DM patients are characterized by low basal fat oxidation 
and increased lipogenesis rates (25). The current study showed that only a VLCD with exercise 
increased the reliance on lipid oxidation and lipolysis during fasting after the intervention.
It has been shown that the reduced muscle mitochondrial content and functional capacity 
in obese subjects are reversible with moderate weight loss (10%) combined with moderate-
intensity regular physical activity (16,21). This suggests that sedentary behavior might be 
responsible for the reduction in mitochondrial capacity in obese T2DM patients. Indeed, here 
we showed that only combining VLCD with exercise increases mitochondrial copy number. 










































not associated with a further decrease in IMCL and a greater increase in glucose disposal rate 
as compared to VLCD-only group.
We found an identical and significant increase in type 1, and decrease in type 2 muscle 
fibers in both intervention groups. A low capacity to oxidize fat due to a low percentage of 
type 1 (oxidative) muscle fibers might lead to obesity and T2DM, although a causal relation 
has not been established. To the best of our knowledge this is the first study which shows a 
significant increase in type 1 oxidative muscle fibers in T2DM patients after weight loss. Type 
2 muscle fibers are responsible for generating strength and power, the decrease in type 2 
muscle fibers could well be a reflection of reduced weight-bearing, since both groups lost 
similar but excessive amounts of weight after the intervention.
Even moderately-intense regular exercise leads to improved fitness in obese T2DM patients 
as shown in the present and previous studies (20,21,26), whereas aerobic capacity did not 
improve in the group receiving dietary advice without exercise program.
In conclusion, diet-induced weight loss improves insulin sensitivity and glucoregulation, 
decreases intramyocellular lipids, and improves insulin signaling in skeletal muscle. Adding 
exercise to the diet leads to additional loss of fat mass and conservation of lean body mass, 
an increased number of intramyocellular mitochondria and an improvement of maximum 
aerobic capacity. However, despite all these beneficial metabolic effects, exercise does not 
reinforce insulin action in this setting, perhaps because a VLCD per se ameliorates insulin 









































Effect of a VLCD with and without exercise on insulin resistance
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Chapter 4
Quality of life is improved for at least 18 
months by the addition of exercise to a 
16-week very low calorie diet in obese 
patients with type 2 diabetes mellitus
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Objective. To evaluate whether the addition of exercise to a very low calorie diet (VLCD) 
has beneficial short- and long-term effects on health-related Quality of Life (QoL) in obese 
patients with type 2 diabetes mellitus (T2DM).
Methods. We included 27 obese, insulin-dependent T2DM patients in a 16-week VLCD study, 
of whom 13 participated simultaneously in an exercise program (VLCD+E). Before, immedi-
ately after and 18 months after the intervention anthropometric measurements, glucoregu-
lation and QoL (SF-36, HADS, NHP and MFI-20) were assessed. Patients were compared to 
healthy lean and obese (matched for body mass index) controls matched for gender and age.
results. At baseline, T2DM patients had significantly worse QoL scores in 18 and 14 of the 
22 subscales of the QoL questionnaires, compared to lean and obese controls, resp. The 16-
week VLCD (n=27) decreased bodyweight (-25.4±1.3kg, p<0.0001, p=0.179 between groups), 
and improved glucoregulation (HbA1c -1.3±0.3%, p<0.0001, p=0.488 between groups) and 
9 (VLCD-only) and 11 (VLCD+E) of the 22 subscales of QoL. After 18 months, in the VLCD+E 
group the QoL subscales did not differ from those in obese controls and only 4 of the 22 
subscales were significantly worse compared to lean controls. However, in the VLCD-only 
group 17 and 13 of the 22 QoL subscales were significantly worse compared to the lean and 
obese controls, resp.
Conclusion. A 16-week VLCD induces considerable weight loss, metabolic amelioration, and 
major improvements in QoL in obese T2DM patients. The addition of exercise is of paramount 









































Effect of a VLCD with and without exercise on quality of life
inTrODuCTiOn
The number of patients with type 2 diabetes (T2DM) is steadily increasing. Almost 90% of 
T2DM patients are overweight or obese. Medical attention is focused primarily on improv-
ing metabolic control to diminish long-term complications. However, patients with chronic 
diseases such as T2DM also have a poorer health-related quality of life (QoL) compared to 
healthy control subjects (1). Reduced QoL not only affects individual happiness but may 
also have impact on participation in the working process, social functioning, compliance to 
therapy and hence socioeconomic costs.
Improvement of QoL in T2DM patients is associated with an increase in self-management, 
adherence to therapy and positive changes in lifestyle (2). The magnitude of the effects on 
QoL is dependent on the type of intervention. Behavioral interventions have the smallest 
effect, but are nevertheless able to improve QoL, reduce the number of hospitalizations and 
use of medication (2,3). Bariatric surgery has the largest effect on QoL, mainly through the 
loss of excess weight and the waning of obesity-associated symptoms (2,4). However, surgery 
is expensive, invasive, associated with substantial morbidity. Furthermore it is logistically im-
possible to operate all obese patients with T2DM. Therefore, diet and lifestyle interventions 
remain the mainstay of therapy for most obese T2DM patients.
Diet-induced weight loss improves QoL in the short-term but not in the long-term, mostly 
because of regain of bodyweight (3). The effect of exercise on QoL in T2DM patients is less 
clear (5,6).
Therefore, the aim of this study was to assess whether addition of exercise to a 16-week 
very low calorie diet (VLCD) in obese, insulin-dependent T2DM patients has greater effects 
on QoL than a VLCD-only, both immediately after the 16-week intervention and 18 months 
after the intervention. Secondary aims were to compare QoL in our T2DM patients with lean 
and obese healthy controls.
PATiEnTS AnD METhODS
patients
Twenty-seven obese (body mass index (BMI) 37.2±0.9 kg/m2), insulin-dependent T2DM pa-
tients (age 58.0±1.6 years, duration of T2DM 8.9±0.8 years, 58±8 months on insulin therapy) 
participated in the study. Inclusion criteria were insulin-dependent T2DM patients (who 
used at least 20 EH of insulin per day) with or without oral glucose-lowering medication; at 
baseline a BMI above 30 kg/m2; remaining endogenous insulin secretion defined as a fasting 
plasma C-peptide level greater than 0.8 ng/mL and a 2-fold increase of the basal C-peptide 
level in response to administration of 1 mg glucagon intravenously. Exclusion criteria were 










































sion or antidepressant medication and silent cardiac ischemia. Patients were recruited via 
advertisements in local news papers and from the endocrinology and internal medicine 
out-patient clinics of our hospital.
For each T2DM patient, 2 lean and 2 obese control subjects, matched for age, gender, race 
and in the obese group for BMI, were included. Control subjects were recruited via advertise-
ments in local news papers.
The Medical Ethics Committee of the Leiden University Medical Center approved the study 
protocol. Written informed consent was obtained from each subject.
Study design
In all T2DM patients oral blood glucose-lowering medication was discontinued 3 weeks prior 
to the start of the intervention. One day before the start of the intervention, insulin therapy 
was stopped as well. The patients did not use any anti-diabetic medication during the whole 
16-week intervention period.
At day 0 baseline observations were obtained in all patients (outlined below), followed by 
a 16-week intervention period. The intervention period consisted of a 16-week VLCD with or 
without the addition of an exercise program. The VLCD contained a total of ~450 kilocalories 
per day, divided into 3 sachets of Modifast® (Nutrition & Santé, Antwerpen, Belgium). Modi-
fast® provides all necessary vitamins and micronutrients.
Thirteen of the 27 subjects were randomized to follow an exercise program simultaneously. 
This exercise program entailed one-hour in-hospital training per week (primarily aerobic 
exercise, supervised by a physiotherapist) and at least four training sessions at home on a 
cyclo-ergometer at 70% of their maximum aerobic capacity (VO2max).
At the start, immediately after and 18 months after the 16-weeks intervention period, 
patients visited the research center after an overnight fast. Height, weight and waist cir-
cumference were measured. Fat mass was determined by bioelectrical impedance analysis 
(Bodystat® 1500 MDD, Bodystat Ltd., Douglas, Isle of Man, UK). Blood samples were obtained 
for fasting plasma glucose (FPG), insulin and HbA1c levels.
To assess QoL, patients were asked to fill in 4 different questionnaires. Each patient com-
pleted the questionnaires before, directly after, and 18 months after the intervention, result-
ing in a 100% response rate. The healthy (lean and obese) controls were asked to complete 
the QoL questionnaires only once.
During the 16-week intervention the subjects visited the outpatient clinic weekly, for 
measurement of weight and to check glucoregulation. Furthermore, compliance with the 
diet and exercise was established by counting sachets of Modifast that were supplied weekly 
and reading the heart rate monitor, that was worn during the exercise sessions (Polar S610 i
tm, 
Polar Electro Oy, Finland). After the 16-week intervention period patients were treated ac-
cording to current guidelines either in the primary care setting or at the out-patient clinic 









































Effect of a VLCD with and without exercise on quality of life




The 36 items of the SF-36 record general well-being during the previous thirty days. The 
items are formulated as questions or statements and are subdivided into nine subscales: 
(1) physical functioning, (2) social functioning, (3) limitations in usual role activities due 
to physical problems, (4) limitations in usual role activities due to emotional problems, (5) 
bodily pain, (6) general health perception and change in health, (7) general mental health 
and (8) vitality (energy and fatigue) (9) health change. Because the HADS and the MFI-20 (see 
below) are more specific questionnaires for mental health, vitality and general mental health, 
these items were left out in this evaluation. Scores vary between 0 and 100. Higher scores are 
associated with a higher quality of life. (7).
Multidimensional Fatigue Index (MFI-20)
The MFI-20 contains 20 statements to assess fatigue. Five different dimensions of fatigue (four 
items each) are calculated from these statements: general fatigue, physical fatigue, reduced 
activity, reduced motivation and mental fatigue. Scores fluctuate between 0 and 20; higher 
scores indicate more fatigue (8).
Hospital Anxiety and Depression Scale (HADS)
The HADS consists of fourteen items pertaining to the three subscales anxiety, depression 
and total score. Every item is scored on a four-point scale. Scores for the anxiety and depres-
sion subscale range from 0 to 21 and the total score from 0 to 42. A higher score indicates 
more severe anxiety or depression (9).
Nottingham Health Profile (NHP)
The NHP consists of 38 yes/no questions, subdivided in six scales: pain, energy, sleep, emo-
tional reactions, social isolation and disability/ functioning, i.e. physical ability. The scores 
of the subscales are calculated as a weighted mean of the associated items. The scores are 
expressed as a value between 0 and 100 and the total score is the mean of the six subscales. 
A higher score is related to a worse quality of life (10).
total QoL score
For an integral comparison of the QoL parameters addressed in the 4 questionnaires, our 
research-group developed a total QoL score which is the sum of all different QoL question-










































SF-36 scores were inverted so that a higher score is a worse QoL. Subsequently all subscale 
scores were added and a mean was calculated, generating a total QoL score (minimum value 
0, maximum value 100). A higher score indicates a greater impairment of QoL
assays
FPG were measured with a fully automated P-800 module (Roche, Almere, the Netherlands). 
Serum insulin was measured with an immunoradiometric assay (IRMA, Biosource, Nivelles, 
Belgium). HbA1c was measured with a semi automated HPLC machine Primus Ultra 2 (Kordia, 
Leiden, the Netherlands)
Homeostatic Model Assessment of Insulin Resistance (HOMA-IR, normal values approach 
1) was calculated from FPG and insulin levels according to the updated computed version of 
the formulae of Wallace et al (12).
Statistical analyses
Data are presented as mean ± SEM. Data analyses were performed using SPSS for Windows 
version 16.0 (SPSS Inc., Chicago, IL, USA). Differences between all groups (the two interven-
tion groups and the two healthy controls) were analyzed using a one-way ANOVA. Differ-
ences within the group between the three different time points (baseline; directly after 
the intervention and 18 months after the intervention) were analyzed with a general linear 
model (GLM) for repeated measures, with time as within-subject factor. LSD post-hoc tests 
were used in case of a significant F-ratio. Differences in effect of the intervention between 
both intervention groups were analyzed by calculating a delta between two time points. The 
delta values were subsequently compared by non-parametric tests for independent samples 
or, when appropriate, by a two tailed Student’s t-test for unpaired data. A p-value of < 0.05 
was considered to be statistically significant.
rESuLTS
Baseline characteristics
Clinical characteristics of the patients and healthy controls are shown in Table 1. Baseline 
characteristics of the two patient groups (VLCD with exercise (VLCD+E) and VLCD-only) were 
not different. The lean and obese control groups had significantly lower levels of FPG, insulin 
and HbA1c compared to the patients. The obese controls were well matched with respect to 
weight, BMI and waist circumference to the T2DM patients.
Short- and long-term effect of a 16-week VLCD on bodyweight and glucoregulation
After the 16-week intervention both groups (VLCD+E and VLCD-only) showed a significant im-









































Effect of a VLCD with and without exercise on quality of life
all subjects (-27.2±1.9 kg VLCD+E; -23.7±1.6 kg VLCD-only), which consisted mostly of fat mass 
(-21.8±2.2 kg VLCD+E; -16.6±1.7 kg VLCD-only). There was significantly more loss of fat mass 
and waist circumference in the VLCD with exercise group. FPG and HbA1C levels improved 
substantially (respectively p=0.910 and p=0.488 between groups), despite the cessation of all 
glucose-lowering medication throughout the 16-week intervention period (Table 1).
After 18 months both groups had regained some weight. However, weight was still signifi-
cantly decreased compared to baseline observations (Table 1). The beneficial effects of the 
16-week intervention on HbA1c and FPG levels were also decreased. Nonetheless, the pa-
tients still used substantially less glucose-lowering medication than before the intervention 
(Table 2). Fasting insulin and HOMA-IR levels were only significantly better after 18 months 
compared to baseline in the VLCD with exercise group.
Table 1: Clinical and metabolic characteristics at baseline, directly after and 18 months after a 16-week VLCD only or VLCD with exercise in 
obese insulin-dependent T2DM patients and comparisons with (obese and lean) healthy controls.
VLCD + exercise VLCD only controls
baseline 16 weeks 18 months baseline 16 weeks 18 months obese lean
sex (M/F) 8/5 6/8 28/26 28/26
age (years) 53 ± 3 56 ± 2 56 ± 1 59 ± 2
weight (kg) 114 ± 5 * 86 ± 4 ! 98 ± 5 ! 113 ± 6 * 89 ± 4 ! 103 ± 5 ! 112 ± 3 * 73 ± 2
BMI (kg/m2) 36.4 ± 1.1 * 27.7 ± 1.0 ! 31.6 ± 1.2 ! 37.9 ± 1.4 * 30.0 ± 1.1 ! 34.7 ± 1.3 ! 37.6 ± 0.7 * 23.8 ± 0.3
waist (cm) 123 ± 3 * 98 ± 3 ! 107 ± 4 ! 122 ± 3 * 103 ± 3 ! 114 ± 3 ! 118 ± 2 * 87 ± 1
fat mass (kg) 45.4 ± 3.2 * 23.5 ± 2.2 ! 35.4 ± 2.6 ! 49.9 ± 3.6 * 33.2 ± 2.8 ! 44.2 ± 3.0 ! 39.2 ± 2.4 * 33.4 ± 2.2
HbA1c (%) 7.8 ± 0.4 * # 6.3 ± 0.4 ! 7.5 ± 0.6 7.8 ± 0.3 * # 6.7 ± 0.3 ! 8.2 ± 0.5 5.5 ± 0.1 * 5.2 ± 0.0
fasting glucose (mmol/L) 10.9 ± 0.7 * # 6.6 ± 0.8 ! 9.2 ± 1.0 12.1 ± 0.5 * # 7.7 ± 0.6 ! 12.2 ± 1.1 5.5 ± 0.1 * 4.9 ± 0.1
fasting insulin (mU/L) 25 ± 2 * # 9 ± 1 ! 13 ± 2 ! 24 ± 4 * # 13 ± 2 ! 17 ± 6 14 ± 1 * 5 ± 0
HOMA-IR 12.3 ± 1.3 * # 2.5 ± 0.2 ! 4.7 ± 0.8 ! 12.9 ± 2.3 * # 4.3 ± 0.8 ! 9.0 ± 3.1 3.4 ± 0.3 * 1.1 ± 0.1
Data are presented as mean ± SEM. ! significant difference vs. baseline values within the group; * significant difference vs. lean controls; # 
significant difference vs. obese controls
M: male; F: female; BMI: body mass index; HOMA-IR: homeostatic model assessment insulin resistance
Table 2: Overview of medication used at baseline, directly after and 18 months after a 16-week VLCD only or VLCD with exercise in obese 
insulin-dependent T2DM patients.
VLCD + exercise VLCD only controls
baseline 16 weeks 18 months baseline 16 weeks 18 months obese lean
insulin (number of pts) 13 0 0 14 0 6 0 0
insulin (EH/day) 77 0 0 86 0 36 0 0
metformin (number of pts) 10 13 12 9 14 12 0 0
SU derivative (number of pts) 3 0 4 1 0 4 0 0
exercise (minutes/week) 34 180 192 24 0 45 82 167










































Short- and long-term effect of VLCD with or without exercise on QoL
The results of the QoL questionnaires before, immediately after and 18 months after the in-
tervention period are shown in Table 3. At baseline there were no differences in QoL between 
Table 3: Quality of life (QoL) at baseline, directly after and 18 months after a 16-week VLCD only or VLCD with exercise in obese insulin-
dependent T2DM patients and comparisons with (obese and lean) healthy controls. Short form-36 (SF-36): score 1-100 higher scores are 
associated with better QoL. Multidimensional fatigue index-20 (MFI-20): score 1-20 higher scores indicate higher experienced fatigue. Hospital 
Anxiety and depression scale (HADS): scores 0-21, higher score indicated more severe anxiety or depression. Nottingham Health Profile (NHP): 
score 0-100, higher score is related to a worse QoL.
VLCD + exercise VLCD only controls
baseline 16 weeks 18 months baseline 16 weeks 18 months obese lean
Sf-36
Physical functioning 72 ± 6 * # 82 ± 6 ! * 83 ± 5 ! * ? 63 ± 5 *# 78 ± 6 ! * 68 ± 7 *# 81 ± 3 * 94 ± 1
Social functioning 81 ± 6 * # 88 ± 3 87 ± 8 79 ± 5 *# 88 ± 4 80 ± 4 *# 91 ± 2 93 ± 2
Limits due to physical problems 65 ± 11 * # 90 ± 5 ! 75 ± 9 * 68 ± 10 *# 71 ± 10 * 59 ± 11 *# 85 ± 4 94 ± 2
Limits due to emotional 
problems
95 ± 5 100 ± 0 100 ± 0 74 ± 9 *# 86 ± 8 86 ± 8 90 ± 4 94 ± 2
Pain 79 ± 8 * 85 ± 6 82 ± 8 70 ± 6 * 72 ± 6 * 70 ± 6 * 80 ± 3 * 91 ± 2
General health perception 52 ± 6 * # 76 ± 6 ! 68 ± 5 ! * ? 51 ± 5 *# 58 ± 5 *# 51 ± 6 *# 74 ± 2 * 80 ± 2
Health change 50 ± 7 92 ± 3 ! *# 67 ± 7 *# 55 ± 7 *# 88 ± 6 ! *# 66 ± 7 # 51 ± 2 55 ± 2
Mfi-20
General fatigue 12 ± 1 * # 7 ± 1 ! 9 ± 1 ! ? 14 ± 1 *# 10 ± 1 ! * 12 ± 1 *# 9 ± 1 * 7 ± 1
Physical fatigue 12 ± 1 * # 7 ± 1 ! # 8 ± 1 ! ? 13 ± 1 *# 9 ± 1 ! * 12 ± 1 *# 9 ± 1 * 6 ± 0
Reduction in activity 10 ± 1 * 8 ± 1 7 ± 1 ! ? 12 ± 1 *# 8 ± 1 ! 10 ± 1 ! * 8 ± 1 7 ± 1
Reduction in motivation 8 ± 1 * 6 ± 1 ! 7 ± 1 10 ± 1 *# 8 ± 1 10 ± 1 *# 7 ± 1 6 ± 0
Mental fatigue 9 ± 1 7 ± 1 8 ± 1 8 ± 1 7 ± 1 8 ±1 8 ± 1 8 ± 1
hADS
Anxiety 4 ± 1 3 ± 1 ! 4 ± 1 5 ± 1 *# 4 ± 1 ! 4 ± 1 3 ± 0 3 ± 0
Depression 3 ± 1 1 ± 0 2 ± 1 ? 5 ± 1 *# 3 ± 1 ! 5 ± 1 *# 3 ± 0 * 2 ± 0
Total 7 ± 1 4 ± 1 ! 6 ± 1 ? 10 ± 1 *# 7 ± 1 ! 9 ± 1 *# 6 ± 1 5 ± 1
nhP
Energy 18 ± 7 * 2 ± 2 ! 11 ± 8 ? 36 ± 11 *# 9 ± 5 ! 31 ± 12 *# 7 ± 3 4 ± 2
Pain 13 ± 8 * 9 ± 7 15 ± 9 20 ± 6 *# 21 ± 7 *# 18 ± 6 * 8 ± 2 4 ± 2
Emotional reaction 4 ± 2 5 ± 2 3 ± 2 9 ± 3 * 7 ± 3 9 ± 4 * 4 ± 1 2 ± 1
Sleep 10 ± 6 11 ± 6 15 ± 5 ? 21 ± 7 *# 30 ± 10 *# 30 ± 9 *# 9 ± 2 5 ± 2
Physical ability 14 ± 5 * # 4 ± 2 ! 12 ± 5 * 15 ± 5 *# 5 ± 3 15 ± 5 *# 7 ± 2 * 3 ± 1
Social isolation 0 ± 0 0 ± 0 0 ± 0 2 ± 2 0 ± 0 0 ± 0 3 ± 1 1 ± 1
NHP total score 10 ± 3 * 5 ± 2 9 ± 4 ? 17 ± 5 *# 12 ± 3 *# 17 ± 4 *# 6 ± 1 * 3 ± 1
Data are presented as mean ± SEM. ! significant difference vs. baseline values within the group; * significant difference vs. lean controls; # 









































Effect of a VLCD with and without exercise on quality of life
the two intervention groups. All patients scored significantly better directly after the 16-week 
intervention compared to baseline measurements on several subscales but mostly those 
concerning fatigue and physical ability. The VLCD with exercise group scored significantly 
better on 11 of the 22 subscales (i.e. the total of subscales of all four questionnaires) after the 
16-weeks intervention. These results were partly lasting, since after 18 months still 5 of the 22 
subscales remained improved. The VLCD-only group had a similar improvement in 9 of the 22 
subscales directly after the 16-week intervention. However, in this group all but one subscale 
of QoL had returned to baseline levels at 18 months.
The total QoL score (Figure 1) improves equally in both groups directly after the 16-week 
intervention. However only in the VLCD with exercise group this effect is lasting.
QoL in healthy controls vs. patients
At baseline, T2DM patients scored significantly worse on subscales concerning mostly physi-
cal functioning and fatigue compared to both lean and obese healthy controls of the same 
gender, age and ethnicity (Table 3). Also the total QoL score is significantly worse in both 
groups compared to lean and obese controls
Immediately after the 16-week intervention program, most QoL scores improved, even to 
the level of the lean control subjects. In the VLCD with exercise group patients performed 
worse only at 1 of the 22 subscales compared to lean or obese controls. The VLCD-only group 
performed worse at 9 and 4 of the 22 subscales compared to healthy lean and obese controls, 
resp. The total QoL score in the VLCD with exercise group improved to the level of the healthy 
Figure 1. Total Quality of life (QoL) score before (grey bars), directly after (dark grey bars) and 18 months (black bars) after a 16-week VLCD only 


























Data are presented as mean ± SEM. ! significant difference vs. baseline values within the group; * significant difference vs. lean controls; # 










































lean controls. The patients in the VLCD-only group also improved but not beyond the total 
QoL score of the obese control group.
The difference between the two intervention groups became more apparent after 18 
months. In the VLCD with exercise group the improvements in QoL persisted, none of the 
subscales differed from obese controls and only 4 of the 22 subscales were significantly 
worse compared to healthy lean controls after 18 months. The total QoL score also showed 
a persistent improvement; after 18 months there were still no significant differences in total 
QoL scores between patients in the VLCD with exercise group and healthy lean and obese 
controls. However, the QoL scores of the VLCD-only group returned almost back to their 
original levels; 17 and 13 of the 22 items were significantly worse compared to the lean and 
obese healthy controls, resp. In addition, the total QoL score of the VLCD-only group after 18 
months follow-up was significantly worse than that of healthy lean and obese controls.
In one of the subscales of the SF-36 namely health change both patients groups scored 
significantly better directly after the intervention compared to both lean and obese control 
subjects. In the VLCD with exercise group this was a lasting effect up to 18 months after 
start of the intervention. In the VLCD-only group, patients only scored significantly better 
compared to the obese control subjects.
DiSCuSSiOn
This study demonstrates that QoL parameters are considerably impaired in obese, insulin-
treated T2DM patients. Treatment with a 16-week VLCD with or without an exercise regi-
men considerably improved QoL, associated with major improvements in anthropometric 
characteristics and metabolic regulation. However, long-term follow-up shows that exercise 
is vital in maintaining the achieved anthropometric, biochemical and QoL improvements. 
Ultimately, in the VLCD with exercise group the total QoL score did not differ and only 4 of 
the 22 QoL subscales negatively differed from the values obtained in healthy lean controls. In 
contrast, the achieved improvements in QoL and glucoregulation were completely abolished 
in patients in the VLCD-only group after 18 months.
Our patients scored slightly better in the HADS items (anxiety and depression) at baseline 
compared to the T2DM patients described by Pouwer et. al (13). This might be due to the 
exclusion of patients with psychiatric problems and the use of antidepressant drugs in the 
present study. In addition, our patients were slightly younger, which is relevant since increas-
ing age is associated with decreased QoL (14). As far as we know, the MFI-20 questionnaire 
(containing items concerning fatique) has not been performed previously in T2DM patients. 
The NHP questionnaire (containing item regarding physical ability, social isolation energy 
levels) has been used sporadically in T2DM patients (15), whereas the SF-36 is the most used 









































Effect of a VLCD with and without exercise on quality of life
days) regardless of the population that is tested. Our patients and T2DM patients from previ-
ous other studies had comparable scores for the NHP and SF-36 questionnaire at baseline 
(4,15,16).
Our finding that diet-induced weight loss can lead to improvements in QoL directly after 
the intervention is in agreement with other studies (2,16). For example, Kaukua et al. (16) 
reported improvement in physical functioning and perception of health change related to 
weight loss after a low caloric diet in combination with Sibutramine or placebo measured by 
SF-36 in T2DM patients.
Several factors might have contributed to the improvement in QoL in our patients. Firstly, 
all patients lost a considerable amount of weight. Other studies have already shown that 
weight loss per se (e.g. after bariatric surgery) improves QoL (2). Secondly, insulin therapy 
was discontinued during the entire 16-week intervention period in our T2DM patients. After 
the intervention none of the patients in the VLCD with exercise group and almost 2/3 of the 
patients in the VLCD-only group still did not use insulin at 18 months follow-up. The use of 
insulin is associated with a lower QoL because of the burden of injections and self-control 
(1). Thirdly, the oral glucose-lowering medication was stopped as well, which may have de-
creased potentially present side-effects. However, since these medications were reinstituted 
after the intervention they cannot contribute to the lasting effect on QoL found in the VLCD 
with exercise group. The same applies to the fourth issue: improved glycemic control. This 
can ameliorate QoL via a decrease in metabolic oscillations as well as via reduced fear for the 
occurrence of long-term diabetic complications (1). However, improved metabolic control 
was only present at 16 weeks, not at 18 months. Fifthly, the undoubtedly better physical 
condition, due to more minutes of exercise per week at 18 months (Table 2) in the exercise 
group, might have contributed to the lasting effect on QoL. Lastly, there may also be the 
confounding effect of participation in a study, because intensive counseling and education 
has been shown to improve QoL (17). However, this did not apply at 18 months of follow-up. 
In our study none of the above ascribed factors could independently predict the improve-
ments in QoL (data not shown).
In contrast to what we hypothesized, the addition of an exercise program to a VLCD had no 
immediate additional positive effect on QoL as compared to a VLCD-only. This has also been 
reported by some (6,18), but not all previous publications (5,19). One possible explanation for 
this lack of a direct additional effect of exercise on QoL is that the magnitude of the achieved 
weight loss masked the effect of exercise. Moreover, it is possible that exercise also had some 
negative effects. For example, it may have increased muscle or joint pain or interfered with 
social life (19). However, this study clearly shows that exercise is of paramount importance in 
maintaining the diet-induced improvements in QoL, weight loss and glucoregulation.
After the intervention patients were referred to their own health care provider. We were 
not able to influence treatment strategies, neither with respect to weight loss nor on meta-










































by guidelines. Reluctance to reinstitute insulin therapy might have played a role. This makes 
it difficult to compare the two intervention groups regarding glucoregulation. The improve-
ment in HOMA-IR and insulin levels after the 16-week intervention only lasted in the VLCD 
with exercise group. Moreover, in none of the patients in this group insulin therapy was 
restarted. Together these observations are suggestive of a better glucoregulation and less 
insulin resistance after 18 months in the VLCD with exercise group. We observed a lasting 
improvement in body weight in both groups. The long-term effect of a VLCD on bodyweight 
and glucoregulation (20-24) in obese diabetic patients has been addressed before. Some 
investigators found lasting improvements in glucoregulation but not on body weight (21,24) 
whereas others found a deterioration of both body weight and glucoregulation (22,23). Our 
group found improvements in both glucoregulation and body weight (20) 18 months after 
following a 30-day VLCD .
A limitation of the present study is the relatively small sample size. Nonetheless, our results 
are in line with the existing literature regarding the effects of bariatric surgery which also 
causes a significant amount of weight loss, on QoL.
The improvement of QoL in T2DM patients is an important treatment goal. Interventions 
aimed at improving the perceptions of patients of their physical and mental health can 
enhance their commitment to self-management and adherence to therapy which will lead to 
positive lifestyle changes and better diabetes control. Therefore, our finding of an improved 
QoL after a 16-week VLCD with or without exercise in obese, insulin-dependent T2DM patients 
is very relevant. The positive effect of weight loss on QoL, in addition to its beneficial effects 
on glycemic control, insulin resistance and cardiovascular risk factors, should stimulate T2DM 
patients and health care givers to make a serious effort in achieving and maintaining weight 
loss. For that matter, we emphasize the paramount importance of exercise in maintaining the 
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Objective. To assess the short- and long-term effects of addition of exercise to a very low 
calorie diet (VLCD) on low-grade inflammation in obese patients with type 2 diabetes mel-
litus (T2DM).
Methods. 27 obese, insulin-dependent T2DM patients followed a 16-week VLCD with (n=13) 
or without (n=14) exercise (E) and were followed up to 18 months. Anthropometric mea-
surements, metabolic and inflammatory parameters were assessed before, directly after the 
intervention and at 6 and 18 months follow-up. The same measurements were performed 
only once in 56 healthy lean and 56 healthy obese controls.
results. At baseline hsCRP, IL10 and IL8 were significantly elevated in obese T2DM compared 
to lean healthy controls. After 16 weeks, despite substantial weight loss (-25.4±1.3kg), neither 
the VLCD nor VLCD+E had an effect on plasma cytokines. At 6 months, in the weight-stabiliz-
ing period, measures of low-grade inflammation had decreased substantially and equally in 
both intervention groups. Despite subsequent weight regain, beneficial effect was sustained 
upto 18 months in both groups, except for IL1 and hsCRP which had returned to baseline in 
the VLCD-only group.
Conclusion. Our findings suggest that severe caloric restriction increases cytokine produc-
tion by adipose tissue macrophages and that the beneficial effects of weight loss become 









































Effect of a VLCD with and without exercise on low-grade inflammation
inTrODuCTiOn
Insulin resistant states such as obesity and type 2 diabetes mellitus (T2DM) are associated 
with chronic low-grade inflammation, as indicated by higher circulating levels of C-reactive 
protein (CRP), interleukin 6 (IL6) and tumor necrosis factor alpha (TNFα) (1). These pro-inflam-
matory proteins and cytokines can intervene in intracellular signaling pathways involved in 
glucose uptake and insulin secretion (2,3). However, the temporal and causal relationship 
between insulin resistance and elevated markers of inflammation is as of yet unclear.
Both obesity and T2DM are independent risk factors for the development of premature ath-
erosclerosis and ischemic heart disease (1,4). Patients with T2DM have a 2-4 times increased 
cardiovascular disease (CVD) risk compared to healthy controls (5). This increased cardiovas-
cular risk appears to be associated not only with traditional cardiovascular risk factors such as 
smoking, gender, hypertension and dyslipidemia but also with the abovementioned markers 
of inflammation (6,7).
Caloric restriction (CR), weight loss and exercise improve glucoregulation in patients with 
T2DM and ameliorate the classic CVD risk factors hypertension and dyslipidemia (8). CR and 
weight loss induce a decline in CRP levels, both in obese, non-diabetic subjects as well as 
in obese diabetic subjects (9). In addition, weight loss and lifestyle interventions decrease 
plasma IL6 and TNFα levels in obese non-diabetic subjects (10-13). The effect of exercise on 
these two markers of inflammation is controversial (14,15). Moreover, the effects of a very low 
calorie diet (VLCD) on IL6, TNFα and CRP has only been studied after a 3-week intervention 
(16) in obese patients with T2DM and no long-term follow-up data are available. Therefore, 
the aim of this study was to assess the effects of a 16-week VLCD (Modifast, 450 kcal/day) on 
classic cardiovascular risk factors and low-grade inflammation in obese, insulin-dependent 
T2DM patients. We also assessed whether adding exercise to the VLCD had additional benefi-
cial effects on these outcomes. Patients were re-examined at 6 and 18 months after the start 
of the 16-week intervention, to evaluate the durability of the effects. In addition, the levels of 




Twenty-seven (14 males, 13 females) obese, insulin-dependent T2DM patients (disease 
duration 9±0.8 years, mean±standard error of the mean (SEM)) were enrolled in the study 
between June 2006 and June 2007. Clinical characteristics are summarized in Table 1. Exclu-
sion criteria were smoking, known history of CVD and/or other chronic or endocrine disease, 










































measured by an incremental cyclo-ergometer cardiac stress test). Patients had to use a mini-
mum dosage of 20 IU insulin/day.
For each T2DM patient, 2 lean control subjects and 2 obese control subjects, matched for 
age, gender, race, geographical area and in the obese group for BMI were included in the 
study. In Table 1 baseline characteristics of the lean and obese control groups are summarized.
Patients and healthy controls were recruited via advertisements in local newspapers, and 
patients also via the outpatient clinics of the departments of Endocrinology/Internal Medi-
cine in the Leiden University Medical Center. Written informed consent was obtained from all 
subjects. The study was approved by the ethics committee of our center.
Study design
All T2DM patients discontinued their oral glucose-lowering medication three weeks prior to 
the start of the study. Two days before the start of the study the last dose of long-acting insulin 
was given and the day before the start of the study the last dose of short-acting insulin was 
given at the evening meal. The glucose-lowering medication remained discontinued during 
the 16-week intervention. After the baseline study day (as outlined below) T2DM patients 
started a 16-week VLCD (450 kcal/day) consisting of three sachets of Modifast® (Nutrition & 
Santé, Antwerp, Belgium) per day. Modifast® contains all necessary vitamins and micronu-
trients. In addition, 13 of the 27 patients simultaneously followed an exercise program. This 
weekly exercise program comprised a minimum of 4 days training at home for 30 minutes at 
70% of maximum aerobic capacity on a cyclo-ergometer and a one-hour in hospital training 
under supervision of a physiotherapist (the attendance rate was 97%).
Table 1. Clinical characteristics.
VLCD + VLCD controls
exercise only obese lean
sex (M/F) 6/8 8/5 28/26 28/26
age (years) 56 ± 2 59 ± 2 56 ± 1 59 ± 2
weight (kg) 114 ± 5 * 113 ± 6 * 112 ± 3 * 73 ± 2
BMI (kg/m2) 36.4 ± 1.1 * 37.9 ± 1.4 * 37.6 ± 0.7 * 23.8 ± 0.3
waist (cm) 123 ± 3 * 122 ± 3 * 118 ± 2 * 87 ± 1
fat mass (kg) 45.4 ± 3.2 * 49.9 ± 3.6 * 39.2 ± 2.4 * 33.4 ± 2.2
HbA1c (%) 7.8 ± 0.4 * # 7.8 ± 0.3 * # 5.5 ± 0.1 * 5.2 ± 0.0
insulin (IU/day) 77 86 0 0
metformin (number of pts) 10 9 0 0
SU-derivatives (number of pts) 3 1 0 0
Data are presented as mean ± SEM. * significant difference vs. lean controls; # significant difference vs. obese controls.









































Effect of a VLCD with and without exercise on low-grade inflammation
 Patients visited the outpatient clinic weekly, for support, to keep up with the diet, measure-
ment of bodyweight and to check glucoregulation. Compliance with the diet and exercise 
was confirmed by questioning, counting sachets of Modifast that were supplied weekly and 
reading the heart rate monitor which was worn during exercise sessions both at home and in 
the hospital (Polar S610 i
tm, Polar Electro Oy, Finland). After the intervention a regular diet was 
slowly reintroduced with the aim of weight maintenance. Thereafter, patients were referred 
back to their original doctors and treated with routine care. The researchers performed a 
follow-up visit at 6 and 18 months after the start of the intervention.
At day 0 (start of the study), 16 weeks (end of the intervention), 6 and 18 months (follow-
up) patients were studied in the morning after an overnight fast and after 2 days without 
any exercise. All patients performed all the follow-up visits, so no patients were lost to 
follow-up. The lean and obese healthy controls were studied only once. Length, weight, BMI 
and waist circumference were measured according to the World Health Organization rec-
ommendations. Blood pressure was measured with an Omron 705IT blood pressure device 
(Omron Matsusaka Co., Ltd., Japan) and recorded within the limits of 1 mmHg. Fat mass was 
assessed by bioelectrical impedance analysis (Bodystat® 1500 MDD, Bodystat Ltd., Douglas, 
Isle of Man, United Kingdom). Fasting blood samples were drawn for the measurement of 
plasma glucose, insulin, hemoglobin A1c (HbA1c), high-sensitive C-reactive protein (hsCRP), 
IL1, IL2, IL6, IL8, IL10, TNFα and interferon gamma (INFγ), total cholesterol (TC), high density 
lipoprotein (HDL)-cholesterol, triglyceride (TG) levels and free fatty acids (FFA). Low density 
lipoprotein (LDL)-cholesterol was calculated with the Friedewald formula. Ten-year CVD risk 
was calculated with the United Kingdom Prospective Diabetes Study (UKPDS) risk engine 
(17). Only at baseline and after the 16-week intervention rate of appearance (Ra) of glycerol 
and free fatty acid levels were measured. Basal rates of glycerol appearance were measured 
after a 1.5 hours of continuous infusion of [2H5]-glycerol (Cambridge Isotopes, Cambridge, 
USA) as described previously. A physiological and isotopic steady-state was achieved during 
the last 30 min therefore, the Ra of glycerol were calculated as the tracer infusion rate divided 
by the tracer-to-tracee ratio.
assays
Plasma glucose, TC, HDL-cholesterol and TG concentrations were measured with a fully 
automated P-800 module (Roche, Almere, the Netherlands). Insulin was detected with an 
immunometric assay on an automated Immulite 2500 (Siemens, Breda, the Netherlands). Gly-
cosylated hemoglobin (HbA1c) levels were measured with a high-performance liquid chro-
matography (HPLC) system (Variant, Biomed, Hercules, California, USA). hsCRP levels were 
determined with an enzyme-linked immonosorbent assay (DSL, Webster, Texas, USA). Plasma 
free fatty acids (FFAs) concentrations were measured by a commercial kit (Wako Chemicals, 
Neuss, Germany). Plasma levels of the various cytokines were assessed using precoated 










































enzyme linked immunosorbent assay (ELISA) based electrochemiluminiscence assay. Briefly, 
plates were incubated with plasma or calibrator (25 µl/well) for 2 hours. After washing (3x, 
PBS with 2% Tween 20), detection antibody labeled with MSD SULFO-TAG (1 µg/mL) was 
added and incubated for another 2 hours. Wells were washed and reading buffer was added. 
Plates were immediately read using the SECTOR Imager 2400 and cytokine concentrations 
were determined by a non-linear standard curve fit.
Statistical analyses
A general linear model for repeated measurements analyzed differences within the patient 
groups at the various time points. Differences between both intervention groups were 
analyzed by calculating a delta between two time points. The deltas were subsequently 
compared using the two-tailed Student’s t-test for unpaired data or, when appropriate, by 
non-parametric tests for independent samples. Differences between all groups (the two in-
tervention groups and the two healthy controls) were analyzed using a one-way ANOVA, LSD 
post-hoc tests were used in case of a significant F-ratio. Data are presented as mean±SEM. 
Data analyses were performed using SPSS for Windows version 16.0 (SPSS Inc., Chicago, IL, 
USA). A p-value <0.05 was considered statistically significant.
rESuLTS
effect on bodyweight and glucoregulation
The VLCD with exercise (VLCD+E) and VLCD-only groups did not differ with respect to clinical 
and metabolic parameters at baseline (Table 1). Moreover, gender, age, weight, BMI and waist 
circumference of the obese control group were well matched with the T2DM patients. The 
lean and obese control groups had significantly lower levels of fasting glucose and HbA1c as 
compared to the two patient groups. Medication use of the patients can be found in Table 1.
Bodyweight and glucoregulation improved significantly (baseline vs. after the 16 week 
intervention bodyweight: VLCD+exercise 114±5 vs. 86±4 p<0.0001; VLCD only 113±6 vs. 
89±4 p<0.0001 HbA1c: VLCD+exercise 7.8±0.4 vs. 6.3±0.4 p<0.0001; VLCD only 7.8±0.3 vs. 
6.7±0.3 p<0.0001) and to an equal extent in both intervention groups directly after the 16-
week VLCD despite the cessation of all glucose-lowering medication. The VLCD+E group lost 
significantly more fat mass and waist circumference compared to the VLCD-only group (delta 
VLCD+exercise vs. delta VLCD fat mass -21.8±2.7 vs. -16.6±2.7 p=0.020; waist -24.8±1.5 vs. 
-19.3±1.7 p=0.049). At 6 and 18 months, both groups had gained weight. However, weight, 
fat mass and waist circumference were still significantly lower compared to baseline values in 
both groups (Table 2). Nevertheless at 18 months, glucoregulation had deteriorated in both 









































Effect of a VLCD with and without exercise on low-grade inflammation
Table 2. Clinical, metabolic characteristics and cholesterol levels before, directly after 6, and 18 months after a 16-week VLCD only or VLCD with 
exercise in obese insulin-dependent T2DM patients and comparisons with (obese and lean) healthy controls.
VLCD + VLCD controls
exercise only obese lean
weight (kg) baseline 114 ± 5 * 113 ± 6 * 112 ± 3 * 73 ± 2
16 weeks 86 ± 4 ! 89 ± 4 !
6 months 90 ± 5 ! ? 93 ± 5 ! ?
18 months 98 ± 5 ! ? 103 ± 5 ! ?
BMI (kg/m2) baseline 36.4 ± 1.1 * 37.9 ± 1.4 * 37.6 ± 0.7 * 23.8 ± 0.3
16 weeks 27.7 ± 1.0 ! 30.0 ± 1.1 !
6 months 28.9 ± 1.3 ! ? 31.1 ± 1.2 ! ?
18 months 31.6 ± 1.2 ! ? 34.7 ± 1.3 ! ?
waist (cm) baseline 123 ± 3 * 122 ± 3 * 118 ± 2 * 87 ± 1
16 weeks 98 ± 3 ! 103 ± 3 !
6 months 101 ± 3 ! 105 ± 3 !
18 months 107 ± 4 ! ? 114 ± 3 ! ?
fat mass (kg) baseline 45.4 ± 3.2 * 49.9 ± 3.6 * 39.2 ± 2.4 * 33.4 ± 2.2
16 weeks 23.5 ± 2.2 ! 33.2 ± 2.8 !
6 months 29.5 ± 2.8 ! ? 35.2 ± 2.9 ! ?
18 months 35.4 ± 2.6 ! ? 44.2 ± 3.0 ! ?
systolic bloodpressure (mmHg) baseline 145 ± 5 161 ± 4 149 ± 3 141 ± 3
16 weeks 132 ± 5 ! 140 ± 4 !
6 months 136 ± 4 ! 142 ± 4 !
18 months 146 ± 5 ? 157 ± 4 ?
diastolic bloodpressure (mmHg) baseline 81 ± 3 87 ± 3 87 ± 1 82 ± 1
16 weeks 75 ± 2 78 ± 2 !
6 months 77 ± 3 83 ± 2 ?
18 months 82 ± 2 ? 89 ± 3 ?
heart rate (beats/min) baseline 79 ± 2 * 82 ± 3 * 70 ± 2 67 ± 2
16 weeks 64 ± 3 ! 69 ± 3 !
6 months 65 ± 3 ! 70 ± 3 !
18 months 70 ± 4 76 ± 3
HbA1c (%) baseline 7.8 ± 0.4 * # 7.8 ± 0.3 * # 5.5 ± 0.1 * 5.2 ± 0.0
16 weeks 6.3 ± 0.4 ! 6.7 ± 0.3 !
6 months 6.1 ± 0.4 ! 6.7 ± 0.3 !
18 months 7.5 ± 0.6 8.2 ± 0.5 ?
fasting glucose (mmol/L) baseline 10.9 ± 0.7 * # 12.1 ± 0.5 * # 5.5 ± 0.1 * 4.9 ± 0.1
16 weeks 6.6 ± 0.8 ! 7.7 ± 0.6 !
6 months 7.4 ± 0.7 ! 8.4 ± 0.8 !











































VLCD + VLCD controls
exercise only obese lean
fasting insulin (mU/L) baseline 25 ± 2 * # 24 ± 4 * # 14 ± 1 * 5 ± 0
16 weeks 9 ± 1 ! 13 ± 2 !
6 months 9 ± 2 ! 11 ± 2 ! ?
18 months 13 ± 2 ! 17 ± 6
HOMA-IR baseline 12.3 ± 1.3 * # 12.9 ± 2.3 * # 3.4 ± 0.3 * 1.1 ± 0.1
16 weeks 2.5 ± 0.2 ! 4.3 ± 0.8 !
6 months 2.7 ± 0.5 ! 4.3 ± 1.0 !
18 months 4.7 ± 0.8 ! ? 9.0 ± 3.1
TC (mmol/L) baseline 5.4 ± 0.4 6.1 ± 0.4 6.0 ± 0.1 6.0 ± 0.1
16 weeks 4.5 ± 0.3 ! 5.5 ± 0.3
6 months 4.4 ± 0.4 ! 4.7 ± 0.3 ?
18 months 4.3 ± 0.3 ! 5.5 ± 0.4
TG (mmol/L) baseline 2.5 ± 0.5 * # 2.3 ± 0.2 * # 1.6 ± 0.1 * 1.1 ± 0.1
16 weeks 1.2 ± 0.1 ! 1.5 ± 0.2 !
6 months 1.2 ± 0.2 ! 1.5 ± 0.2 !
18 months 1.9 ± 0.3 ? 2.8 ± 0.6 ?
HDL (mmol/L) baseline 1.1 ± 0.0 * # 1.2 ± 0.1 * # 1.4 ± 0.0 * 1.8 ± 0.1
16 weeks 1.2 ± 0.1 1.2 ± 0.1
6 months 1.4 ± 0.1 ! ? 1.5 ± 0.1 ?
18 months 1.2 ± 0.1 1.4 ± 0.1 !
Chol:HDL ratio baseline 4.9 ± 0.4 * 5.3 ± 0.4 4.2 ± 1.4 * 3.5 ± 1.4
16 weeks 4.0 ± 0.3 ! 4.8 ± 0.4 !
6 months 3.0 ± 0.2 ! 3.1 ± 0.2 !
18 months 3.7 ± 0.3 ! 4.1 ± 0.3 !
LDL (mmol/L) baseline 3.6 ± 0.3 4.4 ± 0.4 3.8 ± 0.1 3.7 ± 0.1
16 weeks 3.0 ± 0.3 ! 3.7 ± 0.3 !
6 months 2.4 ± 0.2 ! ? 2.8 ± 0.2 ! ?
18 months 2.5 ± 0.7 ! 3.5 ± 1.0
FFA (mmol/L) baseline 0.9 ± 0.1 1.0 ± 0.1
16 weeks 0.9 ± 0.0 1.0 ± 0.1
Ra glycerol (µmol/kgFFM/min) baseline 12.9 ± 1.0 11.3 ± 1.2
16 weeks 15.9 ± 1.1 ! 11.3 ± 1.3
Data are presented as mean ± SEM. ! significant difference vs. baseline values within the group; ? significant difference vs. 16 weeks values 
within the group; * significant difference vs. lean controls; # significant difference vs. obese controls.
BMI: Body mass index; HOMA-IR: homeostatic model assessment of insulin resistance; TC: total cholesterol; TG: triglyceride; HDL: high-density 









































Effect of a VLCD with and without exercise on low-grade inflammation
effect on lipids and blood pressure
After the 16-week VLCD ± exercise intervention, systolic blood pressure, TG, cholesterol /HDL-
cholesterol ratio and LDL-cholesterol decreased significantly (Table 2), whereas TC improved 
only in the VLCD+E group. At 18 months the effects on blood pressure and TG were com-
pletely abolished in both intervention groups while the beneficial effect on the cholesterol/
HDL-cholesterol ratio was maintained. The decline in LDL-cholesterol was sustained only in 
the VLCD+E group.
Ten year coronary heart disease risk estimates (UKPDS risk score) showed a non-significant 
improvement in both intervention groups (baseline vs. 18 months follow up: 17.4±2.9% to 
11.0±1.8% VLCD+E group and 24.7±4.3% to 19.2±3.5% VLCD-only group).
effect on low-grade inflammation
Directly after the 16-week intervention hsCRP levels declined only in the VLCD+E group 
(p=0.011) (Table 4). All plasma cytokines in both intervention groups were equal or even 
higher compared to baseline values immediately after the intervention. On the contrary, at 
6 months hsCRP was lower in both the VLCD-only group (p=0.005) and the VLCD+E group 
(p=0.005). Moreover, all pro-inflammatory cytokines (including TNFα and IL6) were sig-
nificantly lowered in both groups. At 18 months, hsCRP and all measured pro-inflammatory 
cytokines were still reduced compared to baseline in the VLCD+E group (p=0.038). In the 
VLCD-only group, hsCRP (p=0.065) and IL1 (p=0.410) returned to baseline whereas other 
plasma cytokine levels remained lowered.
Table 3. Use of medication before, directly after 6 and 18 months after a 16-week VLCD only or VLCD with exercise in obese insulin-dependent 
T2DM patients.

















insulin (IU/day) 77 0 0 0 86 0 2 36
metformin (*) 10 13 13 12 9 14 13 12
SU-derivatives (*) 3 0 1 4 1 0 5 4
statine (*) 9 13 13 12 9 14 13 10
0/1 antihypertensiva (*) 6 8 8 6 3 6 7 7
2 antihypertensiva (*) 3 3 3 4 6 4 3 1
3 of more antihypertensiva (*) 4 2 2 3 5 4 4 6
exercise (min/week) 34 180 132 192 24 0 75 45










































Table 4. Low-grade inflammation before, directly after 6 and 18 months after a 16-week VLCD only or VLCD with exercise in obese insulin-
dependent T2DM patients and comparisons with (obese and lean) healthy controls.
VLCD + VLCD controls
exercise only obese lean
hsCRP baseline 5.1 ± 0.9 * 5.5 ± 1.1 * 4.5 ± 0.7 * 1.7 ± 0.5
16 weeks 2.8 ± 0.7 ! 4.9 ± 2.0 *
6 months 1.6 ± 0.4 ! # 2.2 ± 0.5 !
18 months 2.2 ± 0.7 ! 3.3 ± 0.5
IFNγ baseline 2.6 ± 0.9 2.3 ± 0.2 2.7 ± 0.5 1.8 ± 0.4
16 weeks 2.5 ± 0.4 2.0 ± 0.1
6 months 1.0 ± 0.3 ! ? 1.6 ± 0.3 !
18 months 2.0 ± 0.9 ! 1.6 ± 0.3 !
IL10 baseline 10.2 ± 2.9 * # 6.7 ± 1.8 * 4.2 ± 0.6 3.5 ± 0.7
16 weeks 15.2 ± 6.9 * # 6.7 ± 2.0
6 months 7.4 ± 3.7 * ? 3.6 ± 1.9 ! ?
18 months 5.4 ± 2.2 ! 3.8 ± 1.5 ! ?
IL1 baseline 0.5 ± 0.1 0.5 ± 0.1 0.2 ± 0.0 0.4 ± 0.1
16 weeks 0.4 ± 0.1 0.8 ± 0.2 * #
6 months 0.2 ± 0.1 ! 0.3 ± 0.1 ! ?
18 months 0.1 ± 0.0 ! ? 0.4 ± 0.1
IL2 baseline 0.6 ± 0.1 1.0 ± 0.2 * 0.6 ± 0.1 0.3 ± 0.1
16 weeks 0.7 ± 0.1 1.2 ± 0.2 * #
6 months 0.1 ± 0.0 ! ? 0.3 ± 0.1 ! ?
18 months 0.2 ± 0.1 ! ? 0.3 ± 0.1 ! ?
IL6 baseline 2.0 ± 0.3 2.4 ± 0.4 3.1 ± 0.6 1.6 ± 0.4
16 weeks 1.9 ± 0.2 2.2 ± 0.4
6 months 1.0 ± 0.1 ! ? 1.1 ± 0.2 ! ?
18 months 1.1 ± 0.2 ! ? 1.2 ± 0.2 ! ?
IL8 baseline 6.3 ± 0.7 * # 7.5 ± 1.3 * # 2.6 ± 0.2 * 2.1 ± 0.1
16 weeks 5.9 ± 0.5 * # 7.0 ± 0.9 * #
6 months 2.8 ± 0.4 ! ? 2.2 ± 0.3 ! ?
18 months 2.8 ± 0.3 ! ? 2.9 ± 0.4 ! ?
TNFα baseline 7.6 ± 1.3 6.6 ± 0.5 6.2 ± 0.6 5.8 ± 0.5
16 weeks 7.2 ± 0.5 * # 7.0 ± 0.7
6 months 4.2 ± 0.5 ! ? 4.5 ± 0.6 ! ?
18 months 4.4 ± 0.5 ! ? 4.5 ± 0.6 ! ?
Data are presented as mean ± SEM. ! significant difference vs. baseline values within the group; ? significant difference vs. 16 weeks values 
within the group; * significant difference vs. lean controls; # significant difference vs. obese controls.









































Effect of a VLCD with and without exercise on low-grade inflammation
parameters of low-grade inflammation in healthy controls vs. patients
At baseline, both patient groups and the healthy obese controls had significantly higher 
hsCRP and IL8 levels compared to healthy lean controls, also patients had higher levels of the 
presumed anti-inflammatory cytokine IL10. Directly after the 16-week intervention hsCRP 
declined only in the VLCD+E group and not to the level of healthy lean controls. It was only 
2 months after the cessation of both interventions (i.e. at 6 months), when patients were on 
a eucaloric diet, that parameters of chronic inflammation improved to the levels of healthy 
lean controls, with the exception of IL8 in the VLCD+E group (Table 4). At 18 months pro-
inflammatory markers were still reduced and comparable to healthy lean controls in both 
patient groups.
DiSCuSSiOn
This study shows that a 16-week VLCD or a 16-week VLCD+E have equal effects on lower-
ing body weight and improving glucoregulation and dyslipidemia. Remarkably, this led not 
to an immediate lowering of markers of low-grade inflammation with the exception of a 
decrease in hsCRP in the VLCD+E group. Surprisingly, at 6 months all measured cytokines 
and hsCRP were significantly lower and comparable to the values in healthy lean controls. 
These effects were sustained after 18 months of follow-up. The direct effect of the 16-week 
intervention on the cardiovascular risk factors hypertension and dyslipidemia was not last-
ing; only cholesterol-HDL ratio and LDL-cholesterol were still lower compared to baseline at 
18 months in the VLCD+E group.
The effect of dietary interventions on hsCRP levels has mostly been studied in obese 
non-diabetic subjects. Weight loss was clearly associated with a decrease in hsCRP in these 
subjects and is related to the amount of weight loss (9). Exercise had no, or only a minimal 
effect on hsCRP levels in either obese non-diabetic or obese diabetic patients (14,15,18). 
We showed that hsCRP levels decreased immediately after the intervention in the VLCD+E 
group. In the VLCD-only group, hsCRP levels declined just at six months when energy intake 
was eucaloric and weight loss still preserved. Interestingly, another study in obese T2DM 
patients, using a diet of ~1600 kcal for 8 weeks leading to 5-6 kg weight loss, also showed 
no improvement in hsCRP directly after the intervention but did so at 12 months follow-up 
(19). These findings could suggest that a VLCD combined with exercise is lowering activation 
of the acute phase response by the liver, while VLCD-only does not. The exact mechanism by 
which diets and exercise lower hsCRP levels needs further investigation.
In obese non-diabetic patients, diet, exercise or combined interventions have controver-
sial effects on plasma IL6 and TNFα levels (10-13,20-22). Studies performed in obese T2DM 
patients are scarce. In one study, 7 obese T2DM women received a VLCD for 3 weeks which 










































effect of a VLCD of longer duration (16 weeks) on IL6 and TNFα levels but at 6 and 18 months 
both were improved compared to baseline in the two intervention groups alike. It should 
be noted that the effects of acute and chronic exercise are different (23). Acute exercise 
can elicit a pro-inflammatory response whereas chronic exercise is thought to mediate an 
anti-inflammatory effect. To purely study the chronic effects of exercise we performed our 
measurements after 2 days of abstinence of exercise. At 16 weeks no effects of a VLCD+E on 
plasma TNFα and IL6 levels were observed but at 6 and 18 months TNFα and IL6 levels were 
decreased compared to baseline. In several other exercise studies the effects on IL6 were 
equivocal and there were no effects on TNFα (15,22).
The effects on the presumed anti-inflammatory cytokine IL10 are paradoxical. We found 
elevated levels in both patient groups compared to healthy lean controls at baseline and a 
slow decrease in IL10 levels during the intervention with near-normalization at 18 months. 
On the contrary, a 4-week aerobic exercise training (3 times/week 60 minutes, level of inten-
sity not specified) had no effect on IL10 levels in twenty obese T2DM patients (14) whereas a 
6-month aerobic exercise intervention (4 times/week 45-60 minutes) significantly increased 
IL10 levels in 60 obese T2DM patients (24). Perhaps patient characteristics (obese vs. obese 
diabetics on insulin therapy), differences in intervention and/or assays used can explain the 
discrepancy found.
We could not find articles discussing the effects of a VLCD±exercise on the other cytokines 
measured (IL1, IL2 and INFγ). All these cytokines are pro-inflammatory cytokines. We hypoth-
esize that this is the reason why these cytokines show the same trend as IL6 and TNFα.
The mechanisms by which CR, weight loss and exercise decrease plasma pro-inflammatory 
cytokines and increase anti-inflammatory cytokines are largely unknown. One putative mech-
anism is the decrease in visceral fat mass. Visceral adipose tissue (which consists of fat cells, 
adipose tissue macrophages (ATMs) and stromal vascular fraction) releases several so-called 
adipocytokines among which IL1, IL6 and TNFα that in turn stimulate CRP-production by the 
liver (25). Indeed, waist circumference, an indirect measure of visceral fat mass was decreased 
significantly as compared to baseline at all measured time points. Furthermore, the decrease 
in waist circumference was larger in the VLCD+E group, which indeed exhibited the greatest 
although non-significant beneficial effects on plasma cytokines. However, we could not find a 
correlation between the change in waist circumference and the change in plasma cytokines. 
The lack of an immediate effect of a VLCD+/-E on low-grade inflammation has been observed 
by others. In 22 obese women undergoing a 4 week VLCD (800 kcal/day) followed by a 2-month 
hypocaloric diet (-600 kcal of estimated energy requirements) a euglycaemic hyperinsulinae-
mic clamp with adipose tissue biopsies for adipocyte and macrophage gene expression and 
markers were performed (26). It appeared that adipocyte genes involved in metabolism were 
downregulated during the VLCD and upregulated during weight stabilization (hypocaloric 
diet) whereas macrophage genes involved in inflammatory pathways were upregulated dur-









































Effect of a VLCD with and without exercise on low-grade inflammation
hypocaloric diet (with decreased plasma inflammatory markers). This is compatible with our 
findings of lower levels of inflammation after the 16 week-intervention during the weight sta-
bilization period, and has recently been further investigated in mice (27). CR led to a gradual 
decrease in body weight and fat mass in previously high-fat fed mice due to a decrease in 
adipocyte size not number. However, ATM content increased during the first 3 days of the 
diet (and these were lipid-loaded macrophages) to gradually decrease thereafter. This rise 
and fall of ATM content was closely correlated with plasma free fatty acid levels and adipose 
tissue lipolysis. Total lipolysis is the sum of basal lipolysis (which is elevated in adiposity and 
greater in visceral vs. subcutaneous adipose tissue) and demand lipolysis (which is driven by 
hormones in response to nutritional demands). The authors speculate that in early weight 
loss, adipocyte size is the same and therefore basal lipolysis remains high. However, demand 
lipolysis increases with an increase in local free fatty acids that subsequently attract ATMs. 
These ATMs phagocytose excess lipids and might even secrete antilipolytic factors followed 
by a decrease of the free fatty acid-driven cytokine production. We only measured rate of 
appearance of glycerol and plasma free fatty acids in the patients before and after 16 weeks 
of a VLCD+/-E. Indeed, at 16 weeks free fatty acids levels were equal as compared to the start 
of the diet and rate of appearance of glycerol, which was high at baseline, had not changed 
in the VLCD-only group whereas it was further increased in the VLCD+E group. This suggests 
that our patients were still having a high (demand) lipolytic rate at 16 weeks (while still on the 
VLCD) with probably still elevated levels of ATMs, explaining the lack of decrease in plasma 
cytokines at 16 weeks. We presume that when a eucaloric diet was reinstituted the demand 
lipolysis decreased with lower local free fatty acid levels, a decrease in ATMs and subsequent 
decrease in plasma cytokines. This hypothesis, already tested in mice (27), should be further 
investigated in obese humans during various stages of CR with adipose tissue biopsies. The 
set-up will be limited however, by the fact that it is difficult to obtain visceral fat biopsies.
A limitation of the present study is the relatively small sample size. Nonetheless, our results 
are in line with the existing literature. Furthermore we measured the control population once 
only. The reason for this is that the lean control subjects were not able to perform a 16 week 
VLCD. Another limitation is the lack of fat biopsies. Fat biopsies could have provided more 
information for example with regard to the amount of macrophages in the fat mass. A pos-
sible confounder in the data could be that all patients in who insulin therapy was reinstated 
at 18 months came from the VLCD-only group, this could mean higher advanced glycated 
end products in this group. However fasting glucose levels and HbA1c levels were similar in 
both groups at 18 months, other advanced glycated end products have not been measured.
In conclusion, a 16-week VLCD with or without exercise does not directly decrease pro-
inflammatory plasma cytokine levels despite a large decrease in body weight and waist cir-
cumference and an improvement in dyslipidemia and glucoregulation. The beneficial effects 
on chronic inflammation became apparent only when patients were on a eucaloric regular 










































gain and deterioration of glucoregulation. Our findings are compatible with the hypothesis 
that demand lipolysis activation during CR leads to local free fatty acid accumulation with 
attraction of ATMs and hence an increased production of cytokines (27). When nutritional 
status is eucaloric and demand lipolysis decreases the amount of ATMs will decrease along 
with a reduction in cytokine production. This hypothesis should be confirmed in humans 
with adipose tissue biopsies during various amounts of calorie restriction. The initial ques-
tion was whether exercise has additional beneficial effects on low-grade inflammation. This 
appears to be true only for hsCRP. Nonetheless, since chronic inflammation is associated with 
cardiovascular risk this study again shows the importance of weight reduction and exercise 
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Objectives. Myocardial triglyceride (TG) content is increased in patients with type 2 diabetes 
mellitus (T2DM) and may reflect altered myocardial function. It is unknown whether myocar-
dial TG content is influenced during a therapeutic intervention. This study sought to assess 
the effects of prolonged caloric restriction in obese patients with T2DM on myocardial TG 
content and myocardial function.
Methods. Myocardial TG content (magnetic resonance [MR] spectroscopy), myocardial func-
tion (MR imaging), plasma hemoglobin A1c, and body mass index (BMI) were measured in 12 
obese, insulin-treated T2DM patients before and after a 16-week very low calorie diet (VLCD) 
(450 kcal/day) to achieve substantial weight loss. Insulin was stopped during the VLCD.
results. The BMI decreased from 35.6 ± 1.2 kg/m2 (baseline, mean ± SEM) to 27.5 ± 1.3 kg/
m2 (after the VLCD, p <0.001) and was associated with an improvement in hemoglobin A1c 
from 7.9 ± 0.4% (baseline) to 6.3 ± 0.3% (after the VLCD, p = 0.006). Myocardial TG content 
decreased from 0.88 ± 0.12% to 0.64 ± 0.14%, respectively (p = 0.019), and was associated 
with improved diastolic function (reflected by the ratio between the early and atrial filling 
phase) from 1.02 ± 0.08 to 1.18 ± 0.06, respectively (p = 0.019).
Conclusions. Prolonged caloric restriction in obese T2DM patients decreases BMI and 
improves glucoregulation associated with decreased myocardial TG content and improved 
diastolic heart function. Therefore, myocardial TG stores in obese patients with T2DM are 









































Short-term effect of a VLCD on myocardial triglyceride content and function
inTrODuCTiOn
Obesity and type 2 diabetes mellitus (T2DM) are associated with increased deposition of 
triglycerides (TG) in nonadipose tissue, such as the heart, liver, pancreas, and skeletal muscle 
(1-4). There are indications from animal experiments and human observations that the in-
crease in myocardial TG content is associated with altered myocardial function. In animal ex-
periments, increased myocardial TG content is associated with impaired myocardial function 
(5,6) via complex routes involving free fatty acid (FFA) derivatives, such as FFA acyl-coenzyme 
A and diacylglycerol (7-9).
In humans, myocardial TG content can be measured noninvasively in vivo by proton mag-
netic resonance spectroscopy (1H-MRS) (10-14). Studies have documented that increased 
myocardial TG stores in obese subjects are accompanied by increased left ventricular (LV) 
mass (13) and changes in LV diastolic function (2).
In healthy subjects, myocardial TG stores are not fixed, but vary depending on nutritional 
conditions. For instance, short-term caloric restriction dose-dependently increases myocar-
dial TG content (15), whereas a single high-fat meal does not affect myocardial TG stores (12). 
Recently, we reported that the increase in myocardial TG content induced by short-term 
caloric restriction is associated with impaired diastolic function in healthy normal-weight 
subjects (15,16).
Caloric restriction is an important lifestyle factor in the treatment of obese patients with 
T2DM. However, the effects of caloric restriction on myocardial TG content have not been 
studied in these patients. Therefore, the primary goal of the present study was to evaluate 
the effects of prolonged caloric restriction in obese patients with T2DM on myocardial TG 
content and LV myocardial function in relation to metabolic regulation. In addition, T2DM 
is associated with ectopic deposition of TG in the liver (17,18). To assess the tissue-specific 
effects of caloric restriction, we also assessed liver TG content in these obese T2DM patients.
PATiEnTS AnD METhODS
patients
We studied 12 obese (body mass index (BMI), mean ± SEM: 35.6 ± 1.2 kg/m2) T2DM patients 
(7 men, 5 women). The mean duration of T2DM was 9.6 ± 1.4 years. The patients’ age was 48.3 
± 2.8 years. Patients were recruited from the outpatient clinic. All subjects used insulin treat-
ment (mean dosage 93 ± 21 IU/day) with or without concomitant use of oral blood glucose-
lowering agents. Exclusion criteria were smoking; an abnormal stress electrocardiogram 
(ECG); the use of other medication known to influence lipolysis and/or glucose metabolism; 
and renal, hepatic, or other endocrine disease. Furthermore, subjects were excluded if the 










































ng/l and/or <2-fold increase after glucagon stimulation (1.0 mg intravenously). This criterion 
was included because we documented in a previous study that preservation of the capacity 
of beta cells to secrete insulin predicts a favorable metabolic response to a very low calorie 
diet (VLCD) in obese T2DM patients (19,20). Body weight was stable for at least 3 months, and 
subjects were instructed not to change lifestyle habits (eating, drinking, and exercise) from 
screening until the start of the study. The protocol was approved by the institutional ethical 
committee, and all subjects provided written informed consent before participation.
Study design
The study consisted of 2 study occasions separated by a 16-week intervention period, during 
which the subjects used a VLCD to induce substantial weight loss. The VLCD consisted of 3 
sachets of Modifast per day (450 kcal/day, Nutrition & Santé, Antwerp, Belgium), providing 
about 50 g protein, 50 to 60 g carbohydrates, and 6 g lipids daily. Three weeks before start 
of the intervention period, all oral blood glucose–lowering drugs were discontinued and 
the insulin therapy was intensified. Baseline magnetic resonance (MR) measurements were 
obtained in the postprandial state (4 h after the last meal) within 1 week before the start of 
the VLCD. Baseline blood samples were obtained after an overnight fast. At the start of the 
VLCD and during the whole intervention period, all glucose-lowering medication, including 
insulin, was discontinued. Six of the 12 subjects followed an exercise program in addition to 
the VLCD, but were not different with respect to outcome parameters. After 16 weeks, MR 
measurements (4 h after the last meal) were repeated. Blood samples were taken after an 
overnight fast.
1h-MrS of the heart and the liver
All measurements were performed on a 1.5-T Gyroscan ACS-NT MR imaging scanner (Philips 
Medical Systems, Best, the Netherlands) in the supine position. For 1H-MRS measurements, 
a body coil for radiofrequency transmission and a surface coil (diameter of 17 cm) for signal 
receiving were used. A point-resolved spatially localized spectroscopic pulse sequence was 
used to acquire single-voxel (8 ml) spectra. For the heart, the voxel was placed in the myo-
cardial septum on 4-chamber and short-axis images at end systole, avoiding contamination 
with epicardial fat. Data acquisition was double-triggered using ECG triggering and naviga-
tor echoes to minimize breathing artifacts (14). For the liver, voxel sites were matched at the 
study occasions (by using the 12th thoracic vertebra as an anatomical landmark), carefully 
avoiding blood vessels and bile ducts. Water-suppressed spectra with 128 averages were col-
lected to detect lipid signals from the heart, and suppressed spectra with 64 averages were 
acquired from the liver. Spectral parameters included: repetition time of at least 3,000 ms, 
echo time 26 ms, and 1,024 data points over 1,000-kHz spectral width. Furthermore, unsup-
pressed spectra with 4 averages were acquired in the same voxel, using the same parameters 









































Short-term effect of a VLCD on myocardial triglyceride content and function
advanced MR algorithm in the Java-based MR user interface software (jMRUI version 2.2, A. 
van den Boogaart, Katholieke Universiteit Leuven, Leuven, Belgium) (21), as described earlier 
(14). Peak estimates of lipid resonances of myocardial and hepatic TG at 1.3 and 0.9 ppm were 
summed and calculated as a percentage of the unsuppressed water signal (%TG, TG/water × 
100) and used in further analysis.
Left ventricular function
Imaging was performed at 1.5 T in a single session together with spectroscopy measure-
ments, using a body coil for radiofrequency transmission and a 5-element synergy coil for 
signal receiving. The heart was imaged in the short-axis orientation using an ECG-triggered, 
sensitivity-encoding balanced steady-state free procession sequence to assess systolic func-
tion. Imaging parameters were: field-of-view = 400 × 320 mm, matrix size = 256 × 256, slice 
thickness = 10 mm, slice gap = 0 mm, flip angle = 35°, echo time = 1.67 ms, and repetition 
time = 3.34 ms. Temporal resolution was 25 to 39 ms (depending on the heart rate). End-
diastolic and –systolic images were identified on all slices, and dedicated postprocessing 
software (MASS, V2007-EXP, Leiden University Medical Center, Medis, Leiden, the Nether-
lands) was used to quantify LV ejection fraction, LV mass, cardiac output, stroke volume, and 
end-diastolic and -systolic volume as described previously (22). Furthermore, we calculated 
cardiac index, LV mass index, stroke volume index, end-diastolic index, and end-systolic index 
by dividing the parameter by body surface area. To asses LV diastolic function, an ECG-gated 
gradient echo sequence with velocity encoding was performed to measure blood flow across 
the mitral valve (23). Imaging parameters were: echo time = 5 ms, repetition time = 14 ms, 
flip-angle = 20°, slice thickness = 8 mm, field of view = 350 mm, matrix size = 256 × 256, veloc-
ity encoding = 100 cm/s, and scan percentage = 80%. Flow velocities in early diastole (E) and 
at atrial contraction (A) were measured and their peak flow ratio was calculated (E/A ratio) 
using the FLOW analytical software package (V2006-EXP, Leiden University Medical Center, 
Medis). Furthermore, the downslope of the early filling phase (E deceleration) and an estima-
tion of LV filling pressures (E/Ea) (24) were calculated. During MR imaging, blood pressure and 
heart rate were measured with an automatic device (Dinamap DPC100X, Freiburg, Germany).
assays
Plasma glucose, total cholesterol, and TG concentrations were measured on a fully automated 
P800 analyzer (Roche, Almere, the Netherlands). Insulin was measured with an immunoradio-
metric assay (Biosource, Nivelles, Belgium). Coefficients of variation were <2% for glucose 
and <5% for insulin. Plasma levels of free fatty acids (FFA) were measured using a commercial 
kit (FFA-C, Wako Chemicals, Neuss, Germany). The hemoglobin A1c levels were measured 
with an HPLC system (Variant, Biomed, Hercules, California). Leptin and adiponectin were 
measured with a radioimmunoassay from Linco Research (St.Charles, Missouri), with coef-










































sensitivity of 0.5 µg/l. The high-sensitivity C-reactive protein enzyme-linked immunosorbent 
assay came from DSL (Webster, Texas). The sensitivity was 0.03 mg/l, and the coefficient of 
variation was between 3% and 6%.
Statistical analyses
All statistical analyses were performed with SPSS version 14.0 (SPSS Inc., Chicago, Illinois). 
Statistical comparisons between baseline measurements and measurements after prolonged 
caloric restriction were made by paired t test. Data are shown as mean ± SEM. A value of p < 
0.05 was considered to reflect significant differences.
rESuLTS
Metabolic parameters
Caloric restriction reduced BMI from 35.6 ± 1.2 kg/m2 at baseline to 27.5 ± 1.3 kg/m2 after the 
intervention period (p < 0.001) (Figure 1). Metabolic parameters before and after prolonged 
caloric restriction are shown in Table 1 and Figure 2. After a 16-week VLCD, glycemic control 
was significantly improved; fasting plasma glucose levels decreased from 11.4 ± 0.6 mmol/l 
at baseline (despite glucose-lowering therapy by high-dose insulin) to 6.7 ± 0.6 mmol/l after 
prolonged caloric restriction (only on a VLCD without any glucose-lowering therapy for 16 
weeks, p < 0.001). Furthermore, HbA1c levels decreased from 7.9 ± 0.4% to 6.3 ± 0.3% at 
baseline and after prolonged caloric restriction, respectively, p = 0.006). Plasma FFA levels 
were 0.92 ± 0.07 mmol/l at baseline and decreased to 0.67 ± 0.05 mmol/l after prolonged 
caloric restriction (p < 0.001) (Figure 2A). Furthermore, plasma levels of liver enzymes, total 
cholesterol, TGs, leptin, and C-reactive protein were significantly decreased after the VLCD 
compared with baseline, whereas plasma adiponectin levels were increased (Table 1, Fig-
ure 2).
Figure 1. Fat stores and body mass index. Example of a transverse slice at the level of the 5th lumbar vertebrae showing visceral and 
subcutaneous fat depots, illustrating the effects of a 16-week very low calorie diet (VLCD) in the same patient (A and B). Body mass index (BMI) 













































Short-term effect of a VLCD on myocardial triglyceride content and function
Table 1. Metabolic response to 16 weeks of caloric restriction in obese patients with type 2 diabetes mellitus.
baseline after 16 wks
Glucose (mmol/l) 11.4 ± 0.6 6.7 ± 0.6 *
HbA1c (%) 7.9 ± 0.4 6.7 ± 0.6 !
Insulin (mU/l) 39 ± 9 10 ± 3 !
AST (mmol/l) 44 ± 5 27 ± 3 !
ALT (mmol/l) 52 ± 12 23 ± 3 !
γGT (mmol/l) 38 ± 5 18 ± 2 !
Total cholesterol (mmol/l) 5.7 ± 0.5 4.8 ± 0.2 !
Free fatty acids (mmol/l) 0.92 ± 0.07 0.67 ± 0.05 *
TG (mmol/l) 2.1 ± 0.3 1.1 ± 0.1 *
Leptin (µg/l) 21.5 ± 4.3 7.6 ± 3.4 *
Adiponectin (µg/l) 5.2 ± 0.7 7.8 ± 1.1 !
hsCRP (mg/l) 18.5 ± 4.2 7.5 ± 2.0 !
Data are mean ± SEM. * p < 0.001; ! p < 0.01 versus baseline.
γGT: gamma-glutamyl transferase; ALT: alanine aminotransferase; AST: aspartate aminotransferase; hsCRP: high sensitive c-reactive protein; TG: 
triglyceride.
Figure 2. Metabolic changes at baseline and after a 16-week very low calorie diet (VLCD). Changes in plasma free fatty acids (FFA) (A), plasma 


















































Myocardial and hepatic tG content
Typical myocardial proton spectra of a patient at baseline and after caloric restriction are 
shown in Figure 3. Myocardial TG content decreased from 0.88 ± 0.12% (baseline) to 0.64 ± 
0.14% (after the VLCD, p = 0.019, based on n = 11 successful myocardial spectral measure-
ments) (Figure 2C). Concomitantly, hepatic TG content decreased from 21.2 ± 4.2% to 3.0 ± 
0.9%, respectively (p < 0.001) (Figure 2D).
Figure 3. Myocardial Proton Spectra. Typical unsuppressed proton spectra of the same patient at baseline and after a 16-week very low calorie 





ppm: parts per million; TG: triglyceride.
Myocardial systolic and diastolic function
Systolic blood pressure decreased from 144 ± 8 mm Hg to 118 ± 6 mm Hg at baseline and 
after substantial weight loss, respectively (p < 0.001). Diastolic blood pressure decreased 
from 81 ±2 mm Hg at baseline to 71 ± 2 mm Hg after weight loss (p < 0.001). Heart rate was 
significantly decreased after substantial weight loss (Table 2). During caloric restriction, myo-
cardial function improved. Cardiac output decreased significantly from 7,971 ± 601 ml/min at 
baseline to 6,508 ± 401 ml/min after prolonged caloric restriction (p = 0.001). Furthermore, LV 
mass was significantly decreased as well (from 118 ± 7 g to 99 ± 6 g, respectively, p < 0.001) 
(Figure 4A). The E/A ratio increased from 1.02 ± 0.08 at baseline to 1.18 ± 0.06 after the VLCD 









































Short-term effect of a VLCD on myocardial triglyceride content and function
Table 2. Effects of 16 weeks of caloric restriction on systolic and diastolic function in obese patients with type 2 diabetes mellitus.
baseline after 16 wks
Systolic blood pressure (mm Hg) 144 ± 8 118 ± 6 *
Diastolic blood pressure (mm Hg) 81 ± 2 71 ± 2 *
Heart rate (beats/min) 78 ± 3 61 ± 2 *
LVEF (%) 57 ± 2 58 ± 2
Stroke volume (ml) 102 ± 6 103 ± 8
Stroke volume index (ml/m2) 45 ± 2 51 ± 3 !
Cardiac output (ml/min) 7971 ± 601 6508 ± 401 !
Cardiac Index (l/min/m2) 3.5 ± 0.2 3.2 ± 0.2
LV Mass (g) 118 ± 7 99 ± 6 *
LV mass index (g/m2) 53 ± 3 49 ± 3 !
ED volume (ml) 177 ± 8 177 ± 11
ED index (ml/m2) 79 ± 3 88 ± 4 !
ES volume (ml) 76 ± 4 74 ± 5
ES index (ml/m2) 34 ± 2 37 ± 2
E deceleration (ml/s2 x 10-3) 4.04 ± 0.50 4.30 ± 0.42
E/A peak ratio 1.02 ± 0.08 1.18 ± 0.06 !
E/Ea 11.9 ± 1.2 11.4 ± 1.5
Data are mean ± SEM. * p < 0.001; ! p < 0.05 versus baseline.
A: atrial filling phase; E: early filling phase; E/Ea: estimated left ventricular filling pressure;
ED: end-diastolic; ES: end-systolic; LV: left ventricular; LVEF: left ventricular ejection fraction.
Figure 4. Changes in myocardial function. Intraindividual changes in left ventricular (LV) mass (A) and the ratio between the early filling phase 























































This study shows that prolonged caloric restriction decreases BMI and considerably improves 
glucoregulation, associated with decreased myocardial TG content and beneficial effects on 
blood pressure and myocardial function in insulin-treated obese patients with T2DM. The 
data prove that myocardial TG stores in obese patients with T2DM are flexible and amendable 
to therapeutic intervention by caloric restriction.
Myocardial TG accumulation is the net result of excessive FFA uptake in relation to oxida-
tive FFA requirements. In animal experiments, this increased myocardial TG pool is associated 
with impaired myocardial function (5,6). In human studies, myocardial TG accumulation is 
also associated with impaired myocardial function. For instance, a post-mortem study in 
obese patients with severe metabolic dysregulation and heart failure documented myocar-
dial lipid accumulation that was higher in subjects suffering from obesity and T2DM (25). 
Recently, McGavock et al. (2) documented that in patients with T2DM myocardial TG content 
is increased, and suggested that myocardial TG accumulation precedes overt changes in 
systolic function. Therefore, myocardial TG content may be an interesting marker for the risk 
of nonischemic heart disease, and a potential surrogate marker for assessing the effects of 
metabolic interventions on the heart. In rodents, the restoration of myocardial TG metabolism 
is associated with improvements in cardiac function (6,26), in accordance with our findings. 
Nonetheless, the improvement in myocardial function on caloric restriction in the present 
study cannot merely be ascribed to the decreased myocardial TG stores, because there were 
also major alterations in other factors that affect cardiac mass and function, such as BMI and 
blood pressure.
Others reported beneficial effects of weight loss on cardiac function after bariatric surgery 
(27) or VLCD (28). Moreover, we found a decrease in heart rate, which is beneficial because 
heart rate is independently associated with increased mortality (29). In addition to this 
decreased heart rate, we observed a decrease in cardiac output and LV mass, in line with 
previously reported data (30). The LV ejection fraction was normal and did not change after 
the intervention period, in accordance with previous data showing that normal LV ejection 
fraction was unchanged 3 months after weight loss in obese subjects (31). The LV mass is 
predictive of cardiovascular morbidity and mortality and can be decreased by improvements 
in blood pressure (32). In addition, the decrease we found in LV mass is influenced by the 
substantial weight loss (33) and possibly by the improvements in insulin sensitivity (34). 
Because of the dramatic changes in body size, some of the indexed values for LV dimen-
sions were changed after the intervention period. The LV mass index decreased, whereas 
the end-diastolic index was increased. The decrease in LV mass can directly influence LV 
filling pressures, and consequently, parameters of LV diastolic function (35). However, the 
presently used estimation of LV filling pressures (E/Ea) showed no changes after prolonged 









































Short-term effect of a VLCD on myocardial triglyceride content and function
be improved elastic properties of the LV, in line with results from animal models, document-
ing the relationship between myocardial TG accumulation and myocardial function (5,6). One 
of the alternative mechanisms may be that changes in plasma FFAs change the calcium ho-
meostasis in the myocardium (36), which influences LV diastolic function (37). Furthermore, 
the present improvements in the inflammatory parameter C-reactive protein may influence 
myocardial function as well (38).
In addition to the decrease in myocardial TG content, the VLCD dramatically decreased 
hepatic TG content, associated with improvements in plasma lipid profile and liver enzymes. 
Moreover, insulin sensitivity was markedly increased after substantial weight loss, in accor-
dance with previous studies (19,20,39,40). The improvement in hepatic TG content indicates 
that there is a general reduction in ectopic deposition of TG in nonadipose tissues, including 
the liver and heart.
There are limitations to this study. First, the study is descriptive and does not establish a 
causal relationship between myocardial TG accumulation and myocardial function, although 
the results are in accordance with data obtained in different animal models of obesity and, 
additionally, show the metabolic flexibility of the diabetic heart. Second, the sample size 
is relatively small. However, the patients are their own controls, and the magnitude of the 
metabolic and functional changes is illustrative because it indicates dynamic features of 
myocardial TGs and diastolic function.
In conclusion, prolonged caloric restriction in obese T2DM patients decreases BMI and 
improves glucoregulation associated with decreased myocardial TG content and improved 
diastolic heart function. Therefore, myocardial TG stores in obese patients with T2DM are 
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Objective. A 16-week very low calorie diet (VLCD) in type 2 diabetes mellitus (T2DM) patients 
results in cardiac remodeling and improved diastolic function. It is unknown how long these 
effects sustain after reintroduction of a regular diet. Therefore, we aimed to assess the long-
term effects of initial weight loss by a VLCD on cardiac dimensions and function in patients 
with T2DM.
Methods. Fourteen patients with insulin-dependent T2DM (mean ± SEM: age 53 ± 2 years; 
body mass index (BMI) 35 ± 1 kg/m2) were treated by a VLCD (450 kcal/day) during 16 weeks. 
Cardiac function was measured by magnetic resonance imaging before and after the 16-
week VLCD and again after 14 months of follow-up on a regular diet.
results. BMI decreased from 35 ± 1 kg/m2 to 28 ± 1 kg/m2 after the VLCD and increased 
again to 32 ± 1 kg/m2 at 18 months (both p<0.05 vs. baseline). Left ventricular (LV) end-
diastolic volume index increased after the 16-week VLCD (80 ± 3 to 89 ± 4 ml/m2, p<0.05) and 
remained increased after 14 months of follow-up (90 ± 3 ml/m2; p<0.05 vs. baseline) at com-
parable filling pressures. The improvement in LV diastolic function after the 16-week VLCD, 
was sustained after 14 months of follow-up (early (E) / atrial (A) diastolic filling phase ratio: 
0.96 ± 0.07 (baseline); 1.12 ± 0.06 (after VLCD); 1.06 ± 0.07 (18 months, p<0.05 vs. baseline)).
Conclusion. Weight reduction by a 16-week VLCD in T2DM patients results in sustained 
cardiac remodeling and improved diastolic function after 14 months of follow-up, despite 









































Long-term effect of a VLCD on myocardial triglyceride content and function
inTrODuCTiOn
Diastolic dysfunction in type 2 diabetes mellitus (T2DM) is associated with an increased risk of 
development of heart failure and mortality, independent of coronary disease and hyperten-
sion (1). Moreover, even well-controlled patients with uncomplicated T2DM have significantly 
lower left ventricular (LV) end-diastolic volume indices compared to age-matched healthy 
controls (2). Accordingly, cross-sectional data from the Framingham Offspring cohort have 
indicated an association between increased insulin resistance and concentric remodeling of 
the LV (3). Several mechanisms underlying diastolic dysfunction in T2DM have been proposed 
including: hypertension, fibrosis and deposition of advanced glycation end products (AGEs), 
altered calcium handling and myocardial lipotoxicity (4,5).
Weight loss and lifestyle alteration are important cornerstones in the treatment of T2DM. 
In obesity, diet-induced weight loss not only improves insulin resistance, but also diastolic 
cardiac function (6-8). In obese patients with T2DM, we showed that a 16-week VLCD im-
proves diastolic function, associated with a decrease in myocardial triglyceride (TG) content 
(9). There are no data available on long-term effects of diet-induced initial weight loss on 
cardiac function and myocardial TG content, particularly in T2DM. Therefore, we performed a 
14 month follow-up study after completing a 16-week very low calorie diet (VLCD) in obese 
patients with insulin-dependent T2DM. We assessed cardiac function by cardiac MR imaging 
and myocardial triglyceride (TG) content by MR spectroscopy.
PATiEnTS AnD METhODS
patients
We included 14 insulin-dependent T2DM patients (8 men, mean age: 53 ± 2 years, diabetes 
duration: 9±1 years). Patients were eligible for inclusion if they: had stable weight at baseline, 
were non-smoking, had a normal stress electrocardiogram, did not use medication which 
is known to influence lipolysis and/or glucose metabolism, had no other endocrine disease 
and had sufficient residual insulin secretory capacity. The details of the initial VLCD study 
have been previously described (9). To increase the power we included 2 extra patients who 
underwent the VLCD and were studied after 14 months of follow-up, therefore the exact 
numbers at baseline and at 16 weeks in this follow-up study, are slightly different from our 
previous publication (9).
Patients were studied on three occasions: at baseline (within 1 week before the start of the 
VLCD), directly after the 16-week VLCD and at 18 months (78.9 ± 1.6 weeks) from baseline. 
The VLCD consisted of 3 meals per day containing 450 kcal/day and all essential micro- and 
macronutrients (Modifast, Nutrition & Santé, and Antwerpen, Belgium). During the 16-week 










































VLCD, patients were reintroduced to a regular diet. Six months after the start of the interven-
tion all patients were referred back to their own specialist, for regular medical care including 
if necessary reintroduction of glucose-lowering medication.
This study was approved by the local ethics committee. Written informed consent was 
obtained from all patients and the study was performed in accordance with the Declaration 
of Helsinki.
Cardiac function
All MR measurements were performed in the postprandial state (4 hours after the last meal) 
and in supine position. During MR imaging, blood pressure and heart rate were measured, 
using an automatic device (Dinamap, DPC100X, Freiburg, Germany).
We used a 1.5 Tesla Gyroscan ACS-NT MR imaging scanner (Philips, Medical Systems, 
Best, The Netherlands), with a body coil for radiofrequency transmission and 5-element 
synergy coil for signal receiving. A sensitivity encoding balanced steady-state free processing 
sequence, with ECG-gating and breath holding, was used with the following parameters: 
echo time (TE) = 1.7ms, repetition time (TR) =3.4 ms, slice gap = 0 mm, flip angle = 35°, field 
of view = 400 * 320 mm, reconstructed matrix size = 256*256, slice thickness = 10 mm, to 
image the heart in short-axis orientation from apex to base with 12 slices. All images were 
quantitively analyzed using dedicated software (MASS, Medis, Leiden, the Netherlands) to as-
sess left ventricular (LV) end-diastolic volume, LV end-systolic volume, stroke volume, cardiac 
output, LV ejection fraction and LV mass (10). We calculated cardiac index, LV end-diastolic 
volume index, LV end-systolic volume index, LV stroke volume index and LV mass index, by 
dividing the parameters by the body surface area. Flow dynamics across the mitral valve 
were assessed using an ECG-gated gradient-echo sequence with velocity encoding with the 
following scan parameters: TE = 4.8 ms, TR = 14 ms, flip angle = 20°, slice thickness = 8 mm, 
field of view = 350*350 mm, matrix size = 256*256, velocity encoding = 100 cm/s and scan 
percentage = 80%. Flow encoded MRI data were analyzed using the FLOW software package 
(Medis, Leiden, the Netherlands). The early filling phase (E) and atrial contraction (A) were 
analyzed and the maximum flow rate of E and A were calculated to obtain an E/A peak flow 
ratio. Furthermore we quantified an estimation of filling pressure (E/Ea) (11).
proton magnetic resonance spectroscopy
The body coil was used for radiofrequency transmission and a surface coil (17 cm) for signal 
receiving. A point resolved spectroscopy sequence was used to acquire single-voxel spectra 
(12). The voxel (8 ml) was placed in the interventricular spectrum and data were acquired at 
end-systole. Spectral parameters were: TR of at least 3000 ms, TE = 26 ms. A total of 1024 data 
points was collected over a 1000-Hz spectral width. Data acquisition was ECG-triggered and 
with respiratory echoes, to minimize breathing influences. Water-suppressed spectra with 









































Long-term effect of a VLCD on myocardial triglyceride content and function
the same voxel location. Spectra were analyzed using Java-based MR user interface software 
(jMRUI version 2.2) as previously described (12). Myocardial triglycerides (peak at 1.3 parts 
per million (ppm) and 0.9 ppm were summed) were calculated as percentage of the unsup-
pressed water signal (TG/water*100).
Statistical analyses
All statistical analyses were performed using SPSS 17.0 (SPSS Inc.Chicago, Illinois, USA). A 
2-tailed probability value of 0.05 or less was considered statistically significant. Data are ex-
pressed as mean values ± standard error of the mean (SEM) or median (interquartile range). 
Non-normally distributed data were log-transformed and checked for normality after trans-
formation. A general linear model for repeated measures, with time as within-subject factor 
was used for comparison between the three assessments. LSD post-hoc tests were used in 
case of a significant F-ratio. GraphPad Prism 5.0 (GraphPad Software, Inc., La Jolla, USA) was 
used for creation of the figures.
rESuLTS
Body mass index (BMI) decreased from 35 ± 1 kg/m2 to 28 ± 1kg/m2 (p<0.05) after the VLCD. 
Patients regained weight during the 14 months of follow-up to a BMI of 32 ± 1 kg/m2 (p<0.05 
vs. baseline, Table 1). At baseline, all patients used insulin, 8 patients used metformin and 3 
patients a sulfonylureum (SU)-derivate. During the 16 week-VLCD all patients had stopped 
insulin therapy and oral glucose-lowering medication. Directly after the VLCD 14 patients 
used metformin and 3 patients a SU-derivate. At 18 months, four patients had restarted 
insulin therapy, 12 patients used metformin and 4 patients used a SU-derivate.
Table 1. Changes in metabolic parameters at baseline, after a 16-week very low calorie diet and after 14 months of follow-up on a regular diet.
baseline 16 week VLCD 18 months
Body mass index (kg/m2) 35.3 ± 1.1 27.5 ± 1.1 * 31.7 ± 1.1 * !
HbA1c (%) 8.4 ± 0.3 7.0 ± 0.4 7.7 ± 0.5
fasting glucose (mmol/L) 11.9 ± 0.6 7.8 ± 0.8 * 10.4 ± 1.0 !
fasting insulin (mU/L) 23.5(14.3-29.3) 10.0(6.8-12.0) * 6.5(5.0-14.3)
Free fatty acids (mmol/L) 0.97 ± 0.07 0.76 ± 0.08 * 0.68 ± 0.06 *
Triglycerides (mmol/L) 2.3 ± 0.2 1.2 ± 0.1 * 2.8 ± 0.6 !











































Systolic and diastolic blood pressures decreased from 155 ± 5 mmHg and 89 ± 3 mmHg 
respectively at baseline to 136 ± 4mmHg and 80 ± 2 mmHg directly after the 16-week VLCD 
(p<0.05, Table 2). At 18 months both systolic and diastolic blood pressures returned to base-
line values (149 ± 5 mmHg and 88 ± 3 mmHg resp.). Heart rate decreased from 85 ± 2 beats/
min at baseline to 69 ± 3 beats/min after the VLCD (p<0.05) and remained decreased at 18 
months (71 ±3 beats/min, p<0.05 vs. baseline). This resulted in a decreased rate pressure 
product after the VLCD and at 18 months compared to baseline (baseline: 13218 ± 636 beats/
min·mmHg vs. 16 weeks: 9426 ± 550 beats/min·mmHg, p<0.05; 18 months: 10592 ± 576 
beats/min·mmHg, p<0.05 vs. baseline).
Prescription of antihypertensives did not significantly change during the study (number 
of classes of antihypertensives prescribed: at baseline: 2.4 ± 0.3; after VLCD: 1.9 ± 0.3; 18 
months: 2.1 ± 0.3 (p>0.05). Statin use did not significantly change during the study either.
Table 2. Changes in hemodynamic parameters and cardiac function at baseline, after a 16-week very low calorie diet, after 14 months of 
follow-up on a regular diet.
baseline 16 week VLCD 18 months
Hemodynamics
Systolic blood pressure (mmHg) 155 ± 5 136 ± 4 * 149 ± 5
Diastolic blood pressure (mmHg) 89 ± 3 80 ± 2 * 88 ± 3
Heart rate (beats/min) 85 ± 2 69 ± 3 * 71 ± 3 *
Rate pressure product 13218 ± 636 9426 ± 550 * 10592 ± 576 *
(beats/min.mmHg)
Cardiac function and dimensions
LVEDV (ml) 177 ± 9 177 ± 11 190 ± 9
LVEDV index (ml/m2) 80 ± 3 89 ± 4 * 90 ± 3 *
LVESV (ml) 78 ± 5 75 ± 5 80 ± 4
LVESV index (ml/m2) 35 ± 2 38 ± 2 38 ± 2
LV stroke volume (ml) 99 ± 6 102 ± 7 110 ± 7 *
LV stroke volume index (ml/m2) 45 ± 2 51 ± 3 * 52 ± 2 *
Cardiac index (L/min/m2) 4 ± 0.2 3.3 ± 0.2 3.6 ± 0.2
Ejection fraction (%) 56 ± 2 57 ± 2 57 ± 1
LV mass (g) 119 ± 8 102 ± 7 * 109 ± 9 *
LV mass index (g/m2) 54 ± 3 51 ± 3 51 ± 3
LV mass/LVEDV 0.67 ± 0.03 0.59 ± 0.03 * 0.56 ± 0.03 *
E/A ratio 0.96 ± 0.07 1.12 ± 0.06 * 1.06 ± 0.07 *
E/Ea 10.0 ± 1.4 10.2 ± 1.3 9.9 ± 0.8
Data is expressed as mean ± SEM. * p<0.05 vs. baseline, ! p<0.05: 18 months vs.16 weeks.
LV: left ventricular; EDV: end-diastolic volume; ESV: end-systolic volume; E: early diastolic filling phase; A: diastolic atrial contraction; E/Ea: 









































Long-term effect of a VLCD on myocardial triglyceride content and function
Cardiac dimensions and function
LV end-diastolic volume, end-systolic volume and end-systolic volume index did not change 
significantly after the 16-week VLCD and at 18 months (Table 2). End-diastolic volume index 
showed a sustained increase (baseline: 80 ± 3 ml/m2, 16 weeks: 89 ± 4 ml/m2, 18 months: 90 ± 
3 ml/m2 (both p<0.05 vs. baseline)). This increase occurred with unchanged filling pressures 
(Figure 1). Simultaneously, LV stroke volume index increased from 45 ± 2 ml/m2 to 51 ± 3 ml/
m2 after the VLCD and 52 ± 2 ml/m2 at 18 months (both p<0.05 vs. baseline).
Cardiac index and ejection fraction did not significantly change directly after the VLCD 
and at 18 months compared to baseline (Table 2). LV mass showed a sustained decline from 
119 ± 8 grams to 102 ± 7 grams at 16 weeks and 109 ± 9 grams at 18 months (both p<0.05 
vs. baseline). LV mass index was unchanged between the occasions (Table 2). A reduction in 
LV mass / LV end-diastolic volume was observed (0.67 ± 0.03 at baseline to 0.59 ± 0.03 at 16 
weeks and 0.56 ± 0.03 at 18 months resp. (both p<0.05 vs. baseline, Figure 1)). Diastolic E/A 
Figure 1. Relation of LV end-diastolic volume index and LV filling pressure. Relation of LV end-diastolic volume index (LVEDVI) and E/Ea ratio 
(estimate of LV filling pressure) at baseline (●), after a 16-week very low calorie diet (VLCD) (■) and after an additional 14 months of follow-up 
on a regular diet (▲) in 14 patients with T2DM. Bars represent means ± SEM. Note the increase in LVEDVI from 80±3 ml/m2 at baseline to 89±4 












Figure 2. Change in left ventricular diastolic function. Changes in E/A ratio at baseline (white bar), after a 16-week VLCD (grey bar) and after 
an additional 14 months of follow-up on a regular diet (black bar) in 14 patients with T2DM. Note the sustainment of improved diastolic heart 













Data are expressed as mean ± SEM. * p<0.05










































ratio increased after the VLCD and remained increased compared to baseline at 18 months 
(baseline: 0.96 ± 0.07; after VLCD: 1.12 ± 0.06, 18 months: 1.06 ± 0.07, both p<0.05 vs. baseline, 
Figure 2). E/Ea did not significantly change compared to baseline.
Myocardial tG content
Myocardial TG content decreased from 0.74 (0.41-1.10)% at baseline to 0.45 (0.31-0.54)% after 
the VLCD (p<0.05 vs. baseline, based on n = 11 successful 1H-MRS measurements on all three 
occasions), but had returned to baseline values at 18 months (0.76 (0.65-1.32)%, p>0.05 vs. 
baseline).
DiSCuSSiOn
This study aimed to assess the long-term effects of an initial 16-week VLCD on cardiac 
measures and function in obese patients with insulin dependent T2DM. Our previous study 
demonstrated that a 16-week VLCD decreased LV mass and improved diastolic function in 
insulin-dependent, obese T2DM patients (9). The present study extends these observations 
by showing that cardiac remodeling and diastolic function remains improved even after 14 
months of follow-up on a regular diet, despite some weight regain.
Systolic and diastolic blood pressures decreased upon the use of the VLCD, but returned 
to baseline values after 14 months of follow-up. Nonetheless, the sustained decreased heart 
rate resulted in a decreased rate pressure product at 16 weeks and 18 months compared 
to baseline. The rate-pressure product is an estimate of myocardial oxygen consumption 
(13,14). In diabetic mice, cardiac efficiency is decreased, which is related to increased myocar-
dial oxygen consumption (15). Therefore, the sustained decreased rate pressure product in 
our patients may reflect improved cardiac efficiency. Accordingly, short-term clinical studies 
found that weight loss induced a decrement in blood pressure (6,8,16) and rate pressure 
product (8) in obese, non-diabetic subjects.
Previously, it was shown that T2DM patients have decreased LV end-diastolic volume 
indices compared to healthy controls, associated with diminished compliance (2). In this 
study we show that weight loss can reverse this process up to 14 months of follow-up, by 
an increase in LVEDV index at comparable estimated LV filling pressure (E/Ea, Figure 1). The 
E/A ratio, a load-dependent parameter, also remained improved during long-term follow-up. 
However since the E/Ea ratio did not change, this change in E/A ratio most likely reflects an 
improvement in diastolic function. In accordance with our observation in T2DM patients, a 
2-year caloric restriction study (maximum weight loss at 6 months) performed in obese, non-
diabetic subjects found an improvement in diastolic function, which lasted up to 2 years after 
the start (6). Rider et al. (17) accordingly found an improvement in LV diastolic function after 
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in LV remodeling. Our study is the first to show that weight reduction also leads to sustained 
improvement in diastolic function and an increase in compliance of the left ventricle in T2DM 
patients.
Little is known about the underlying pathophysiological mechanisms of the improved 
diastolic function after weight loss. Van Heerebeek et al. (18) demonstrated that heart failure 
in patients with normal ejection fraction is associated with an increase in cardiomyocyte 
diameter and a higher resting tension of the cardiomyocytes, whereas AGEs and collagen de-
position were more important in patients with restricted ejection fraction. In obese diabetic 
mice, diet-induced weight loss also resulted in improved diastolic function, which could be 
partly attributed to normalization in SERCA2 activity, which determines the Ca2+ removal 
from the myofilaments
We aimed to assess changes in myocardial triglyceride content, because previous studies 
showed an inverse correlation between myocardial triglyceride content and cardiac function 
(9,20,21). This association was explained by the concept of lipotoxicity. Accordingly, we found 
a decrease in myocardial TG content directly after the VLCD. However, after 14 months of 
follow-up, myocardial TG content returned to baseline values, even though there was sus-
tained improvement in cardiac function. Viljanen et al. (8) studied the effect of a 6-week VLCD 
in obese subjects, without diabetes and similarly found a decrease in myocardial TG content. 
Apparently the regain in myocardial TG content does not immediately correspond with 
deterioration in diastolic function, which argues against a simple relation between cardiac 
triglyceride content and cardiac dysfunction. In previous short-term nutritional interventions 
(20,21) we showed a relation between increases in myocardial TG content and deteriorated 
diastolic function in healthy subjects and subjects with T2DM. It could be hypothesized that 
the regain in myocardial TG content precedes deterioration in diastolic function. Otherwise, 
the contribution of the positive effects on cardiac remodeling may be more substantial to 
diastolic function than the regain in myocardial TG content.
In accordance with our results, other studies have demonstrated a decrease in LV mass 
(6-8,16,17,22) after diet-induced weight loss in obesity, however no change in LV mass in-
dex (16,17,22). As insulin acts as a growth factor and can induce cardiac hypertrophy, the 
persistently decreased plasma insulin levels could contribute to the decrease in LV mass in 
our study. Accordingly, in obese rats a VLCD decreased myocardial mass, due to a decrease 
in myocardial cell size during weight loss and a strong association between the relative 
decrease in heart weight and the decrease in body weight was found (23).
A limitation of the present study is the relatively small sample size. The extensive dietary 
intervention, long-term follow-up and imaging protocol did not allow to include more 
patients. However, patients served as their own controls. Moreover, we used the highly 
reproducible and sensitive techniques of MRI and 1H-MRS in controlled metabolic conditions. 
Using this study design, we observed major short-term effects on hemodynamic and cardiac 










































In conclusion, weight reduction by a 16-week VLCD in T2DM patients results in sustained 
cardiac remodeling and improved diastolic function after 14 months of follow-up, despite 
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Objective. Pericardial fat accumulation has been associated with an increased cardiovascular 
risk. A very low calorie diet (VLCD) improves the cardiovascular risk profile in patients with 
type 2 diabetes mellitus (T2DM), by improving the metabolic profile, heart function and 
triglyceride (TG) stores in (non)adipose tissues. However, long-term effects of a VLCD on 
pericardial fat volume and tissue-specific TG accumulation have not been documented. The 
aim of this study was therefore to assess the effects of a 16-week VLCD and of subsequent 14 
months follow-up on a regular diet on pericardial fat in relation to other TG stores in obese 
T2DM patients.
Methods. We included 14 obese patients with insulin-treated T2DM (mean±SEM: age 53±2 
years; BMI 35±1 kg/m2). Pericardial fat and other (non)adipose TG stores were measured using 
magnetic resonance (MR) imaging and proton spectroscopy before and after a 16-week VLCD 
and after a 14-month follow-up without dietary interventions.
results. A 16-week VLCD reduced bodyweight, pericardial fat, hepatic TG content, visceral 
and subcutaneous abdominal fat volumes to 78, 83, 16, 40 and 53% of baseline values re-
spectively, (all p<0.05). After an additional 14 months of follow-up on a regular diet, the 
reduction in pericardial fat volume sustained, despite a substantial regain in body weight, 
visceral abdominal fat and hepatic TG content (resp. 90, 83 and 73% of baseline values).
Conclusion. VLCD-induced weight loss in obese T2DM patients is accompanied by a sub-










































Long-term effect of a VLCD on ectopic fat depositions and pericardial fat
inTrODuCTiOn
One of the cornerstones in the treatment in type 2 diabetes mellitus (T2DM) is lifestyle inter-
vention with diet-induced weight reduction and exercise. A very low calorie diet (VLCD) is 
safe and effective to induce considerable weight loss and to improve insulin resistance, even 
in patients with insulin-dependent T2DM (1-3). During short-term weight loss, there is a close 
relationship between tissue-specific decreases in triglyceride (TG) stores and improvement in 
insulin sensitivity in obese nondiabetic and diabetic patients. Even a small reduction in weight 
can induce major reductions in hepatic TG content already within the first two weeks of a diet 
(4,5) and visceral abdominal fat even within 3 days of a VLCD in patients with T2DM (6). Reduc-
tions in hepatic TG content and visceral fat are associated with improvements in hepatic and 
peripheral insulin sensitivity (7,8). Studies on the long-term effects of a period of VLCD in T2DM 
have only focused on weight reduction and metabolic effects. The long-term effects of a VLCD 
on TG accumulation in pericardial fat and other (non)adipose tissues have not been studied.
Pericardial fat is adipose tissue surrounding the heart, which consists of two layers: epi-
cardial and paracardial fat (9). An increased pericardial fat volume has been associated with 
insulin resistance in non-diabetic obese subjects (10) and T2DM patients (11). Moreover it has 
been associated with an increased cardiovascular risk (9,12-17). Recently, it has been docu-
mented by ultrasound studies that weight loss is associated with a decrease in pericardial fat 
stores in non-diabetic obese subjects (18,19). These studies also reported a larger decrease in 
visceral fat volume compared to pericardial fat volume (19). Dietary effects on pericardial fat 
have been studied only to a limited extent in patients with T2DM.
Therefore, the aim of this study was to assess the effects of a 16-week VLCD and subsequent 
14-month follow-up on a regular diet on pericardial fat in relation to other TG stores in obese 
insulin-dependent patients with T2DM, using magnetic resonance imaging and spectroscopy.
PATiEnTS AnD METhODS
patients
Fourteen obese patients (8 men/6 women) with T2DM were studied (mean ± standard error 
of mean (SEM): age: 53 ± 2 years). Patients were diagnosed with T2DM since 9 ± 1 years and 
used 81 ± 16 units of insulin per day. Selection criteria were: body mass index (BMI) > 30 kg/
m2, use of at least 20 units of insulin per day with or without oral blood glucose-lowering 
agents, remaining endogenous insulin secretory capacity (defined as fasting C-peptide levels 
> 0.8 ng/liter and/or a twofold increase in C-peptide levels upon infusion of 1 mg glucagon) 
and stable bodyweight during 3 months before inclusion. Exclusion criteria were: smoking, 
abnormal stress-electrocardiogram (ECG), renal, hepatic or other endocrine disease and 










































This study was approved by the local ethics committee. Written informed consent was 
obtained from all patients and the study was performed in accordance with the Declaration 
of Helsinki.
Study procedure
The study procedure during the 16-week VLCD has been described in detail before, but 
will be summarized here (2). After screening, the patients entered a three week run-in pe-
riod, in which all oral blood glucose-lowering medication was omitted and insulin therapy 
was intensified. Within one week before the start of the intervention a baseline magnetic 
resonance (MR) scan was performed to assess the different fat compartments (see below). 
The intervention consisted of a very low calorie diet (VLCD), prescribed during 16 weeks, to 
achieve considerable weight loss. During the VLCD, patients consumed 3 sachets of Modifast 
Intensive per day (containing 450 kcal, 50 g protein, 50-60 g carbohydrates and 6 g lipids per 
day, Nutrition & Santé, Antwerpen, Belgium). At the start and, subsequently, during the whole 
period of the VLCD all glucose-lowering medication including insulin was discontinued. Five 
of the 14 patients additionally followed an exercise program during the VLCD, however this 
had no effect on the outcome parameters. At the end of the 16-week VLCD a second MRI-scan 
was performed. Subsequently, patients received dietary advice and were slowly reintroduced 
to their diet of choice. Twenty weeks after the start of the study, patients were referred back 
to their own specialists for regular medical care either in primary care or at the out-patient 
clinic of our department. Fourteen months after the end of the VLCD a third MRI-scan was 
performed. The average caloric intake was estimated on basis of the food intake three days 
before the study days. Blood was drawn on each occasion after an overnight fast.
pericardial fat
All MR imaging and proton MR spectroscopy (1H-MRS) studies were performed using a 1.5 
Tesla whole body MR scanner (Gyroscan ACS-NT15; Philips Medical Systems, Best, The Neth-
erlands) in supine position. All MR-measurements were made in the postprandial state (4 
hours after the last meal). Pericardial fat was quantified using electrocardiographically gated 
breath-holds with a balanced turbo-field echo MR sequence (20). Imaging parameters in-
cluded: echo time (TE) = 1.60 ms, repetition time (TR) = 3.2 ms, flip-angle = 50°, slice thickness 
= 10 mm. The whole four chamber view was analyzed. To quantify the pericardial fat volume, 
contours around the pericardial fat of the ventricles and atria were drawn manually at end 
systole and multiplied by the thickness of the slice to yield a volume. We used MASS analytical 
software (Medis, Leiden, the Netherlands) for post processing. Contours were drawn by two 
independent observers and we used the mean volume of the two observers. A representative 
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Visceral and subcutaneous fat
Abdominal fat was quantified with a turbo spin echo imaging (6). Imaging parameters were: 
TE = 11ms, TR =168ms, flip angle = 90°, slice thickness = 10mm. Three transverse images 
were obtained during one breath hold, at the level of the 5th lumbar vertebrae. With post-
processing software (MASS analytical software, Medis, Leiden, The Netherlands), the volumes 
of the visceral and subcutaneous fat depots were quantified. The number of pixels were 
converted to square centimeters and multiplied by the slice thickness. The total fat volume 
was calculated by summing the fat volumes of the three individual slices.
hepatic magnetic resonance spectroscopy
Hepatic 1H-MRS was performed as previously described (21). The bodycoil was used for radio-
frequency transmission and a 17 cm diameter circular coil for signal receiving. An 8 ml voxel 
was placed in the liver, carefully avoiding large vascular structures. To ascertain the same 
position of the voxel at all study days, we used the twelfth thoracic vertebrae as marker. A TR 
of 3000 ms and TE of 26 ms were used. A spectrum with water suppression to detect small 
TG peaks and a spectrum without water suppression as internal standard were obtained. 
Sixty-four averages were collected without water suppression. The spectra were fitted using 
Java-base MR user interfase software (jMRUI version 2.2), as previously described (21). The 
percentage of hepatic TG signals was calculated as: (signal amplitude of hepatic triglycer-
ides)/ (signal amplitude of water) x 100.
Figure 1. Pericardial fat (P) as visualized by a four chamber view of the heart on a 1.5 Tesla whole body MR scanner (Gyroscan ACS-NT15; Philips 
Medical Systems, Best, The Netherlands). To quantify the pericardial fat volume, contours around the pericardial fat of the ventricles and atria 













































Serum insulin and C-peptide were measured with an automated immunoluminometric assay 
(ILMA) on an Immulite 2500 analyzer of Siemens Diagnostics (Breda, The Netherlands, intra-
assay coefficient of variant (CV) 6-7.5%, inter-assay CV 7-8.2% respectively). Serum glucose, 
cholesterol and triglycerides were measured using a  Modular P800 chemistry analyzer of 
Roche Diagnostics (Mannheim, Germany, total CV for glucose, cholesterol and triglyceride 
<2%). Plasma FFA concentrations were measured by a commercial kit (FFA-C; Wako Chemi-
cals, Neuss, Germany).
Statistical analysis
Data are expressed as mean values ± standard error of the mean (SEM) or as median (in-
terquartile range) if not normally distributed. Differences between the three measurements 
were analyzed with a general linear model for repeated measures, with time as within-subject 
factor. LSD post-hoc tests were used in case of a significant F-ratio. The plots were created 
with GraphPad Prism 5.0 (GraphPad Software, Inc., La Jolla, USA). Statistical analyses were 
performed using SPSS 17.0 (SPSS Inc.Chicago, Illinois, USA). A P-value of 0.05 or less was 
considered statistically significant.
rESuLTS
Caloric intake and weight gain
The VLCD reduced caloric intake from 2471±115 kcal/day at baseline to 450 kcal/day, which 
resulted in a 22% weight reduction compared to baseline (P<0.05, Table 1). After discontinua-
tion of the VLCD, after an additional 14 months of follow-up, the estimated caloric intake was 
1889±62 kcal/day, P<0.05 vs. baseline). During follow-up patients regained weight to 90% of 
baseline (P<0.05 vs. baseline, Table 1).
antidiabetic medication, glycemic control and lipids
At baseline, before start of the VLCD, all patients used insulin, 8 patients used metformin and 
3 patients a sulfonylureum (SU)-derivate. During the 16 week-VLCD all patients had stopped 
insulin therapy and oral glucose-lowering medication. Directly after the intervention metfor-
min was prescribed to all patients and 3 patients were prescribed an additional SU-derivate. 
After an additional 14 months of follow-up (patients were treated by their specialists accord-
ing to the standard guidelines), four patients had restarted insulin therapy, 12 patients used 
metformin and 4 patients used a SU-derivate.
The VLCD significantly improved glycemic control, reflected in decreased fasting plasma 
glucose and HbA1c levels, even though all patients had stopped the use of insulin and oral 









































Long-term effect of a VLCD on ectopic fat depositions and pericardial fat
however, HbA1c and fasting plasma glucose returned to baseline values, albeit with less 
intensive anti-diabetic medication.
Total plasma cholesterol levels did not change after the VLCD. HDL-cholesterol levels were 
higher and LDL cholesterol levels lower after the VLCD which was sustained after 18 months 
of follow-up, despite the above described weight regain (Table 1).
pericardial fat and other fat compartments
After the 16-week VLCD, pericardial fat significantly decreased by 17% (from 39±4 ml at 
baseline to 31±2 ml after 16 weeks). Fourteen months after discontinuation of the VLCD, peri-
cardial fat volume remained stable, despite the considerable weight regain and deterioration 
of glycemic control.
A preferential loss of visceral fat compared to subcutaneous fat was observed after the 16-
week VLCD (40% and 55% resp. of baseline values (both P< 0.05, Figure 2)). After an additional 
14 months of follow-up, both visceral and subcutaneous fat volumes increased to 83% and 
82% resp. of baseline values (both P<0.05 compared to baseline, Figure 2). Accordingly, the 
ratio between visceral and subcutaneous fat decreased significantly from 0.52 to 0.33 after 16 
Table 1. Metabolic changes and changes in fat distribution at baseline, after a 16-week VCLD and after an additional 14 months of follow-up on 
a regular diet.
baseline 16 week VLCD 18 months
Weight (kg) 107 ± 4 83 ± 4 * 96 ± 4 * !
Body Mass Index (kg/m2) 35.3 ± 1.1 27.5 ± 1.1 * 31.7 ± 1.1 * !
Fasting plasma concentrations
HbA1c (%) 8.4 ± 0.3 7.0 ± 0.4 * 7.7 ± 0.5
Fasting glucose (mmol/L) 11.9 ± 0.6 7.8 ± 0.8 * 10.4 ± 1.0 !
Fasting insulin (mmol/L) 23.5(14.3-29.3) 10.0(6.8-12.0) * 6.5(5.0-14.3)
Fasting C-peptide (mmol/L) 2.8 ± 0.3 2.1 ± 0.3 1.0 ± 0.1 * !
Total cholesterol (mmol/L) 6.0 ± 0.4 5.3 ± 0.3 5.2 ± 0.4
Triglycerides (mmol/L) 2.3 ± 0.2 1.2 ± 0.1 * 2.8 ± 0.6 !
HDL (mmol/L) 1.13 ± 0.05 1.25 ± 0.09 * 1.29 ± 0.07 *
LDL (mmol/L) 4.4 ± 0.4 3.7 ± 0.3 * 3.2 ± 0.2 *
Fat distribution
Hepatic TG content (%) 22.8 ± 3.9 3.6 ± 1.0 * 13.4 ± 2.2 * !
Subcutaneous abdominal fat (ml) 1194 ± 105 701 ± 108 * 978 ± 89 * !
Visceral abdominal fat (ml) 553 ± 37 228 ± 46 * 456 ± 51 * !
Visceral/subcutaneous fat 0.52 ± 0.07 0.33 ± 0.04 * 0.53 ± 0.09 !
Pericardial fat (ml) 39 ± 4 31 ± 2 * 32 ± 2 *
Data are mean ± SEM or median (interquartile range). * p<0.05 vs. baseline, ! p<0.05 18 months vs. 16 weeks.










































weeks, but returned to a ratio of 0.53 after an additional follow-up of 14 months. Therefore, 
the preferential loss of visceral fat had disappeared.
Due to technical problems abdominal fat and hepatic TG content could not be assessed 
in 1 patient at 18 months. The VLCD decreased hepatic TG content to 16% of baseline levels. 
However, 14 months after discontinuation, hepatic TG content increased to 73% of baseline 
values (P<0.05 vs. baseline, Figure 2).
DiSCuSSiOn
This study is the first to assess the long-term effects of caloric restriction on pericardial fat 
and other fat compartments in patients with T2DM using state of the art MR imaging and 
spectroscopy. Our data reveal differential short- and long-term effects of a 16-week VLCD 
and 14 months follow-up on weight, pericardial fat and other fat compartments. In general, 
we found a substantial regain in (non)adipose TG compartments with as clear exception 
pericardial fat.
We found that the beneficial effects of a 16-week VLCD on weight and metabolic param-
eters partially deteriorated 14 months after reinstating a regular diet, which is in line with 
previous studies (22-25). However, in those studies, effects on fat compartments were not 
studied. Interestingly, despite the fact that the relative reduction in pericardial fat volume 
after the VLCD was the smallest of all fat compartments, this was the only fat compartment 
which did not expand during the additional follow-up of 14 months. Previous studies on ca-
loric restriction in non-diabetic subjects, also reported a larger decrease in visceral fat volume 
Figure 2. Relative changes in bodyweight, hepatic triglyceride (TG) content, subcutaneous and visceral abdominal fat and pericardial fat after 
16 weeks of a very low calorie diet (grey box) and after 14 months of follow-up on a regular diet (black box) compared to baseline.
16 weeks compared to baseline









































































Long-term effect of a VLCD on ectopic fat depositions and pericardial fat
as compared to pericardial fat volume (19). Likewise, in a short-term caloric restriction study 
in overweight women, cross-sectional, but no longitudinal associations between pericardial 
fat volume and other fat compartments and metabolic parameters were found (26). However, 
in these studies, no long-term effects after reinstating a regular diet were assessed. We previ-
ously found that treatment with pioglitazone in patients with T2DM, increased pericardial fat, 
but did not change visceral fat volumes (20). The results of the previous and present studie(s) 
clearly suggest that pericardial fat and visceral fat volumes are differentially influenced by 
diet and drugs (like thiazolidinediones), and cannot be considered as metabolically identi-
cal compartments. As pericardial fat volume has been associated with cardiovascular risk in 
cross-sectional studies (11,13,27), it can be hypothesized that our finding is compatible with 
a sustained beneficial effect of a VLCD on cardiovascular risk.
We observed a preferential loss of visceral fat compared to subcutaneous fat volume imme-
diately after the 16-week VLCD. After 14 months of follow-up this preferential loss of visceral 
fat was no longer present. This short-term effect can be explained by a higher susceptibility 
of visceral fat to lipolysis than subcutaneous fat via a diminished response to insulin (28) and 
a greater sensitivity to norepinephrine (29,30).
The weight reduction of 22% immediately after the VLCD observed in our study was associ-
ated with a major reduction of 84% in hepatic TG content. Reductions in hepatic TG content 
are strongly associated with improved hepatic insulin sensitivity and lipoprotein metabolism 
through different mechanisms, including effects of fatty acids metabolites and inflammatory 
intermediates on insulin receptor signaling and VLDL synthesis (8). Therefore, the regain in 
hepatic TG content after 14 months on a regular diet is likely related to the deterioration in 
fasting plasma glucose and TG levels, although remarkably, beneficial effects of the VLCD on 
HDL- and LDL cholesterol were preserved after long-term follow-up.
In conclusion, diet-induced weight loss and subsequent regain of weight during regular 
diet induces tissue-specific variations in (non)adipose TG stores in T2DM patients. Whereas 
visceral fat volume and hepatic TG content largely parallel changes in weight and metabolic 
parameters, sustained effects on pericardial fat are observed. These observations are most 
likely the consequence of differences in sensitivity to regulatory mechanisms, controlling TG 
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The prevalence of type 2 diabetes mellitus (T2DM) is rising steadily. The World Health Orga-
nization estimates that by the year 2030 more than 5% of the adult population worldwide 
is suffering from T2DM (1). Prevention is of utmost importance, as for the time being all 
interventions are insufficient. It is thus important for practical, economical as well as medi-
cal reasons to optimize treatment for T2DM patients. Eighty to ninety percent of the T2DM 
patients suffer from overweight or obesity. In obese T2DM patients insulin resistance plays 
a pivotal role in the pathophysiology of the disease and therapeutical interventions should 
aim at least to improve insulin resistance. Cornerstones in the treatment of T2DM are lifestyle 
interventions, oral glucose-lowering medication and insulin (2). Nowadays, it seems that 
pharmaceutical solutions are more important than lifestyle interventions while these have at 
least equal therapeutic strength.
Lifestyle interventions traditionally include diet-induced weight reduction. It has been 
shown that diet-induced weight loss can improve insulin resistance and its associated meta-
bolic abnormalities (3-6). Exercise is still underutilized in the treatment of obese T2DM patients 
since the effects on both weight reduction and insulin resistance are not as large (7-9).
In this thesis we evaluated both short- and long-term effects of a 16-week very low calorie 
diet (VLCD)-only and in combination with an exercise program in obese insulin-dependent 
T2DM patients.
firST AiM: SySTEMATiC rEViEw Of ThE LiTErATurE rEgArDing ThE 
EffECT Of DiET-inDuCED wEighT rEDuCTiOn AnD ExErCiSE On ECTOPiC 
fAT DEPOSiTiOnS
In Chapter 2, we describe in a systematic review the literature regarding the effect of diet-
induced weight loss and exercise on ectopic fat depositions. Ectopic fat deposition is defined 
as triglyceride (TG) droplets stored in tissue other than adipose tissue, such as the liver, 
skeletal muscle and the heart.
In skeletal muscle, ectopic fat (intramyocellular lipid (IMCL) accumulation) is associated 
with insulin resistance and T2DM (10-12). Moderate diet-induced weight loss (less than 10% 
bodyweight reduction) does not affect IMCL accumulation or peripheral insulin sensitivity 
(13-15). In contrast, substantial weight reduction does lead to a significant decrease in IMCLs 
and improvement in peripheral insulin sensitivity (6,16). The effect of exercise is less clear, 
exercise has been shown to be accompanied either by increased (17), unchanged (7,18), or 
decreased (9,19) IMCL accumulation in skeletal muscle.
In the liver, ectopic fat deposition (non alcoholic fatty liver disease (NAFLD)) is associated 










































reduction (5-10 %) is associated with a substantial drop in hepatic TG content (15,21). The 
reduction of hepatic TG content is associated with an amelioration of hepatic insulin resis-
tance (15,21). The effect of exercise on hepatic TG content is less clear since data are scarce 
and most studies combine exercise with a diet. In these studies diet already leads to weight 
reduction. Because a relatively modest decline in body weight already affects hepatic TG 
content the unique effect of exercise is difficult to determine.
Pericardial fat (the fat deposition around the heart) is positively associated with coronary 
heart disease and whole body insulin resistance (22). The exact function of the pericardial 
fat remains unknown. There is only limited data available, however, these data show that 
weight loss and exercise induce a significant decrease in pericardial fat. In one study this was 
accompanied by an improvement in diastolic cardiac function (23-25).
Cross-sectional data show that myocardial TG accumulation is associated with impaired 
diastolic function (26). Only one study showed that diet induced weight reduction is associ-
ated with a non-significant decrease in myocardial TG content (27).
In conclusion, ectopic fat depositions are associated with disruption of normal metabolic 
processes in the cell. Whether the ectopic fat depositions are a cause or consequence of insu-
lin resistance is still under investigation. Lifestyle interventions affect ectopic fat depositions 
and ameliorate organ function (hepatic/peripheral insulin resistance or cardiac function).
In this thesis we describe the results of a 16-week randomized intervention study combin-
ing exercise and a VLCD to further investigate the effects on insulin sensitivity and ectopic 
fat depositions.
firST PArT Of ThE ThESiS
In the first part of this thesis we evaluate and compare the effects of a 16-week VLCD and 
a 16-week VLCD combined with an exercise program. The study population, consisting of 
27 sedentary obese (body mass index (BMI) 37.2 ± 0.9 kg/m2) insulin-dependent T2DM 
patients (14 men, 13 women) with residual beta-cell capacity, all followed a 16-week VLCD. 
Three weeks before the intervention all oral glucose-lowering medication was discontinued, 
one day before the intervention insulin therapy was omitted, during the whole intervention 
period no blood glucose-lowering medication (including insulin) were prescribed. The diet 
contained a total of ~450 kcal/day divided over 3 sachets of liquid food providing all neces-
sary vitamins and micronutrients (Modifast®). Thirteen subjects participated simultaneously 
in an exercise program which consisted of one hour in-hospital training weekly, primarily 
aerobic exercise, under supervision of a physiotherapist. And 4 training sessions at home on 
a cyclo-ergometer for 30 minutes at 70% of maximum aerobic capacity.
Before the start of the intervention, directly after, 6 months and 18 months after the start 










































circumference and blood pressure. At each time point fasting blood samples were drawn 
to determine among others fasting plasma glucose, insulin, leptin, cholesterol, cytokines 
and highly sensitive C reactive protein (hsCRP) levels. Also at the above ascribed time points 
quality of life (QoL) questionnaires were filled out by the participants. Only at baseline and 
directly after the intervention a hyperinsulinaemic euglycaemic clamp was performed with 
stable isotopes ([2H5]-glycerol en [6,6-
2H2]-glucose) to determine peripheral and hepatic insu-
lin sensitivity. During the clamp both under basal and hyperinsulinaemic conditions indirect 
calorimetry (to measure lipid and glucose oxidation rates) and muscle biopsies (to measure 
the insulin signaling pathway, muscle morphology and mitochondrial DNA content) were 
performed.
SECOnD AiM: ThE ADDiTiOnAL EffECTS Of ExErCiSE On wEighT LOSS, 
inSuLin SEnSiTiViTy, inSuLin SignALing, MuSCLE MOrPhOLOgy AnD 
MiTOChOnDriAL DnA COnTEnT
Baseline characteristics were identical in both groups. Substantial weight reduction occurred 
in both groups (-23.7 ± 1.7 kg VLCD-only vs. -27.2 ± 1.9 kg VLCD with exercise, p=NS). The 
VLCD with exercise group lost significantly more fat mass and waist circumference. Our a 
priori hypothesis was that the addition of exercise would further improve and might even 
normalize insulin sensitivity. However, glycemic control, hepatic and peripheral insulin sensi-
tivity improved similarly in both intervention groups. Peripheral insulin sensitivity improved 
considerably in both intervention groups by approximately 150% (glucose disposal rate: 
baseline vs. after 16 weeks 15.5 ± 1.2 vs. 38.6 ± 4.6 µmol/kgLBM/min (VLCD-only); 16.6 ±1.2 vs. 
41.8 ± 3.66 µmol/kgLBM/min (VLCD with exercise)).
The similar improvement in insulin sensitivity in both groups is in accordance with the 
observed identical amelioration in insulin signaling pathway as reflected by increased 
proline-rich AKT substrate (PRAS40) phosphorylation and increased levels of insulin receptor 
expression. AKT substrate 160 (AS160) showed the same trend however did not reach signifi-
cance. The insulin receptor expression increased even further with the addition of exercise; 
however this was not accompanied by further improvement of glucoregulation.
As ascribed above, IMCL accumulation in the skeletal muscle is associated with insulin re-
sistance and T2DM. We observed a significant decrease in IMCL accumulation in the skeletal 
muscle in both the VLCD-only and VLCD with exercise group after the 16-week intervention. 
The improvements in insulin signaling found in our study might be related to the observed 
decrement in IMCL accumulation and its metabolic products.
Only in the VLCD with exercise group, maximum aerobic capacity, mitochondrial copy 
number and basal lipid oxidation rate improved whereas in the VLCD-only group no change 










































A low capacity to oxidize fat due to a low percentage of type 1 (oxidative) muscle fibers 
might lead to obesity and T2DM, although a causal relation has not been established. To the 
best of our knowledge we were the first to observe a significant identical increase in both 
intervention groups in type 1 (oxidative) muscle fibers after weight reduction.
Our a priori hypothesis that exercise would further improve insulin sensitivity is thus 
proven wrong. A possible explanation could be that the 16-week VLCD ameliorates insulin 
resistance to a maximal extent in these patients and that the additional effect of exercise is 
too small to detect in this relatively small patient population.
ThirD AiM: ThE LOng-TErM EffECTS Of A VLCD-OnLy AnD 
COMbinED wiTh An ExErCiSE PrOgrAM On gLyCEMiC COnTrOL AnD 
AnThrOPOMETriC MEASurEMEnTS
After the 16-week VLCD with or without exercise patients were given advice on a healthy diet, 
and regular exercise. After a weight-stabilizing period, in which normal meals were reintro-
duced, patients were referred back to their own health care provider at 6 months after the 
start of the intervention. During the time thereafter we were not able to influence treatment 
strategies, especially not with respect to bodyweight or glycemic control.
Eighteen months after the start of the intervention both groups had regained some 
weight and waist circumference. However, both weight and waist circumference were still 
significantly diminished compared to baseline values. Eighteen months after the start of the 
intervention there was still a decline in bodyweight of more than 10% compared to baseline 
in both intervention groups. We did not observe any difference in the amount of weight loss 
18 months after the start of the intervention between the VLCD-only group and the VLCD 
with exercise group.
As stated above we could not adjust treatment strategies with regard to metabolic regula-
tion. This may be one of the reasons that glycemic control was not as tightly regulated as 
guidelines require. Another reason is that patients probably feel reluctant to resume insulin 
therapy. Regrettably, 18 months after the start of the intervention both fasting plasma 
glucose and HbA1c levels had returned to baseline values. However, homeostatic model as-
sessment of insulin resistance (HOMA-IR) (a measure for insulin resistance) and fasting insulin 
levels showed a sustained improvement in the VLCD with exercise group. Also, in none of 
the patients in the VLCD with exercise group insulin therapy was reinstituted, whereas in 
the VLCD-only group 6 patients received insulin therapy again. Altogether these results sug-
gest less insulin resistance in the VLCD with exercise group 18 months after the start of the 
intervention. Eighteen months after the start of the intervention patients in the VLCD with 
exercise group were still exercising for more than 3 hours a week. This might partially explain 










































fOurTh AiM: ShOrT- AnD LOng-TErM EffECTS On QOL AfTEr A VLCD-
OnLy AnD COMbinED wiTh An ExErCiSE PrOgrAM
QoL is reduced in patients with chronic diseases such as T2DM (28,29). It is very important 
to improve QoL in patients, since this can lead to better social functioning, compliance to 
therapy and adherence in self-management (29). In our study QoL was measured with four 
different questionnaires (short form-36 (SF-36), hospital anxiety and depression scale (HADS), 
multidimensional fatigue index-20 (MFI-20) and the Nottingham health profile (NHP)). All 
patients completed the questionnaires three times, at baseline, directly after the 16-week 
intervention and 18 months after the start of the intervention. Patients were compared to 
two (lean and obese) healthy well-matched (age, gender and race) control populations.
At baseline QoL was significantly impaired at scores for physical and social functioning, as 
well as fatigue and pain in the two patients groups, compared to both healthy lean and obese 
control subjects. Immediately after the 16-week intervention, we observed a significant and 
similar improvement in all QoL scores, especially those concerning physical functioning, 
fatigue, and self confidence in both intervention groups. Directly after the intervention, most 
of the QoL scores of the T2DM patients improved even to the level of that of the lean and 
obese control subjects. Only in the VLCD with exercise group improvements in QoL sustained 
up to 18 months after the start of the intervention, whereas in the VLCD-only group QoL 
returned to baseline values, despite persistent weight loss and reduced drug use compared 
to baseline.
Several factors might have contributed to the improvements in QoL of our patients such as 
the loss of a considerable amount of weight, discontinuation of insulin therapy, improvement 
of glycemic control and better physical condition. The last reason could explain the lasting 
amelioration in QoL in the VLCD with exercise group since these patients were still exercising 
for more than 3 hours a week 18 months after start of the intervention.
fifTh AiM: ShOrT- AnD LOng-TErM EffECTS On LOw-grADE 
infLAMMATiOn AnD riSk fACTOrS fOr CArDiOVASCuLAr DiSEASE (CVD) 
AfTEr A VLCD-OnLy AnD COMbinED wiTh An ExErCiSE PrOgrAM
Visceral adipose tissue is characterized by large adipocytes, active adipocyte lipolysis, abun-
dant adipose tissue macrophages, which secrete pro-inflammatory cytokines such as tumor 
necrosis factor alpha (TNFα), interleukin (IL)6, IL8 and IL1, which subsequently promote 
hsCRP production by the liver (30). This chronic low-grade inflammatory state can interfere 
with the insulin signaling pathway in other tissues but can also be an additional risk factor for 










































Directly after the 16-week intervention classical risk factors for the development of CVD 
such as hypertension and dyslipidemia improved dramatically and similarly in both groups. 
However, this was not a lasting effect, since blood pressure returned to baseline values 18 
months after the start of the intervention. The beneficial effect on cholesterol/HDL ratio and 
LDL-cholesterol were maintained in the long run in both intervention groups and only in the 
VLCD with exercise group, respectively.
The effects of the 16-week VLCD with or without exercise on low-grade inflammation be-
came only apparent after patients were on a eucaloric diet after the weight stabilizing period, 
thus 6 months after the start of the intervention. Directly after the intervention no change 
was observed in low-grade inflammation, whereas 6 months after the start of the interven-
tion the low-grade inflammatory state was completely abolished and values of hsCRP and 
pro-inflammatory cytokines (such as TNFα, IL6 and IL1) were decreased to the level of normal 
healthy lean control subjects. This effect persisted in the long run up to 18 months after the 
start of the intervention. The addition of an exercise program had a beneficial effect on hsCRP 
only, no other additional effects were observed.
The mechanism by which a VLCD can ameliorate the low-grade inflammatory status may 
be the decrease in visceral fat mass (and thereby the number of adipose tissue macrophages). 
Indeed in our study we observed a significant decrease in waist circumference (an indirect 
measure of visceral fat storage). During weight loss the number of adipocytes is the same, 
while the size decreases, therefore basal lipolysis remains high. This attracts macrophages, 
which phagocytose the excess lipids, leading to an increase concentration of macrophages in 
the adipose tissue (34,35). The lack of an immediate effect of the VLCD on low-grade inflam-
mation might be explained by the increase in macrophages in the adipose tissue during the 
VLCD and the gradual decline in the weight stabilizing period thereafter.
SECOnD PArT Of ThE ThESiS
In the second part of this thesis we focused on ectopic fat depositions and the amount of 
visceral and subcutaneous fat mass. Fourteen patients (8 men and 6 women), a subpopula-
tion of the above described study population of obese (BMI 35 ± 1 kg/m2) insulin-dependent 
T2DM, who fitted in the magnetic resonance imaging (MRI) scanner, were studied at baseline, 
directly after and 18 months after the 16-week VLCD with or without the exercise program. In 
the liver and myocardium ectopic fat depositions were measured in vivo by proton magnetic 
resonance spectroscopy (1H-MRS). Measuring myocardial ectopic fat deposition by 1H-MRS 
is a new technique developed by our group (36). Pericardial, visceral, subcutaneous fat mass 
and cardiac function was measured using 1.5 Tesla MRI. IMCL accumulation in the skeletal 











































SixTh AiM: ShOrT- AnD LOng-TErM EffECTS Of A 16-wEEk VLCD wiTh Or 
wiThOuT ExErCiSE On QuAnTiTy AnD funCTiOnAL EffECTS Of ECTOPiC 
fAT DEPOSiTiOnS in ThE hEArT
Even in well-controlled T2DM patients diastolic function is impaired compared to a healthy 
control population. In T2DM patients diastolic dysfunction is associated with increased risk of 
development of heart failure and mortality independently of coronary artery disease (37). In 
cross-sectional studies increased depositions of TG in the myocardium of T2DM patients were 
observed, which were negatively correlated with diastolic cardiac function (26).
The estimate of myocardial oxygen consumption (rate pressure product) (38,39) decreased 
significantly directly after the 16-week VLCD and the effect sustained up to 18 months after 
the start of the intervention, which is compatible with an improved cardiac efficiency.
T2DM patients have a decreased left ventricular (LV) end diastolic volume index compared 
to healthy controls, associated with diminished compliance (40). In this thesis we show 
sustained improvements in diastolic function and diastolic left ventricular distensibility up 
to 18 months after the start of the intervention, as reflected by an increase in LV end diastolic 
volume index at comparable estimated LV filling pressure and sustained improvement in the 
early (E) and atrial (A) diastolic filling phase ratio (E/A ratio). Our study is the first to show that 
weight reduction leads to sustained improvement in diastolic function and an increase in 
compliance of the left ventricle in T2DM patients.
Myocardial TG content decreased directly after the 16-week VLCD. However, 18 months 
after the start of the intervention myocardial TG content returned to baseline values. The 
study design does not allow us to assess the direct relation between myocardial TG stores 
and myocardial function. Apparently the regain in myocardial TG content does not immedi-
ately correspond with diastolic function. It could be hypothesized that the positive effect of 
the VLCD on glucotoxicity or oxidative stress may contribute more to diastolic function than 
the regain in myocardial TG content.
Left ventricular mass serves as an independent predictor of mortality. In this thesis a signifi-
cant decrease in left ventricular mass was observed. Insulin is considered to be a growth fac-
tor and may therefore induce cardiac hypertrophy. The persistent decreased plasma insulin 
level, together with the significant amount of weight loss may be part of the explanation for 










































SEVEnTh AiM: ShOrT- AnD LOng-TErM EffECTS Of A 16-wEEk VLCD wiTh 
Or wiThOuT ExErCiSE On QuAnTiTy Of ViSCErAL AnD SubCuTAnEOuS 
fAT MASS AnD ECTOPiC fAT DEPOSiTiOnS in ThE LiVEr AnD PEriCArDiuM
A 16-week VLCD significantly reduced hepatic TG content, visceral and subcutaneous ab-
dominal fat mass and pericardial fat volume to respectively 16, 40, 53 and 83% of baseline 
values. Directly after the intervention we observed a preferential loss of visceral fat compared 
to subcutaneous fat volume. Eighteen months after the start of the intervention both visceral 
and subcutaneous fat mass had increased but there was still a significant reduction in fat 
mass in both compartments compared to baseline values. The preferential loss of visceral 
fat, however, did not sustain. Also, hepatic TG content tended to return to baseline values 
18 months after the start of the intervention compared to values directly after the 16-week 
VLCD, although there was still a significant reduction compared to baseline.
Interestingly, pericardial fat was significantly reduced by the VLCD with or without an exer-
cise program and it did not increase during the follow-up period. Therefore, pericardial fat is 
apparently less amendable to dietary interventions compared to other (non-)adipose tissue 
stores. As pericardial fat volume has been associated with increased cardiovascular risk (41) it 
can be hypothesized that our finding could point to a sustained beneficial effect of VLCD with 
or without exercise on cardiovascular risk.
OVErALL COnCLuSiOn
In T2DM patients, a VLCD with the discontinuation of all blood glucose-lowering agents can 
be safely used without the risk of severe hyperglycemia, provided that patients still have 
remaining endogenous insulin secretion (42). Using a VLCD, patients can lose substantial 
amounts of body weight. The weight loss consists mainly of the loss of fat mass (both visceral 
and subcutaneous (abdominal) fat) together with the loss of ectopic fat depositions in the 
heart, liver and skeletal muscle. The loss of ectopic fat depositions in the liver and skeletal 
muscle were accompanied by a significant improvement in both hepatic and peripheral insu-
lin sensitivity, which is in accordance with an amelioration of the insulin signaling pathway in 
skeletal muscle biopsies. The loss of ectopic fat depositions in the heart was associated with a 
sustained improvement in diastolic function and LV distensibility, even up to 18 months after 
the start of the intervention.
The addition of an exercise program to a 16-week VLCD did not lead to a further improve-
ment in insulin sensitivity, probably because the effect of the VLCD was so substantial, that 
the relatively modest effects of exercise in our patient population could not be detected. 
However we observed a beneficial effect on mitochondrial copy number, lipid oxidation and 










































reduction after cessation of the VLCD. It seemed that the addition of exercise to the VLCD had 
long-term beneficial effects on glycemic control and QoL but not on weight loss.
Our observations stress the importance of weight-reducing therapies in T2DM patients. 
Besides a VLCD, bariatric surgery can be used for this purpose. Bariatric surgery has the larg-
est effect on weight, insulin sensitivity and QoL. However, surgery is expensive, invasive, has 
substantial morbidity and logistically it is impossible to operate all obese T2DM patients. 
Therefore, diet and lifestyle interventions remain the mainstay of treatment for most obese 
T2DM patients.
furThEr rESEArCh
In this thesis we evaluated the effect of diet-induced weight loss with or without the addition 
of exercise. Because of the substantial beneficial effects of a 16-week VLCD, it is difficult to 
show additional effects of exercise. To really differentiate between the effects of exercise and 
diet a different study must be performed. We propose a study with 2 intervention groups 
of obese insulin-dependent T2DM patients. Both groups first follow a 10-week VLCD and 
thereafter a 10-week weight maintenance diet. During the weight maintenance diet, only 
one group simultaneously participates in a 10-week exercise-program, which consists of a 
one hour in hospital training and at least 4 trainings at home on a cycloergometer at 70% 
of maximum aerobic capacity. This study design would allow evaluation of the impact of 
exercise on insulin action in slimmed patients. We also examined the effect of diet-induced 
weight loss with or without exercise on the amount of mitochondria in skeletal muscle 
(mtDNA content), but we did not investigate mitochondrial function. Impaired fat oxidation 
and low metabolic rate are risk factors for body weight gain and insulin resistance. It would 
thus be interesting to not only measure the number but also the function of mitochondria 
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De wereldwijde prevalentie van type 2 Diabetes Mellitus (T2DM) stijgt nog altijd sterk. De 
Wereldgezondheidsorganisatie schat dat in 2030 meer dan 5% van de volwassen wereldpo-
pulatie lijdt aan T2DM. Op de lange termijn is preventie van T2DM natuurlijk zeer belangrijk. 
Maar gezien het feit dat er weinig goede preventieprogramma’s bestaan, worden alle inter-
venties om de behandeling van T2DM te verbeteren toegejuicht. Het is van essentieel belang, 
voor zowel praktische, economische en medische redenen, dat de behandeling van T2DM 
verder verbeterd wordt.
Van de patiënten met T2DM hebben 80-90% overgewicht of obesitas. Insulineresistentie 
speelt een uitermate belangrijke pathofysiologische rol in obese patiënten met T2DM. Thera-
peutische interventies moeten vooral gericht zijn op het verbeteren van insulineresistentie in 
deze patiëntenpopulatie. Hoekstenen in de behandeling van T2DM zijn; leefstijlinterventies, 
orale glucoseverlagende middelen en insulinetherapie. Tegenwoordig ligt de nadruk echter 
vooral op medicamenteuze therapie, terwijl van leefstijlinterventies op zijn minst vergelijk-
bare therapeutische effecten te verwachten zijn.
Leefstijlinterventies bestaan uit dieet-geïnduceerd gewichtsverlies, inspanningsprogram-
ma’s en psychologische programma’s gericht op gedragsveranderingen. Uit eerdere studies 
blijkt dat dieet-geïnduceerd gewichtsverlies insulineresistentie en de daarmee geassoci-
eerde metabole veranderingen, kan verbeteren. Inspanningsprogramma’s zijn nog steeds 
ondergewaardeerd in de behandeling van obese patiënten met T2DM. Dit omdat de effecten 
op zowel gewichtsreductie als behandeling van insulineresistentie iets minder uitgesproken 
zijn.
In dit proefschrift bestuderen we zowel de korte als de lange termijn effecten van een 
zestien weken durend zeer laagcalorisch dieet (very low calorie diet, VLCD), al dan niet in 
combinatie met een inspanningsprogramma in obese insuline-afhankelijke T2DM patiënten.
EErSTE DOELSTELLing: SySTEMATiSChE SAMEnVATTing VAn DE 
bESChikbArE LiTErATuur OVEr hET EffECT VAn DiEET-gEïnDuCEErD 
gEwiChTSVErLiES En inSPAnningSPrOgrAMMA’S OP ECTOPiSChE 
VETDEPOSiTiES.
In hoofdstuk 2 wordt er een systematische samenvatting van de beschikbare literatuur 
gegeven over het effect van dieet-geïnduceerd gewichtsverlies en inspanningprogramma’s 
op ectopische vetdeposities. Ectopische vetdeposities zijn gedefinieerd als triglyceriden 











































In cross-sectionele studies zijn ectopische vetdeposities in de skeletspier (intramyocel-
lulaire lipiden (IMCL) accumulatie) geassocieerd met insulineresistentie en T2DM. Een relatief 
kleine hoeveelheid lichaamsgewichtreductie (<10%) geïnduceerd door dieet heeft geen 
effect op IMCL accumulatie en insulinegevoeligheid in de skeletspier. Een meer uitgespro-
ken gewichtreductie leidt echter tot een significante daling in IMCL en een verbetering in 
insulinegevoeligheid in de skeletspier. Het effect van inspanningsprogramma’s op de IMCL 
accumulatie is minder duidelijk. Inspanningsprogramma’s gaan gepaard met òf een stijging 
òf een daling òf geen verandering in IMCL accumulatie in de skeletspier.
In cross-sectionele studies zijn ectopische vetdeposities in de lever geassocieerd met insu-
lineresistentie en dyslipidemie. Zelfs een zeer kleine (<5%) door dieet-geïnduceerde afname 
in lichaamsgewicht gaat gepaard met een aanzienlijke vermindering van triglyceriden stape-
ling in de lever. Deze afname in triglyceriden stapeling in de lever is geassocieerd met een 
verbetering in insulinegevoeligheid in de lever. De effecten van inspanningsprogramma’s op 
triglyceriden stapeling in de lever zijn minder duidelijk omdat er nauwelijks onderzoek naar 
is gedaan. In de beschikbare onderzoeken wordt een inspanningsprogramma gecombineerd 
met een dieet. In deze studies leidt alleen het dieet al tot een afname in lichaamsgewicht 
en derhalve tot een aanzienlijke daling in triglyceriden stapeling in de lever. Hierdoor is 
het moeilijk aan te tonen wat het unieke effect van een inspanningsprogramma is op de 
triglyceriden stapeling in de lever.
In cross-sectionele studies is pericard vet (dit zijn vetdeposities rond het hart) positief 
gecorreleerd met een toename van hart- en vaatziekte en insulineresistentie. De exacte 
functie van pericard vet is nog niet bekend. Dieet-geïnduceerd gewichtsverlies en inspan-
ningsprogramma’s leiden tot een significante afname in de hoeveelheid pericard vet. In één 
onderzoek ging dit gepaard met een verbetering van de diastolische functie van het hart.
Cross-sectionele data laten zien dat triglyceriden stapeling in het myocard geassocieerd 
is met een afname van de diastolische functie van het hart. Eén onderzoek laat zien dat 
dieet-geïnduceerd gewichtsverlies geassocieerd is met een niet-significante afname van 
triglyceriden stapeling in het myocard.
Concluderend zijn ectopische vetdeposities geassocieerd met negatieve veranderingen 
in de metabole processen in de desbetreffende organen. Of ectopische vetdeposities de 
oorzaak of het gevolg zijn van insulineresistentie is nog steeds onderwerp van studie. Het 
is in ieder geval duidelijk dat leefstijlinterventies zowel leiden tot een vermindering van 
ectopische vetdeposities als een verbetering van de orgaanfunctie (insulineresistentie in de 
lever en skeletspier en met name de diastolische functie van het hart).
In dit proefschrift worden de resultaten van een zestien weken durende gerandomiseerde 
interventie studie beschreven waarin een VLCD gecombineerd wordt met een inspan-











































EErSTE gEDEELTE VAn hET PrOEfSChrifT
In het eerste gedeelte van het proefschrift vergelijken we de effecten van een zestien weken 
durend VLCD en een zestien weken durend VLCD gecombineerd met een inspanningspro-
gramma. De studiepopulatie bestond uit zevenentwintig obese (body mass index (BMI) 37.2 
± 0.9 kg/m2), niet sportende, insuline-afhankelijke T2DM patiënten (veertien mannen en 
dertien vrouwen). Allen hadden nog endogene insuline secretie uit de β-cel in de pancreas. 
Drie weken voor de start van de interventie werden alle orale glucoseverlagende middelen 
gestopt. Eén dag voor de interventie werd ook de insulinetherapie gestopt. Gedurende de 
gehele interventieperiode werd er geen glucoseverlagende medicatie (inclusief insuline) 
gebruikt.
Het VLCD bestond uit ~450 kcal/dag, verdeeld over drie vloeibare maaltijden en bevat 
alle essentiële vitamines en mineralen (Modifast®). Dertien patiënten namen naast het VLCD 
tegelijkertijd deel aan een inspanningsprogramma. Het inspanningsprogramma bestond 
wekelijks uit een één uur durende training in het ziekenhuis onder leiding van een fysio-
therapeut (met name aerobics), met daarnaast minimaal vier trainingen van dertig minuten 
thuis op een fietsergometer, op 70% van maximale inspanningscapaciteit.
Voor, direct na, zes maanden na de start en achttien maanden na de start van de interven-
tie werden er verschillende metingen verricht. Ten eerste werd er telkens lengte, gewicht, 
buikomvang en bloeddruk gemeten. Tevens werd op elk tijdspunt nuchter bloed afgeno-
men voor bepaling van glucose, insuline, leptine, cholesterolspectrum, cytokines en hoog 
sensitief C reactive protein (hsCRP). Daarnaast werd er door de patiënten op elk tijdspunt 
een kwaliteit van leven (KvL) vragenlijst ingevuld. Alleen voor de start van de interventie 
en direct erna werd een hyperinsulinemische euglycemische clamp uitgevoerd met stabiele 
isotopen ([2H5]-glycerol en [6,6-
2H2]-glucose) om insulineresistentie in de lever en skeletspier 
te bepalen. Gedurende de clamp werd zowel onder basale als onder hyperinsulinemische 
condities een indirecte caloriemetrie (om vet- en glucoseoxidatie snelheid te bepalen) en 
spierbiopten (om de insuline signaaltransductie cascade, spiermorfologie en de hoeveelheid 
mitochondriaal DNA te bepalen) uitgevoerd.
TwEEDE DOELSTELLing: VASTSTELLEn VAn DE ADDiTiOnELE 
EffECTEn VAn EEn inSPAnningSPrOgrAMMA OP gEwiChTSVErLiES, 
inSuLinEgEVOELighEiD, inSuLinE SignAALTrAnSDuCTiE CASCADE En DE 
hOEVEELhEiD MiTOChOnDriAAL DnA
Beide groepen waren voor start van de interventie gelijk in antropometrische waarden, in-
sulineresistentie, duur van de T2DM en medicatiegebruik. Er trad in beide groepen een aan-










































met inspanningsprogramma, p = niet significant). In de groep waar een VLCD gecombineerd 
werd met een inspanningsprogramma trad er een grotere vermindering op in vetmassa en 
buikomvang. De a priori hypothese luidde dat toevoegen van het inspanningsprogramma 
aan een VLCD de insulinegevoeligheid verder zou verbeteren en deze wellicht volledig zou 
normaliseren. Echter, in beide interventiegroepen traden er zowel in glucoregulatie als insu-
linegevoeligheid van de lever en de skeletspier dezelfde grote verbeteringen op. Insulinege-
voeligheid van de skeletspier verbeterde het meeste (meer dan 150%) in beide groepen (de 
insuline gestimuleerde glucose opname in de skeletspier op baseline vs. na de zestien weken 
durende interventieperiode: 15.5 ± 1.2 vs. 38.6 ± 4.6 µmol/kgVVM/min (VLCD alleen); 16.6 ± 
1.2 vs. 41.8 ± 3.66 µmol/kgVVM/min (VLCD gecombineerd met het inspanningsprogramma); 
(VVM: vetvrije massa)).
De vergelijkbare verbetering in insulinegevoeligheid in beide interventiegroepen, direct 
na de zestien weken durende interventie, ging logischerwijs ook gepaard met gelijke ver-
betering in de insuline signaaltransductie cascade in de cel. Er traden significante verbete-
ringen op in de fosforylatie van proline-rich AKT substraat (PRAS40) en de expressie van de 
insuline receptor. Ook de fosforylatie van AKT substraat 160 (AS160) verbeterde met dezelfde 
trend, echter dit bereikte net geen significantie. De expressie van de insuline receptor op 
het celmembraan nam nog verder toe met de toevoeging van het inspanningsprogramma 
aan het zestien weken durende VLCD. Dit laatste ging echter niet gepaard met een verdere 
verbetering in glucoregulatie en glucose opname.
Zoals reeds hierboven beschreven is IMCL accumulatie in de skeletspier geassocieerd met 
een toename van insulineresistentie en T2DM. In ons onderzoek trad er, zowel in de groep die 
alleen het VLCD volgde als in de groep die naast het VLCD ook het inspanningsprogramma 
volgde, een significante daling op in IMCL accumulatie in de skeletspier na de zestien weken 
durende interventie. De verbeteringen die gevonden waren in insulinegevoeligheid en in de 
insuline signaaltransductie cascade zouden gerelateerd kunnen zijn aan de daling van IMCL 
accumulatie in de skeletspier.
Alleen in de groep patiënten die naast het VLCD ook aan het inspanningsprogramma deel-
nam, trad een verbetering op in maximale aërobe capaciteit, de hoeveelheid mitochondrieën 
en de basale vetoxidatie op. De verbeteringen gingen echter niet gepaard met een verdere 
daling van IMCL accumulatie in de skeletspier. In de groep die alleen het VLCD volgde, wer-
den er geen veranderingen gezien in deze parameters.
Theoretisch gezien zou een lagere vetoxidatie capaciteit, door een lager percentage aan 
type 1 (oxidatieve) spiervezels, kunnen leiden tot overgewicht en T2DM. Echter, er zijn nog 
geen onderzoeken die deze causale relatie bewijzen. In dit onderzoek laten we voor het eerst 
zien dat door gewichtsreductie een significante stijging in type 1 (oxidatieve) spiervezels op 
kan treden.
Onze a priopi hypothese dat het toevoegen van een inspanningsprogramma aan een VLCD 










































verklaring kan zijn dat de verbeteringen in insulinegevoeligheid, ontstaan door een zestien 
weken durend VLCD, zo groot zijn dat de additionele effecten van inspanning te klein zijn om 
in deze relatief kleine patiëntenpopulatie waar te nemen.
DErDE DOELSTELLing: DE LAngE TErMijn EffECTEn VAn EEn 
zESTiEn wEkEn DurEnD VLCD ALLEEn En gECOMbinEErD MET EEn 
inSPAnningSPrOgrAMMA OP gLuCOrEguLATiE En AnTrOPOMETriSChE 
wAArDEn.
Na de zestien weekse interventie (VLCD met of zonder het inspanningsprogramma) hebben 
patiënten bewegingsadviezen en adviezen voor gezonde voeding gekregen. In deze periode 
was het doel het gewicht te stabiliseren en langzaam normale maaltijden te herintroduceren. 
Zes maanden na start van de interventie zijn de patiënten terugverwezen naar de eigen 
behandelaar (dit was de huisarts of internist). Gedurende de daaropvolgende tijd hadden 
de onderzoekers geen invloed op behandelstrategieën met betrekking tot gewicht- en 
glucoregulatie.
Achttien maanden na de start van de interventie zijn beide groepen opnieuw onderzocht. 
Er was sprake van een lichte toename in gewicht en buikomvang. Echter, er bestond een 
blijvende gewichtsvermindering van meer dan tien procent ten opzicht van de uitgangs-
waarden in beide interventiegroepen. Wederom was er tussen de beide interventiegroepen 
geen verschil in gewichtsreductie ten opzichte van de uitgangswaarde.
Zoals hierboven beschreven, konden de onderzoekers geen invloed uitoefenen op be-
handelstrategieën met betrekking tot glucoregulatie. Dit was één van de redenen dat de 
glucoregulatie niet zo strikt gereguleerd was als in de richtlijnen is voorgeschreven. Een 
andere reden was dat de patiënten een aversie hadden tegen het herstarten van insulinethe-
rapie. Achttien maanden na de start van de interventie waren de nuchtere glucose en HbA1c 
waarden weer op het niveau terug van de uitgangswaarden. Echter, in de groep die naast 
het VLCD ook deelnam aan het inspanningsprogramma was de nuchtere insulinewaarde en 
de HOMA-IR (een parameter voor insulineresistentie) blijvend verbeterd. Daarnaast was er 
in diezelfde groep niemand bij wie insulinetherapie hervat moest worden, terwijl er in de 
groep die alleen het VLCD gevolgd hadden zes patiënten waren bij wie de insulinetherapie 
hervat moest worden. Al deze resultaten samen suggereren dat achttien maanden na de 
start van de interventie, in de groep die naast het VLCD een inspanningsprogramma volgde, 
de insulineresistentie minder was. Eén van de verklaringen hiervoor kan zijn dat in deze 
groep de patiënten, achttien maanden na start van de interventie, nog steeds meer dan drie 










































DOELSTELLing ViEr: kOrTE En LAngE TErMijn EffECTEn VAn EEn VLCD 
ALLEEn Of gECOMbinEErD MET EEn inSPAnningSPrOgrAMMA OP DE 
kwALiTEiT VAn LEVEn.
De KvL is afgenomen bij patiënten met chronische ziekten zoals T2DM. Het is zeer belangrijk 
de KvL te verbeteren bij patiënten, omdat dit kan leiden tot een beter sociaal functioneren, 
betere compliantie van ingestelde behandeling en betere zelfcontrole. In ons onderzoek werd 
KvL gemeten met vier verschillende vragenlijsten. Alle patiënten vulden de KvL vragenlijsten 
drie keer in; voor, direct na en achttien maanden na de start van de interventie. Patiënten 
werden vergeleken met twee gezonde controlepopulaties van vergelijkbare leeftijd, geslacht 
en ras (één met een normaal gewicht en één met vergelijkbaar overgewicht als de patiënten 
maar zonder T2DM).
Voor de start van de interventie hadden patiënten een significant slechtere KvL in vergelij-
king met beide gezonde controlepopulaties. Met name op scores die betrekking hadden tot 
fysiek en sociaal functioneren, vermoeidheid en pijn. Direct na de interventie was er sprake 
van een significante maar gelijke verbetering in alle KvL-scores in beide interventiegroepen. 
Met name de scores voor fysiek functioneren, vermoeidheid en zelfvertrouwen waren di-
rect na de interventie sterk verbeterd. De verbeteringen direct na de interventie waren zo 
uitgesproken dat de meeste van de KvL-scores gelijk waren aan die van zowel een normaal 
gewichtige als een obese controlepopulaties. Alleen de groep die naast het VLCD deelnam 
aan het inspanningsprogramma liet een blijvende verbetering zien in KvL, achttien maanden 
na start van de interventie. In de groep die alleen het VLCD volgde, verslechterden de KvL 
scores achttien maanden na start van de interventie naar de uitgangswaarden.
Verschillende factoren spelen een rol bij de verbeteringen van KvL van de patiënten. Zowel 
het verlies van een aanzienlijke hoeveelheid gewicht, het stoppen van insulinetherapie, 
verbetering in glucoregulatie en een betere fysieke conditie kunnen (mede) de oorzaak zijn 
van de verbeteringen in KvL. De laatste reden kan tegelijkertijd de verklaring zijn waarom er 
een blijvende verbetering optrad in de groep waarin het VLCD gecombineerd werd met een 
inspanningsprogramma. In deze groep sportten de patiënten nog steeds meer dan drie uur 
per week achttien maanden na start van de interventie.
DOELSTELLing Vijf: kOrTE En LAngE TErMijn EffECTEn VAn EEn 
VLCD ALLEEn Of gECOMbinEErD MET EEn inSPAnningSPrOgrAMMA 
OP LAAggrADigE infLAMMATiE En riSiCOfACTOrEn VOOr hArT- En 
VAATziEkTEn.
Viscerale vetmassa wordt gekenmerkt door grote adipocyten, verhoogde lipolyse in de 










































kines uitscheiden, zoals tumor necrosis factor alfa (TNFα), interleucine (IL) 6, IL8 en IL1. Deze 
pro-inflammatoire cytokines leiden tot een verhoogde productie van hsCRP in de lever en 
interveniëren in de insuline signaaltransductie cascade. Deze chronische laaggradige inflam-
matoire status kan, naast de traditionele risicofactoren, een additionele risicofactor zijn voor 
de ontwikkeling van hart- en vaatziekte in T2DM patiënten.
Direct na de zestien weken durende interventie waren klassieke risicofactoren voor de 
ontwikkeling van hart- en vaatziekten zoals hypertensie en dyslipidemie duidelijk verbeterd 
in beide groepen. Dit was echter geen blijvend effect. De bloeddruk verslechterde naar de 
uitgangswaarde, achttien maanden na start van de interventie. De gunstige effecten op de 
cholesterol/HDL ratio en LDL-cholesterol bleven echter wel bestaan op de lange termijn, 
respectievelijk in beide groepen en in de groep waarin het VLCD gecombineerd werd met 
een inspanningsprogramma.
De effecten van het zestien weken durende VLCD al dan niet gecombineerd met een in-
spanningsprogramma op laaggradige inflammatie werden pas duidelijk na de gewichtstabi-
liserende periode (zes maanden na start van de interventie). Direct na de interventie waren er 
geen veranderingen in laaggradige inflammatie. Daarentegen was zes maanden na de start 
van de interventie de laaggradige inflammatoire status volledig verdwenen en waren de 
waarden van hsCRP en de pro-inflammatoire cytokines (TNF-α, IL-6 en IL-1) vergelijkbaar met 
de waarden van beide gezonde controle populaties. Dit was een blijvend effect in ieder geval 
tot achttien maanden na start van de interventie. De toevoeging van het inspanningspro-
gramma had alleen toegevoegde waarde voor de daling in hsCRP, geen andere additionele 
effecten werden waargenomen.
Het onderliggende mechanisme, waardoor er een verbetering in laaggradige inflammatie 
kan ontstaan door een VLCD, is een afname in viscerale vetmassa (en daarmee de hoeveel-
heid macrofagen in het vetweefsel). In onze studie hebben we inderdaad een daling in 
buikomvang (een indirecte maat voor de hoeveelheid visceraal vet) gevonden. Gedurende 
de periode van gewichtsverlies blijft het aantal adipocyten gelijk, terwijl de grootte afneemt, 
hierdoor neemt de basale lipolyse snelheid toe. Dit trekt een grotere hoeveelheid macrofagen 
aan in het vetweefsel die de overmaat aan vetten fagocyteren. Het ontbreken van een direct 
effect van het VLCD op laaggradige inflammatie kan derhalve verklaard worden door een 
grotere concentratie macrofagen in het vetweefsel gedurende het VLCD. Deze macrofagen 
verdwijnen langzaam in de daaropvolgende gewichtstabiliserende periode.
TwEEDE gEDEELTE VAn hET PrOEfSChrifT
In het tweede gedeelte van het proefschrift ligt de focus op ectopische vetdeposities en 
de hoeveelheid viscerale en subcutane vetmassa. De studiepopulatie bestond uit veertien 










































studiepopulatie van obese (BMI 35 ± 1 kg/m2) insuline-afhankelijke T2DM patiënten die in de 
magnetic resonance imaging (MRI) scanner pasten. Er werden drie keer metingen gedaan, 
namelijk voor, direct na en achttien maanden na de start van het zestien weken durende 
VLCD, al dan niet gecombineerd met het inspanningsprogramma. In de lever en het myocard 
werden ectopische vetdeposities gemeten in vivo met proton magnetic resonance spectros-
copie (1H-MRS). Het meten van ectopische vetdeposities in het myocard met 1H-MRS is een 
nieuwe techniek, ontwikkeld door onze groep. Pericardiale, viscerale, subcutane vetmassa’s 
en hartfunctie werd gemeten met een 1.5 Tesla MRI. IMCL accumulatie in de skeletspier is 
eerder beschreven en is niet gemeten met 1H-MRS maar in spierbiopten.
DOELSTELLing zES: kOrTE En LAngE TErMijn EffECTEn VAn EEn 
zESTiEn wEkEn DurEnD VLCD AL DAn niET gECOMbinEErD MET EEn 
inSPAnningSPrOgrAMMA OP DE ECTOPiSChE VETDEPOSiTiES in hET 
hArT En DE hArTfunCTiE.
In vergelijking met een gezonde controlepopulatie is zelfs bij goed ingestelde T2DM patiën-
ten de diastolische hartfunctie verminderd. Diastolische dysfunctie van het hart is geassoci-
eerd met een verhoogd risico op het ontwikkelen van hartfalen en mortaliteit, onafhankelijk 
van het al dan niet aanwezig zijn van hart- en vaatziekte. Verder wordt in cross-sectionele 
onderzoeken gezien dat er in T2DM patiënten sprake is van verhoogde triglyceriden stape-
ling in het myocard. Dit is geassocieerd met diastolische dysfunctie van het hart.
Door een zestien weken durend VLCD was de geschatte myocardiale zuurstofconsumptie 
(rate pressure product) significant verlaagd. Dit was een blijvend effect, in ieder geval tot 
achttien maanden na de start van de interventie. Dit duidt derhalve op een verbetering in 
efficiëntie van het hart.
Uit eerdere onderzoeken blijkt dat T2DM patiënten, in vergelijking met gezonde controles, 
een verminderde linker ventrikel eind diastolische volume index hebben. Dit is geassocieerd 
met een verminderde compliantie van het hart. In dit proefschrift beschrijven we een blij-
vende verbetering, in ieder geval tot achttien maanden na de start van het zestien weken 
durende VLCD, in diastolische functie en de distensibiliteit van de linker ventrikel gedurende 
de diastole. Ons onderzoek is het eerste dat laat zien dat gewichtsreductie leidt tot een 
blijvende verbetering in diastolische functie en een verbetering van de compliantie van de 
linker ventrikel in T2DM patiënten.
De stapeling van triglyceriden in het myocard nam af direct na de interventie. Achttien 
maanden na de start van de interventie was de triglyceriden stapeling echter weer gelijk aan 
de uitgangswaarde. In dit onderzoek is het niet mogelijk een directe relatie tussen triglyceri-
den stapeling in het myocard en myocardfunctie te leggen. Wat wel uit dit onderzoek blijkt, 










































in diastolische functie. Wellicht zijn de positieve effecten van een VLCD op glucoregulatie en/
of oxidatieve stress belangrijker voor de verbetering in diastolische functie dan de toename 
in triglyceriden stapeling in het myocard.
Linker ventrikel massa is een onafhankelijke voorspeller van mortaliteit. In dit proefschrift 
werd een significante en blijvende daling in linker ventrikel massa gezien na de zestien 
weekse interventie in de T2DM patiënten. Insuline is een groeifactor en zou daardoor cardiale 
hypertrofie kunnen veroorzaken. De blijvende daling in de insulinewaarden, samen met de 
significante daling in gewicht, zouden een goede verklaring kunnen zijn voor de blijvende 
afname in linker ventrikel massa, achttien maanden na de start van de interventie.
DOELSTELLing zEVEn: kOrTE En LAngE TErMijn EffECTEn VAn EEn 
zESTiEn wEkEn DurEnD VLCD AL DAn niET gECOMbinEErD MET EEn 
inSPAnningSPrOgrAMMA OP DE hOEVEELhEiD ViSCErALE En SubCuTAnE 
VETMASSA En ECTOPiSChE VETDEPOSiTiES in hET LEVEr En PEriCArD.
Een zestien weken durend VLCD leidt tot een significante vermindering in triglyceriden 
stapeling in de lever, viscerale en subcutane vetmassa en de hoeveelheid pericard vet. Ze 
namen respectievelijk af met 16, 40, 53 en 83% ten opzichte van de uitgangswaarden. Acht-
tien maanden na de start van de interventie was de hoeveelheid viscerale en subcutane 
vetmassa lichtelijk toegenomen, maar was er een blijvende verbetering ten opzichte van de 
uitgangswaarden. Direct na de interventie is er een sterkere daling in viscerale vetmassa ten 
opzichte van de subcutane vetmassa. Achttien maanden na de start van de interventie was 
dit effect echter verdwenen. Ook de triglyceriden stapeling in de lever nam iets toe, achttien 
maanden na start van de interventie. Er was echter ook hier een blijvende verbetering in 
vergelijking met de uitgangswaarde.
De pericardiale vetmassa daalde significant direct na het zestien weken durend VLCD en 
nam daarna ook niet meer toe in de follow-up periode. Hieruit blijkt dat pericard vet blijkbaar 
minder fluctueert gedurende dieetinterventies in vergelijking met andere ectopische vetde-
posities. Omdat een grotere hoeveelheid pericard vet geassocieerd is met een verhoogd risico 
op hart- en vaatziekte, kan men hypothetiseren dat onze bevinding, een daling in pericardvet, 
zou kunnen leiden tot een verminderd risico op hart- en vaatziekten, in onze patiënten.
COnCLuSiE
In T2DM patiënten is het gebruik van een VLCD, zonder het gebruik van orale glucosever-
lagende middelen en/of insulinetherapie, veilig. Het risico op ernstige hyperglycemie is 










































een VLCD kunnen patiënten een grote hoeveelheid gewicht verliezen. Het gewichtsverlies 
bestaat voornamelijk uit het verlies van vetmassa (zowel viscerale als subcutane vetmassa) 
en de vermindering van ectopische vet deposities in bijvoorbeeld het hart, de lever of de 
skeletspier. Het verlies van ectopische vetdeposities in de lever en in de skeletspier was 
geassocieerd met een significante verbetering in insulinegevoeligheid en in de skeletspier 
biopten met een verbetering van de insuline signaaltransductie cascade. Het verlies van 
ectopische vetdeposities in het hart was geassocieerd met een blijvende verbetering (tot 
achttien maanden na start van de interventie) in diastolische functie en distensibiliteit van 
de linker ventrikel gedurende de diastole.
Toevoeging van een inspanningsprogramma aan een zestien weken durend VLCD verbe-
terde de insulinegevoeligheid niet verder. Waarschijnlijk omdat de effecten van het VLCD 
zo groot waren dat de relatief kleine effecten van inspanning niet detecteerbaar waren in 
onze patiëntenpopulatie. Er werden echter wel verbeteringen gezien in lipiden oxidatie 
snelheid, de hoeveelheid mitochondrieën in de skeletspier en maximale aërobe capaciteit. 
Het is moeilijk op de lange termijn de hoeveelheid gewichtsreductie vast te houden. Toe-
voegen van het inspanningsprogramma aan het zestien weken durend VLCD had voor de 
lange termijn (achttien maanden na de start van de interventie) geen toegevoegde waarde 
voor de hoeveelheid gewichtsverlies, echter wel voor de verbeteringen in KvL en mogelijk 
insulineresistentie.
Onze observaties laten nogmaals zien hoe belangrijk gewichtreducerende therapieën zijn 
in patiënten met T2DM. Naast dieet kan voor dit doel natuurlijk ook bariatrische chirurgie 
gebruikt worden. Bariatrische chirurgie heeft de grootste effecten op gewicht, insulineresis-
tentie en KvL. Maar bariatische chirurgie is duur, invasief en heeft een aanzienlijke mortaliteit 
en morbiditeit. Bovendien is het onmogelijk alle obese patiënten met T2DM te opereren. 
Daarom blijven dieet, inspanning en andere leefstijlinterventies een belangrijk onderdeel in 
de behandeling van de meeste obese patiënten met T2DM.
TOEkOMSTig OnDErzOEk
In dit proefschrift kijken we naar de effecten van dieet-geïnduceerd gewichtsverlies met of 
zonder de toevoeging van een inspanningsprogramma. Door de zeer grote effecten van het 
zestien weken durend VLCD, is het moeilijk additionele effecten van inspanning aan te tonen. 
Om daar goed tussen te kunnen differentiëren, is een andere studie noodzakelijk. Wij stellen 
voor een onderzoek waarin twee interventie groepen van obese insuline-afhankelijke T2DM 
patiënten met elkaar vergeleken worden. Beide groepen volgen eerst een tien weken durend 
VLCD met daarna een tien weken durende gewichtstabiliserende periode. Gedurende de 
tien weken durende gewichtstabiliserende periode, neemt één groep gelijktijdig deel aan 










































ziekenhuis onder leiding van een fysiotherapeut (met name aerobics) en een minimum van 
4 trainingen van 30 minuten thuis op een fietsergometer, op 70% van de maximale inspan-
ningscapaciteit. In dit studieontwerp kan er beter gekeken worden naar het effect van een 
inspanningsprogramma op insulineresistentie in patiënten die al gewicht verloren hebben.
Daarnaast hebben we in dit proefschrift gekeken naar de effecten van dieet-geïnduceerd 
gewichtsverlies al dan niet in combinatie met een inspanningsprogramma op de hoeveelheid 
mitochondrieën in de skeletspier. We hebben niet gekeken naar de mitochondriële functie. 
Een verminderde vetoxidatie en een laag metabolisme zijn risicofactoren voor toename in 
gewicht en insulineresistentie. Het zou derhalve zeer interessant zijn om in de nieuwe studie 
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